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ABSTRACT 
Due to their intimate roles in survival, longevity as well as pathogenesis via “epigenetic” 
and “metabolic” regulatory mechanisms, sirtuins have gained considerable interest toward 
undertaking detailed biochemical/biophysical studies. The present study was designed to 
ascertain the mechanistic details of ligand binding and catalysis in selected sirtuin isozymes (viz., 
SIRT1 and SIRT5) from the point of view of designing isozyme selective inhibitors as potential 
therapeutics. By screening of the in-house synthesized compounds, two barbiturate derivatives 
were identified as the SIRT5 selective inhibitors. These, along with some of known inhibitors of 
SIRT1 and SIRT5, namely, MH5-75, nicotinamide, suramin were investigated by a combination 
of spectroscopic, kinetic, and thermodynamic techniques. The influence of the sirtuin inhibitors 
in modulating the structural features of the enzymes were ascertained by CD spectroscopic, 
lifetime fluorescence, and thermal denaturation studies using wild-type and selected site-specific 
mutant enzymes. The experimental data revealed that the substrate selectivity and inhibitory 
features in SIRT5 were manifested via the mutual cooperation between Y102 and R105 residues 
of the enzyme, and the overall catalytic feature of the enzyme was modulated by changes in the 
protein structure. Whereas the stoichiometry of SIRT1 to suramin remained invariant as 1:1, that 
of SIRT5 to suramin increased from 1:1 to 2:1 upon increase in the molar ratio of the enzyme to 
the ligand. A comparative account of the experimental data presented herein sheds light on the 
structural-functional differences SIRT1 and SIRT5, leading to the design of isozyme selective 
inhibitors as therapeutic tools for the treatment of sirtuin associated diseases.  
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1.  INTRODUCTION 
1.1. Post-translational Lysine Acetylation 
1.1.1. Post-translational modification  
The complexity of the human proteome well exceeds that of the human genome, with 
the estimated 1 million-member proteome encoded by just 25,000 genes (1). This complexity 
partially arises from transcriptional regulation in the forms of alternative splicing, 
recombination events, differential transcriptional activation and termination, and post-
translational modifications. Post-translational modifications (PTMs) are chemical modifications 
of proteins, including phosphorylation, methylation, acetylation, acylation, N-linked and O-
lined glycosylation, ADP-ribosylation, ubiquitination, SUMOylation and biotinylation. PTM 
regulates protein structure and stability, protein cellular localization, protein-DNA/protein-
protein interactions and consequently, they modulate a variety of cellular processes, such as 
gene expression, DNA damage, apoptosis, cell-cycle regulation, metabolism and stress response 
(2-5). 
1.1.2. Lysine acetylation and acylation 
Lysine is one of the most commonly modified amino acid residues in proteins, and the 
positive charge it carries enables it to accommodate different PTMs, including acetylation, non-
acetyllinse acylation, methylation, and ubiquitination. Reversible acetylation on ε-amino group 
of lysine residues was first discovered in histones by Allffrey et al in 1964 (6). Later on, lysine 
acetylation/deacetylation were also found in a variety of important non-histone proteins, such as 
p53, estrogen receptor, Hsp90, tubulin, etc (7). Enzymes that catalyze the addition of acetyl 
group to proteins are classified as histone/lysine acetyltransferases (HAT/KAT) (8). These 
enzymes are grouped into three major protein families, including the MYST family, the GNAT 
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family (Gcn5 related N-acyltransferase) and CBP/p300 family (9). Enzymes that remove the 
acetyl group from proteins are classified as histone/lysine deacetylases (HDAC/KDAC), which 
include HDAC1 to HDAC8 and SIRT1 to SIRT7 (NAD+ dependent deacetylases). Recently, 
several new types of non-acetyllysine acylation have also been identified, including 
succinylation, malonylation (10), glutarylation (11), myristoylation, palmitoylation (12), 
butyrylation, and propionylation (13). It has been well demonstrated that SIRT1-SIRT6 all 
possess the potential to catalyze the deacylation reactions of fatty acyl-lysine conjugates in 
peptides/proteins (14, 15). 
1.2. Discovery of Sirtuins as NAD+ Dependent Deacylases 
1.2.1. History of sirtuins 
Sirtuins (Sir2 proteins) belong to an ancient family of proteins, which are highly 
conserved in various organisms ranging from bacteria to humans. About 30 years ago, the first 
sirtuin gene encoding for Sir2 enzyme was identified in budding yeast (Saccharomyces 
cerevisiae) as MAR1 (mating type regulator 1) (16). Later on in 1987, Herskowitz started to use 
SIR (Silent Information Regulators) nomenclature (17). In 1995, Boeke and his colleagues 
identified 4 homologs of Sir2 genes (HST1-4) from Saccharomyces cerevisiae and concluded 
that the sir2 genes, conserved in both prokaryotes and eukaryotes, involve in gene silencing, 
cell-cycle regulation and chromosome stability (18). In 1999, Frye identified 5 human Sir2 
homologs (SIRT1-5) and named the Sir2 protein family as “sirtuins”. Based on the dependence 
of NAD+, he also speculated that the sir2 proteins were ADP-ribosyltranserases (19). In the 
same year, Moazed et al demonstrated that human SIRT2 and E.coli cob proteins possessed 
ADP-ribosyltransferase activity (20). In 2000, two research groups reported independently that 
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sir2 and its homologs are NAD+ dependent deacetylases (21, 22). Since then, sirtuins have 
increased researchers’ interest as to their physiological roles  especially their correlations with 
life-span expansion process (23). In recently years, novel activities of sirtuins have been 
identified. Hence, the sirtuins are more appropriately names as NAD+ dependent deacylases. 
1.2.2. Classification of sirtuins 
Sirtuins are found in all three domains of life (from bacteria to mammals). General 
speaking, the more complicated the organisms are, the more sirtuins they possess. Most 
prokaryotic genomes only encode one sirtuin, while eukaryotes possess multiple sirtuins. For 
instance, yeast encodes 5 (Sir2 and HST1-4), Drosophila encodes 6, and human genome 
encodes 7 sirtuins. Based on the molecular phylogenetic analysis of 60 sirtuins, the family is 
divided into five classes by Frye (I-IV and U) (24). Class I includes yeast Sir2, HST1, HST2, 
mammalian SIRT1, SIRT2 and SIRT3. Class II is composed of the mammalian SIRT4 and the 
fruitfly D.mel3. Most bacterial siruins are included in class III, which also includes mammalian 
SIRT4, SIRT5 and some other eukaryotic orthologs from Candida albicans and Plasmodium 
falciparum. Class IV is eukaryotic specific, which includes mammalian SIRT6 and SIRT7, and 
are further subdivided into class IVa (SIRT6, D.mel4, C.ele4, P.Fal2, O.sat, and A.tha) and 
class IVb (SIRT7 and D.mel5). Class U is composed of prokaryotic sirtuins with gene sequence 
motifs as being intermediate between classes I, II and classes III, IV.   
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Figure 1.1. Molecular phylogeny of the sirtuins. (A) An unrooted tree diagram of a phylogenetic 
analysis of sirtuins based on the sequences of their conserved core deacylase domain. Sirtuins 
are divided into class I, II, III, IV, and U groups; classes I and IV are further divided into 
subclasses indicated by lowercase letters. (B) Scheme of the conserved catalytic core domains 
in human SIRT1–7, color coded to match the phylogenetic class from (A) are indicated in green, 
blue, red and yellow, respectively. The extended N-terminal and C-terminal regions are 
inidicated in black. The figure is adapted from reference (25) 
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1.3. Structure and Chemistry of Sirtuins 
1.3.1. Structural features of sirtuins 
Structural information of sirtuins is crucial for understanding the catalytic mechanism, 
substrate specificity, and inhibition/activation mechanisms. Of the 60 sirtuin proteins, the 
crystal structures of several ones have been solved (Table 1.1) , including two Sir2 homolog 
from bacteria (CobB from Escherichchia coli, Sir2Tm from Thermatoga maritima ) (26-28), 
two from archaea (Sir2Af1 and Sir2Af2 from Archaeoglobus fulgidus (29, 30)), one from yeast 
(Hst2 from Saccharomyces cerevisiae (31)), and five out of seven human sirtuins (SIRT1, 
SIRT2 (32), SIRT3 (33), SIRT5 (10, 34) and SIRT6 (12, 35)) have been solved. All these above 
structures share a highly conserved catalytic core consisting of approximately 275 amino acids. 
Additionally, some sirtuin proteins have extended N-terminal and C-terminal flanking regions at 
various length and amino acids sequences. The overall catalytic core consists of a large 
Rossmann-fold domain, a small zinc-binding domain, and a cleft consisting of several loops 
between the two domains where the peptide substrate and NAD+ enter (Figure 1.2.). 
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Figure 1.2. Overall Structure of Sirtuin represented by Hst2. Crystal structure of the protein 
bound to acetyllysine and carba-NAD+ substrates represented in stick model (PDB code 1SZC). 
The small domain is shown in green, the large domain in blue, and the four linking loops in 
purple. The figure is adapted from reference (36). 
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Table 1.1. Summary of Sirtuin Structures (36) 
Protein PDB ID Major Findings Reference 
Sir2Af1 + NAD+ 1ICI 
Overal stirtuin fold and NAD+ 
biding site 
Xu et al, 2001 
(29)  
SIRT2 (human) apo 1J8F Overal stirtuin fold 
Finnin et al., 
2001(32) 
Sir2Af2 + p53K382Ac 
peptide 
1MA3 Mode of p53 substrate binding 
Wolberger et 
al., 2002 (37)  
Hst2 (yeast) 1Q14 
Overal Hst fold. 
C- and N-terminal extensions 
interact with NAD+ and acetyllysine 
binding sites, respectively to 
autoregulate the enzyme 
Marmorstein et 
al., 2003, (38) 
 Hst2 + NAD+ 1Q17 
Cofactor binding loop becomes 
ordered compared to apo structure 
Hst2 + NAD+ + 
H4K16AC peptide 
1Q1A 
Model for 2’-OAADPr product and 
acetyllysine substratebinding in the 
same structure 
CobB (E.coli) + 
H4K16Ac peptide 
1S5P 
Model of acetyllysine peptide 
substrate binding 
Marmorstein et 
al, 2004 (26) 
Sir2Af2 + NAD+ + 
NAM 
1YC2 
Free nicotinamide binding observed 
in the C pocket 
Wolberger et 
al, (39)  
Sir2Tm + p53K382Ac 
peptide 
2H2D Residues at -1 and +2 positions of 
the peptide make side chain 
interactions with Sir2Tm 
Avalos et al, 
2006 (37) Sir2Tm + p53K382 
peptide 
2H2F 
Hst2 + ADP-HPD + 
H4K16Ac peptide 
2OD7 
Binding model of an oxocarbenium 
intermediate mimic 
Marmorstein et 
al, 2007  
Hst2 + ADP-HPD + 
H4K16Ac peptide 
+NAM 
2OD9 
Nicotinamide is observed to bind in 
the D pocket 
SIRT5 (human) + NAD+ 2B4Y SIRT5 fold Plotnikov et al, 
2007 (34) SIRT5 + suramin 2NYR Suramin binding model 
Sir2Tm + DADMe-
NAD+ + p53K382Ac 
peptide 
3D4B 
Binding model of a dissociative 
intermediate Hawse et al., 
2008 (40) 
Sir2Tm + S-
alkylamidate 
3D81 
Binding model of an O-alkylamidate 
intermediate mimic 
Sir2Tm + p53 peptide 3JR3 
Putative nucleophilic attack from 
Arg at +2 of acetyllysine peptide for 
ADP-ribosylation 
Wolberger et 
al., 2009 (41) 
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Table 1.1. Summary of Sirtuin Structures (36) (continued) 
Protein PDB ID Major Findings Reference 
SIRT3 (human) apo 3GLS Sirtuin fold 
Perni et al., 
2009 (33) 
SIRT3 + AceCS2-Kac 3GLR Model of acetyllysine binding 
SIRT3 + AceCS2-Ks-ac-
ADPR 
3GLT 
Binding model of an S-alkylamidate 
intermediate 
SIRT3 + AceCS2-K 3GLU 
Binding model of a dethioacetylated 
AceCS2  
SIRT5 + NAD+ + 
H3K9(N-succinyl) 
peptide 
3RIY 
Binding model of a succinyl-lysine 
peptide to SIRT5 
Du et al.,2010 
(10) 
SirTm + 
p53K382(propionyl) 
peptide 
3PDH Binding model of propionyl-lysine 
Wolberger et 
al, 2011 (42) 
SIRT6 (human) + NAD+ 3K35 SRIT6 fold 
Pan et al, 2011 
(35) 
SIRT6 + 2’-N-acetyl-
ADPr 
3PKJ 
Sirtuin bound to 2’-N-acetyl-ADP-
ribose, a non-hydrolyzable analog of 
O-acetyl-ADP-ribose 
SIRT5 + sucH3K9 4F4U 
Binding mode of SIRT5 with 
bicyclic intermediate 
Zhou et al., 
2011 (43) 
SIRT5 + bicyclic 
intermediate 
4F56 
SIRT1 + EX527 analog 
+ NAD+ 
4I5I Binding mode of EX527 to SIRT1 
Zhao et al., 
2013 (44) 
Sir2Tm + EX527 + 
NAD+ 
4BV3 
EX527 occupies the nicotinamide 
site and a neighboring pocket and 
contacts the ribose of NAD+ or of 
the product 2’-OAADPr, stabilizing 
the closed enzyme conformation 
preventing product release. 
Gertz et al., 
2013 (45) 
Sir2Tm + p53 peptide + 
OAADPr + EX527  
4BV2 
SIRT3 + EX527 + 
ADPr 
4BVB 
SIRT3 + 
thioalkylimidate + 
EX527 
4BVF 
SIRT3 + alkylimidate + 
EX527 
4BVG 
SIRT3 + 2’-OAADPR + 
EX527 
4BVH 
SIRT1CAT + CTR + 
ADPR + substrate (open 
state) 
4IG9 
Overall SIRT1 fold; regulatory role 
of C-terminal segment 
Davenport et 
al, 2014 (46) 
SIRT1CAT + CTR 
(closed state) 
4KXQ 
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Figure 1.3. Three-dimensional structure of several representative sirtuin proteins that has been 
determined. The enzymes are shown without bound ligands. (A) S. cerevisiae Hst2 (PDB code 
1Q14). (B) A. fulgidus Sir2-Af1 (1ICI). (C) A. fulgidus Sir2-Af2 (1MA3). (D) T. maritima 
Sir2Tm (2H4J). (E) E. coli cobB (1S5P). (F) H. sapiens SIRT2 (1J8F). (G) H. sapiens SIRT5 
(2B4Y) Figures are adapted from reference (47). 
 
1.3.1.1. The large domain 
The large domain adopts a characteristic α/β Rossmann-fold, consisting of 6 parallel β 
strands that are sandwiched between several α helices. The number of α helices varies in 
different sirtuins. For instance, in human SIRT2, the 6 α helices pack against the 6 β strands; but 
in SIRT5, the number of α helices is 9. The Rossmann-fold has characteristic hallmarks of 
NAD+/NADH binding proteins, such as Gly-X-Gly sequence important for binding of the 
NAD+ phosphate, the small hydrophobic pocket, and polar residues (Asn, Asp/Glu) that 
hydrogen-bond to the adenine ribose 2’ and 3’ OH groups. Interestingly, the Rossmann-fold 
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domain of sirtuin enzymes resembles the inverted Rossmann-fold enzymes, which means the 
NAD+ molecule is oriented in an inverted manner as  compared to  other NAD+-linked 
dehydrogenases (48): the adenine base of NAD+ binds to the C-terminal half and the 
nicotinamide group of NAD+ binds to the N-terminal half of the  sheet.  
1.3.1.2. The small domain 
The small domain is comprised of a zinc-binding module and a helical module with 
three or four helices. This domain is the most diverse region among sirtuin family members for 
which structures have been determined, in terms of secondary structure and the position relative 
to the Rossmann-fold. A conserved salt-bridge (Arg217 and Glu215 in SIRT5) seems to be 
important for positioning the small zinc-binding domain with respect to the large domain (29, 
34) (Figure 1.3).  
The zinc-binding ribbon module is composed of three antiparallel β strands with the 
conserved motifs Cys-X2-4–Cys-X15-40-Cys-X2-4-Cys (X is any amino acid). In most sirtuin 
structures, the zinc molecule is bound with two pairs of Cys, which are highly conserved among 
sirtuins, forming a tetrahedral geometry. The only exception is CobB, which contains only three 
Cys residues expected for the zinc coordination based on sequence alignment (47). The three 
stranded metal-binding ribbon module resembles the zinc-ribbon structure of transcription 
factors TFIIS (49), TFIIB (50), and the RNA polymerase II subunit RPB9 (51). Unlike Class I 
and II HDACs, of which the zinc-binding module is involved in the catalysis by coordinating 
with the substrate, the zinc in sirtuins locates apart from the active site and does not participate 
in the catalysis directly. Charkrabarty et al demonstrated that depletion of zinc in Plasmodium 
falciparum Sir2 by mutating the cysteines or using chelating reagent partially denatures the 
protein structure and knocks down the enzyme activity. The enzyme activity is 
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partially/completely  restored by supplementing the enzyme by zinc, suggesting that the zinc is 
critical for  maintaining the three dimensional structures of sirtuins   (52). 
 
Figure 1.4. Zinc coordination in SIRT5. The zinc molecule is bound with two pairs of Cys, 
which are highly conserved among sirtuins, forming a tetrahedral geometry. 
 
1.3.1.3. The large active site groove  
Four loops connect the large and small domains and form a cleft where both the peptide 
substrate and NAD+ enter, thereby acting as th enzyme’s  active site. The residues of these four 
loops are highly conserved. It has been found that mutations in the large groove blocked the 
deacetylase activity of some sirtuins. The residues of these four loops are highly conserved. It 
has been found that mutations in the large groove blocked deacetylase activity of some sirtuins 
Cys207
Cys212
Cys166
Cys169
Zn(II)
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(32). Three hydrophobic residues (Phe223, Leu227, Val254 in SIRT5), which are highly 
conserved within the sirtuin family, define the entrance of the acyl-lysine binding pocket 
(Figure 1.5). Recent studies have suggested that the size of the hydrophobic pocket varies 
among sirtuin enzymes. The substrate binding site in SIRT6 possesses a relatively larger 
hydrophobic pocket, which enables it to accommodate long-chain fatty-acid modified lysine 
(12). The substrate binding pocket in SIRT5 is also larger as compared to other sirtuin enzymes 
that possess robust deacetylase activity. In addition to the hydrophobic residues, two non-
hydrophobic residues (Tyr102 and Arg105) locate in the deep end of the substrate-binding 
pocket, enabling the enzyme to bind negatively charged acyl groups (succinyl, malonyl, glutaryl) 
and act as a dessucinylase, demalonylase and deglutarylase enzymes (10, 11). 
 
Figure 1.5. The substrates-binding cleft. The substrates-binding cleft is shown in surface 
representation and is colored red for negative charge and blue for positive charge. The NAD+-
binding region is divided into sites A-D. Figure is adapted from reference (36). 
 
A
B
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1.3.1.4. NAD+ binding pocket 
The NAD+ binding pocket locates at the bottom of the large Rossmann-fold domain and 
the loop region (particularly the cofactor binding loop) at the interface between the large 
domain and small domain. It consists of three different regions (Figure 1.5): site A, where the 
adenine-ribose moiety of NAD+ is bound; site B, where the nicotinamide ribose is bound; site C 
that lies deep inside the pocket, where the nicotinamide moiety is bound. The site A is mostly 
hydrophobic, providing van der Waals interactions with the adenine ribose moiety via several 
conserved Gly residues. A conserved Asn (Asn248 in Hst2 and Asn275 in SIRT5) forms 
hydrogen bonds with the 3’-OH and 2’-OH group of the adenine ribose. Other functionally 
conserved residues participate in the hydrogen bond interactions with the pyrophosphate group. 
In the site B, a conserved His residue (His158 in SIRT5) forms hydrogen bond with the 3’-OH 
groups of the nicotinamide ribose, acting as a general base during catalysis (discussed in the 
latter section). The electron density of the nicotinamide moiety of NAD+ is usually not observed 
in the sirtuin structures, which are crystallized in the presence of NAD+, presumably due to the 
slow non-enzymatic hydrolysis of NAD+ or the disorder of nicotinamide moiety upon binding. 
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Figure 1.6. Binding of peptide substrate. Binding of acetyllysine-containing p53 peptide to 
Sir2Tm are shown in A and B. (A) The acetyllysine peptide (light green) forms a β-staple with 
sirtuin residues (dark green). Only the backbone of the residues is shown except for where side 
chain interactions are made: Lys-381 (+1 position) forms hydrogen bonds with Asn165 and 
Gly163, and Met384 (+2 position) makes van der Waals interactions with Phe162 and Val193. 
(B) The acetyllysine side chain is buried in a hydrophobic tunnel and makes van der Waals 
interactions with sirtuin residues (blue stick). (C) Succinyllysine (green) forms hydrogen bonds 
with NAD+ and SIRT5 residues Tyr102 and Arg105. Figures are adapted from reference (36). 
 
 
 
 
A
B C
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Figure 1.7. Binding of NAD+. (A) Site A of the NAD+ binding pocket. Residues represented in 
blue stick form hydrogen bonds (dashed lines) with NAD+. Theadenine base sits in a 
hydrophobic pocket shown in surface representation. yHst2, yeast Hst2. (B) Sites B and C. 
NAD+ forms hydrogen bonds with Ile117, Asp118, and acetyllysine. Gly32, Ala33, Gly34, Ile41, 
and Phe44 make van der Waals interactions with NAD+. Asn116 forms a hydrogen bond with 
an ordered water molecule (indicated as w; blue sphere). (C) Sites B and C of the NAD+ binding 
pocket represented by the Sir2Tm-NAD+-acetyllysine complex. The nicotinamide ribose is 
rotated by 90 °C compared with B. (D) Different conformations of the cofactor-binding loop. 
Hst2 bound to carba-NAD+ (purple) is superimposed on Hst2 bound to ADPR (green), showing 
the different positions of Phe44. Figures are adapted from reference (36). 
 
1.3.1.5. N-terminal and C-terminal extensions 
Outside the catalytic core, sirtuins possess divergent N-terminal and C-terminal 
extenstions that vary in length, amino acids sequence and secondary structure. These two 
domains are absent in most of the solved sirtuin structures. The few structures that include the 
N-terminal and/or C-terminal domains, as well as  molecular modeling based design of 
A B
C D
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minimally functional construct have provided useful information of the roles of these two 
regions in sirtuin catalysis and regulation (31, 53-55).  
In yeast Hst2, seven residues of the N-terminal domain form an extended loop that 
interacts with the active site of a symmetry-related molecule, mediating the formation of a 
homotrimer that blocks the entry of acetylated substrate. In the ternary complex of 
Hst2/NAD+/Histone H4 which is not a trimer, the N-terminal region is disordered and the 
substrate replaces it in the active site, suggesting that the N-terminal region of Hst2 is involved 
in both maintaining the oligomerization state and autoregulating the binding of the substrate 
(31). In human SIRT2 and yeast HST2, an additional -helix packs against the Rossmann-fold; 
however, this helix is absent in bacteria srituins SirTm and CobB, archaea sirtuins Sir2Af1 and 
Sir2Af2, and human SIRT5 (Figure 1.3.). It has been proposed that this packing autoregulates 
the NAD+ binding as evident by the following facts: (1) the helix interacts with the residues in 
the Rossmann-fold that also contact with NAD+, and (2) removal of the C-terminal region 
reduces the Km of NAD
+ (38). 
SIRT1, which is composed of 747 amino acids, possesses an unusually long extended N-
terminal and C-terminal regions. The attempt to solve the structure of the above enzyme in the 
presence of both N-terminal and C-terminal regions has not been successful due to the 
conformational flexibility of these two regions. It has been shown that N-terminal contributes to 
the catalytic rate,  independent of the nature of the acetyl-lysine peptide substrate, while the C-
terminal loweres the Km for NAD
+ (which contrary to that observed with  yeast Hst2)  (56). In 
2013, Davenport et al. identified residues 641-665 as the C-terminal regulatory segment (CTR) 
and crystalized SIRT1 catalytic core in complex with this CTR (46). The CTR forms a  hairpin 
loop that complements the parallel  sheet of the Rossmann-fold where NAD+ is bound (Figure 
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1.4). Two residues, Arg276 and Glu656 form a salt bridge between the catalytic core and the 
CTR. This CTR-mediated “augmentation” seems to stabilize the active site.  
The N-terminal region of SIRT1 has also been demonstrated to be critical for the 
binding of sirtuin-activating compounds (STACs). Recently, Dai et al. engineered and 
characterized a mini SIRT1 construct containing only the minimal structural elements required 
for the catalysis and activation of STACs, including the catalytic core, the STAC-binding 
domain (SBD) and the CTR (55). Their structural and biochemical studies demonstrated that 
STACs bind to the N-terminal domain (will be discussed into detailed in the latter section). 
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Figure 1.8. Structure of H. sapiens SIRT1. (a) Crystal structure of the quaternary 
SIRT1CAT·CTR·ADPR·Substrate complex in ribbon representation. (b) Crystal structure of the 
SIRT1CAT·CTR heterodimer, displayed in the same orientation as in (a). Views rotated 90° are 
shown on the right. Figures are adapted from reference (46). 
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1.3.2. Catalytic mechanism of sirtuins 
The most common reaction catalyzed by sirtuin enzymes is NAD+ dependent protein 
deacetylation, resulting in the formation of dacetylated lysine, nicotinamide, and 2’-O-acetyl-
ADP-ribose (OAADPr) (Figure 1.10) (57). The overall reaction couples amide hydrolysis to 
ester synthesis with the help of NAD+. Structural studies of sirutins, in conjunction with other 
biochemical approaches, such as isotope-labeling and chemical probes, provide insights into the 
catalytic mechanism of siruins. In general, the reaction proceeds via the nucleophilic attack of 
the carbonyl oxygen of the acylated substrate to the C1’ ribose of NAD+, resulting in the 
cleavage of the nicotinamide moiety of NAD+ and formation of C1′-O-alkylimidate 
intermediate (Figure 1.11). The alkylimidate intermediate undergoes the cyclization reaction 
followed by hydrolysis, generating the deacylated product and 2′-O-acyl-ADP-ribose (OAADPr) 
species. The latter is slowly isomerized (non-enzymatically) to form 3′-OAADPr. 
 
Figure 1.9. Overal deacylation reactions catalyzed by sirtuins. 
 20 
 
 
Figure 1.10. Schematic representation of the sirtuin catalyzed reaction mechanism. The sirtuin 
catalyzed reaction proceeds via the nucleophilic attack of the carbonyl oxygen of the acylated 
substrate to the C1’ ribose of NAD+, resulting in the cleavage of the nicotinamide moiety of 
NAD+ and formation of C1′-O-alkylimidate intermediate. The alkylimidate intermediate 
undergoes the cyclization reaction followed by hydrolysis, generating the deacylated product 
and 2′-O-acyl-ADP-ribose (OAADPr) species. The latter is slowly isomerized (non-
enzymatically) to form 3′-OAADPr. 
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1.3.2.1. Cleavage of the glycosidic bond 
The deacetylation reaction of sirtuins is initiated by the binding of both acetyllysine and 
NAD+ to the catalytic site. The first chemical step of the sirtuin reaction involves the cleavage 
of the glycosidic bond of NAD+ and addition of the acetyl oxygen to C1’ of the nicotinamide 
ribose, forming a C1’-O-alkylamidate intermediate. It has been debated as to how the cleavage 
of the glycosidic bond occurs, and three mechanisms have been proposed in literature, including 
stepwise SN1, SN2, or highly asynchronous SN2 mechanism (Figure 1.11) (58). The SN1 
mechanism requires the full dissociation of the nicotinamide to form an enzyme-stabilized 
oxacarbenium ion prior to nucleophilic attack of the acetyl oxygen of acetyllysine at the 1’-
carbon of the nicotinamide ribose. Zhao et al. crystallized a non-active ternary complex of the 
yeast Sir2 homolog Hst2 with an acetyl-lysine peptide and a nonhydrolyzabe NAD+ analog 
(carba-NAD+). This observed conformation precluded attack of the acetyl oxygen at the 1’-
carbon of the nicotinamide ribose and thus  appears to support the stepwise SN1 mechanism (39). 
However, a different NAD+ conformation was also observed in the ternary complex structure of 
Sir2Tm bound with native substrates acetyllysine and NAD+ (59). The acetyl oxygen was placed 
3.2 Å from the 1’-carbon on the α face of the nicotinamide ribose  in this NAD+ conformation, 
which seemed to satisfied the positioning requirements for aceyl oxygen attack without the 
formation of the an oxacarbenium intermediate. Biochemical studies by Smith and Denu 
proposed a SN2 mechanism (60), in which the association of the nucleophile (acetyllysine) at the 
transition state is required. By performing single-turnover kinetics of Hst2 monitoring 
nicotinamide formation with acetyl-lysine analogues containing electron withdrawing groups 
(monofluoroacetyllysine, difluoroacetyllysine, trifluoroacetyllysine, etc), Smith and Denu 
revealed that the nicotinamide formation rate decreased with decreasing nucleophilicity of the 
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amide oxygen. Importantly, the Kd values for these acetyllysine analogues to the enzyme was 
not diminished, thus the reduced formation rates observed was not due to the reduced binding 
affinity. Their results appeared to rule out the stepwise SN1 mechanism, in which nicotinamide 
formation should be independent on the nucleophilicity of the amide oxygen. As an alternative 
to either SN1 or SN2 mechanism, the asynchronous SN2 mechanism appears to be more 
attractive, in which an oxacarbenium ion is formed at the transition state during the time of both 
extensive bond cleavages to the leaving group and weak bond formation to the nucleophile 
(Figure 1.7, middle). More recently, ab initio QM/MM computational studies on TmSir2 by Hu 
et al. support this mechanism (61). The results of molecular dynamic simulations suggest that 
no stable oxocarbenium intermediate needs to be formed during the reaction. Instead, the 
calculated transition state is very loose and dissociative and requires the participation of the 
acetyl-lysine, indicating that the nicotinamide cleavage reaction employs “a highly dissociative 
and concerted displacement mechanism”. Kinetic isotope effects and computational studies on 
AfSir2 catalyzed reaction by Cen et al. also reached at a similar conclusion, providing 
additional support for the asynchronous SN2 mechanism (62). Despite of the intensive studies in 
past years, several important questions regarding the nicotinamide cleavage still remain 
unanswered. Do all sirtuin isozymes follow the identical mechanism? Is substrate 
destabilization required prior to the nucleophilic attack? Answers to the above questions are 
expected to assist a more comprehensive understanding of sirtuin chemistry. 
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Figure 1.11. Mechanisms of reaction of NAD+ with acetyllysine nucleophile. Three mechanistic 
possibilities can be considered for reaction of acetyllysine with NAD+, as shown by top (SN2), 
middle (SN1) and bottom (asynchronous SN2) reaction pathways. Figure is adapted from 
reference (63). 
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1.3.2.2. From imidate intermediate to products 
C1’-O-alkylamidate intermediate is formed after the cleavage of the glycosidic bond 
linking nicotinamide to the N-ribose and the transfer of the ADP-ribose to the acetyllysine. 
Isotope labeling by Sauve et al. and Kinetic experiments by Smith et al. support the existence of 
this intermediate (64-66). The most direct support of the above mechanism emerges from the 
crystal structure of Sir2Tm in complex with an S-alkylamidate intermediate, which is an analog 
of the naturally occurring O-alkylamidate intermediate (Figure 1.12) (28). The imidate 
intermediate is proposed to have two fundamental reaction pathways. The first pathway is the 
reversal to NAD+ via β-face attack of nicotinamide on the anomeric carbon (so called “base 
exchange” reaction). This base exchange mechanism has been implicated in the inhibition of 
enzyme reaction in the presence of nicotinamide (67, 68). The other pathway is to proceed to 
complete the sirtuin deacetylation reaction. After formation of the O-alkylamidate, the 2’-OH of 
the nicotinamide ribose is activated by deprotonation of the conserved histidine residue (His135 
in Hst2) at the active site of the enzyme followed by the attack the O-alkylamidate carbon to 
form a 1’,2’-intermediate (58). Mutation of His135 to Ala does  not affect the base-exchange 
reaction, but slows down the overall deacetylation reaction, suggesting that the above  His 
residue is involved in the chemical steps after the formation of O-alkylamidate and 
nicotinamide (65). Moreover, β-2’-deoxy-2’-fluororibo-NAD+, which lacks the 2’-OH group, 
also reacts with Hst2 to form a similar imidate intermediate, but only results in the release of 
acetate when the reaction is quenched with alkaline solution, suggesting that the 2’-OH is 
required to complete the sirtuin deacetylation reaction (27). The 1’,2’-cyclic intermediate has 
yet to be directly observed in sirtuin deacetylation reactions, although kinetic and mass 
spectrometry experiments suggests its existence (65, 66). Zhou et al. obtained the crystal 
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structure of SIRT5 (which catalyzes desuccinylation reaction faster than deacetylation) in 
complex with 1’,2’-cyclic intermediate by incubating SIRT5-H3K9 with the thiosuccinyl 
peptide and NAD+ (Figure 1.13), providing the first bicyclic intermediate for a sirtuin-catalyzed 
deacylation reaction (43). 
 To complete the reaction, the bicyclic intermediate is further hydrolyzed to a free lysine 
and 2’-acetyl-O-ADPR (2’-OAADPR). Following release from the sirtuin active site, OAADPR 
undergoes nonenzymatic interconversion between 2’-OAADPR and 3’-OAADPR (69). 
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Figure 1.12. Structure of a Sir2Tm-S-Alkylamidate intermediate complex. Hydrogen bond 
network between side chains in Sir2Tm (grey) and the S-alkylamidate intermediate (cyan). 
Hydrogen bonds are shown in orange (40). 
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Figure 1.13. Structure of a SIRT5-bicyclic intermediate complex. Bicyclic intermediate 
interacts with SIRT5 via hydrophobic interaction and hydrogen bonding. The hydrogen bonds 
are shown in orange (43).  
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1.3.3. ADP-ribosyl transferase activity 
Although protein deacetylation is thought to be the primary activity displayed by sirtuins, 
several reports have suggested that some sirtuins (e.g., SIRT4 and SIRT6) exhibts ADP-
ribosyltransferase activity (70-72), the possible mechanism of NAD+-dependent protein ADP-
ribosylation has not been explicitly demonstrated, and the nature of the linkage, the site 
modification and the final products remain unclear. Kowieski et al. has proposed two distinct 
ADP-ribosylation mechanisms, both of which require an acetyl-lysine substrate (73). In one 
mechanism, acetyl-lysine reacts with NAD+ to form the O-alkylamidate intermediate. 
Importantly, Smith et al. demonstrated that the O-alkylamidate intermediate is able to react with 
other exogenous alcohol nucleophiles, such as methanol or ethanol (65), indicating that an 
amino acid side chain nuceophile from bound histone might intercept and react with the O-
alkylamidate intermediate, resulting in ADP-ribosylation instead of deacetylation. In a second 
ADP-ribosylation mechanism, the acetyl-lysine substrate and NAD+ bind to the active site and 
follow the deacetylation process to form OAADPr, which then interacts and reacts with the 
protein substrate possibily noneznymatically, resulting in the ADP-ribosylation reaction. 
However, it has also been suggested that Pfsir2 catalyzes the ADP-ribosyltransfer to protein 
nucleophiles directly in the absence of an acetyl-lysine substrate and/or in a nicotinamide-
insensitive manner, though the acetyllysine independent hydrolysis activity was much less than 
the acetyllysin-dependent hydrolysis activity (74). 32P blots demonstrated that SIRT4 might also 
possess ADP-ribosyltransferase activity in the absence of acetyl-lysine substrates (70, 71). 
However, the specific residue that is ADP-ribosylated during the catalysis has not been 
determined. In this case, it is possible that some amino acids residues such as Asn or Gln 
replace acetyl-lysine to form a similar O-alkylamidate intermediate. 
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1.4. Cellular Regulation of Sirtuin Activity 
In cells, sirtuin activity may be affected by the quantity of sirtuin molecules, reversible 
post-translational modifications (PTM) of sirtuin, availability of NAD+ and nicotinamide. 
1.4.1. Post-translational modifications (PTM) 
Post-translational modifications (PTM) of sirtuins, including phosphorylation, 
sumoylation, methylation and transnitrosylation, usually occur in N-terminal and C-terminal 
extensions (so-called regulatory regions). Phosphorylation sites have been identified in all 
sirtuins, but the biological outcome associated with phosphorylation has only been studied in 
SIRT1 and SIRT2 (75). Phosphorylation activates SIRT1, but inhibits SIRT2. Multiple 
phosphorylation sites located in N- and C-terminal domains of SIRT1 have been reported, and 
several kinases that regulate the activity of SIRT1 have been identified, including DYRK (dual 
specificity tyrosine phosphorylation-regulated kinase), JNK1 (c-Jun N-terminal kinase 1), 
cyclin B/Cdk1 (cyclin-dependent kinase 1) and protein kinase A (PKA) (76-78). Sasaki et al. 
identified 13 phosphorylation sites in SIRT5 and cyclinB/Cdk1 as a cell cycle-dependent kinase 
that phosphorylates and activates SIRT1 (76). Gerhart-Hines et al. demonstrated that 
cAMP/PKA pathway activates SIRT1 activity and promote fatty acid oxidation (78). The 
cAMP-dependent phosphorylation at Ser434 of SIRT1 increases its deacetylase activity, 
presumably by reducing the Km for NAD
+ (78). However, the detail mechanism of SIRT1 
activation via phosphorylation remains unclear. SIRT2 is phosphorylated at Ser331and Ser335 
within the C-terminal region by cyclin E-Cdk2, cyclin A-Cdk2, and p35-Cdk5 both in vitro and 
in cells (79). Phosphorylation of Ser331 is catalyzed by cyclin-dependent kinase and inhibits the 
activity of SIRT2, whereas the enzyme and effect of phosphorylation of Ser335 remain 
unknown. 
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1.4.2. Role of NAD+  
The catalytic activities of sirtuins are ascribed to be strictly regulated by the levels of 
intracellular co-substrate NAD+ and product nicotinamide. The unique catalytic consumption of 
NAD+ indicates that sirtuins might be sensitive to changes in intracellular NAD+ concentration. 
Generally speaking, decrease in the NAD+ level, that accompanies organismic aging, has been 
found to downregulate the sirtuin activity. On the other hand,  increase in NAD+ level that 
occurs during exercise, fasting, and caloric restriction, due to multiple ways of cellular 
regulations, can activate sirtuin activity (80). It has been suggested that increasing NAD+ 
synthesis through the NAD+ salvage pathway could increase sirtuin activity. For example, 
nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the formation of NMN by the 
addition of 5-phosphoribosylpyrophosphate to nicotinamide (81). NMN is then converted to 
NAD+ by NMN adenylyltransferase. Small molecules that inhibit NAMPT have been 
demonstrated to decrease SIRT2 activity, providing evidence that sirtuin activity could be 
regulated by changes in the cellular NAD+ concentration (82). Moreover, AMP activated kinase 
(AMPK), which is stimulated by decrease in the energy status, nutrient and oxygen deprivation, 
and increased energy expenditure, have been demonstrated to activate NAD+ synthesis through 
stimulated transcription of NAMPT (83).  
1.5. Physiological and Pathological Roles of Human Sirtuins 
There are seven homologous sirtuins in humans (SIRT1-SIRT7), most of which catalyze 
the deacetylation reactions. Sirtuins exhibit their functional roles both via “epigenetic” and 
“metabolic” regulatory pathways, which are manifested in promoting longevity by modulating 
cytoskeletal formation/rearrangement, stress factors, energy metabolism, DNA repair and 
silencing, inflammation, differentiation, among others. The biological functions SIRT isozymes 
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are different due to their subcellular localizations, expression pattern, binding partners, and 
substrate specificity in terms of recognizing and cleaving the acyl-moieties from their cognate 
protein surfaces. Due to their involvement in such diverse biological processes, sirtuins play 
important pathological roles, thereby becoming attractive targets for drug design. 
1.5.1. Cellular localizations of seven human sirtuins 
The functional diversification of seven human sirtuins is clearly illustrated by their 
different cellular locations and their ability to shuttle between organelles. Three of them, SIRT1, 
SIRT6 and SIRT7 mainly localize in the nucleus. SIRT2 is the only isozyme that mainly 
localizes to cytoplasm. Recent finding suggests that SIRT2 shuttles to the nucleus during certain 
conditions such as mitosis and bacterial infection (84, 85). SIRT3, SIRT4, and SIRT5 are 
mainly localized in mitochondria. The localization of SIRT3 has been debated (86-88). SIRT3 
is also found in the nucleus under normal condition (87). SIRT4 is exclusively located in 
mitochondria, whereas SIRT5 is present both mitochondrially and extramitochondrially (5, 89, 
90). 
1.5.2. Substrate specificity of sirtuins 
The number of reported sirtuin substrates is continually increasing in recent years (Table 
1.2). SIRT1, the most studied member of the sirtuin family so far, deacetylates more than 20 of 
histone and non-histone proteins, including, but not limited to, histone H1, H3, H4, p53, p300, 
PGC-1 and a number of transcriptional factors. SIRT2 also deacetylates histone H4 (H4K16) 
(91), p53, p300, and a number of other non-histone substrates, such as α-tubulin (92), p53, p300 
(93), CDH1 (94), CDC20 (94). SIRT3 deacetylates H3, H4, and a number of metabolic 
enzymes. No deacetylation substrate for SIRT4 has yet been found. However, SIRT4 has been 
reported to inhibit the activity of glutamate dehydrogenase (GDH) by ADP-ribosylation (71). 
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SIRT5 deacetylates, desuccinylates and deglutarylates carbamoyl phosphate synthase 1 (CPS1) 
(10, 11, 95); It also desuccinylates a number of other metabolic enzymes, including pyruvate 
dehydrogenase complex (PDC) and succinate dehydrogenase (SDH)(5). SIRT6 was recently 
found to deacetylate histone H3 and C-terminal-binding protein-interacting protein (CtIP) (96, 
97). The only substrate that has been explicitly identified for SIRT7 is H3 (H3K18)(98), while 
indirect evidence suggests that SIRT7 deacetylates p53 (99). A more detailed account of the 
roles sirtuins plays in the physiological system is reviewed in the next section. 
Although a thorough understanding of the protein substrate selectivity of sirtuins is 
lacking, recent structural and computational studies shed light on the peptide sequence 
preferences of sirtuins. Initial structural studies on sirtuins bound with non-native substrates 
revealed that the binding of acetyllysine peptide to sirtuins is dominated by the peptide 
backbone hydrogen bonding, forming an enzyme-substrate β sheet (β staple; Figure 1.5) (37). 
These findings suggested that sirtuins possess relatively little substrate specificity. Some other 
studies also supported this conclusion: peptide library screening and steady-state kinetic studies 
by Blander et al. indicated that SIRT1 had no substrate specificity (100); in vitro deacetylation 
assays using a variety of acetylated substrate by Khan et al. suggested that Hst2 employed 
conformational rather than sequence specificity for substrate recognition (101). However, other 
later studies led to different conclusions. Garske et al. investigated substrate specificity of 
SIRT1 using a one-bead, one-compound (OBOC) acetyl-peptide library followed by mass 
spectroscopy and in-solution deacetylase assay and found that SIRT1 displayed considerable 
preference for some substrate sequences (102). Structural studies of Sir2Tm bound with five 
different substrates suggested that the first residue N-terminal to the acetyllysine (position 1) 
and the second residue C-terminal to the acetlyllysine (position +2) are important for siruin 
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substrate binding (103). Rauh et al. used an acetylome peptide microarray to identify several 
sirtuin substrates and also characterized the substrate preferences of the human sirtuins by 
statistical analysis (104). Such unbiased methods are important for identifying the in vivo 
substrates of sirtuin isoforms, especially SIRT4 and SIRT7. 
Table 1.2. Selected Human Sirtuin Substrates 
 Histone Substrates Non-histone Substrates 
SIRT1 H1 (105), H3 (105), 
H4 (105) 
p53 (106), p300 (107), AceCS1 (108), 
PCG1-(109), Ku70 (110), FOXO 1 
(111) and 4 (112), NF-κB (113), Tat 
(114), CRTC2, CREB (115), etc. 
SIRT2 H4 (91) -tubulin (92), p53, p300 (93), CDH1 
(94), CDC20 (94), RIP1 
(116),PEPCK, CDK9 (117), etc. 
SIRT3 H3 (118), H4 (87) p53, AceCS2 (108, 119), GDH (120), 
Ku70 (121), SdhA (122), MnSOD 
(123), ALDH2 (124), CypD (125), 
LCAD (126), etc. 
SIRT4 N/A GDH (71) 
SIRT5 N/A CPS1 (95), PDC (5), SDH (5) 
SIRT6 H3 (96) CtIP (97, 127) 
SIRT7 H3 (98) p53 (99) 
N/A: No histone substrate has been identified for the corresponding enzyme. 
 
1.5.3. Physiological roles of human sirtuins 
In 2000, Sir2, the first sirtuin enzyme identified in budding yeast, was found to increase 
the life span of yeast (23). Since then more than 1000 peer-reviewed publications have shown 
the importance of sirtuin involved in promoting health span (128). Extensive studies cemented 
the roles of sirtuins in various biological processes, including transcriptional regulation, DNA 
repair, metabolism, aging, and cancer development.  
 34 
 
1.5.3.1. Transcription regulation 
In eukaryotic cells, the chromatin is composed of DNA and histone that pack together 
other via electrostatic interaction. Reversible acetylation is a common way to regulation gene 
expression by modulating the compact state of chromatin (129). Acetylation of lysine residues 
in histone tail neutralizes the positive charge and loosens the compact state of chromatin, 
making it accessible for gene transcription and protein expression. To the contrary, 
deacetylation of histone inhibits the gene transcription. Indeed, the histone deacetylase activity 
of sirtuins has been linked to transcription regulation both directly and indirectly (130).  
In mammals, except for SIRT4 and SIRT5, all other sirtuins (SIRT1-SIRT3, SIRT6 and 
SIRT7) have been reported to deacetylate histones (Table 1.2.). SIRT1 deacetylates H1, H3 
lysine and H4 lysine, with the preference for H4K16 (105). SIRT1 initiates gene repression 
through deacetylation of H4K16, recruitment of H1 and loss of methylated H3-K7. SIRT2 also 
deacetylates H3 and H4. SIRT3 and SIRT7 have been recently found to deacetylate H3K18 and 
promote transcriptional regression. 
Sirtuins also regulate transcription by acting on a number of transcriptional factors (p53, 
FOXO1, PGC1, etc.) which regulate a set of gene expressions that play important roles in 
biological functions, including DNA repair, metabolism and cancer. SIRT1 also deacetylates 
and activates the human  immunodeficiency virus (HIV) transactivator Tat, leading to the Tat-
mediated transactivation of HIV promoter (114).  
1.5.3.2. Metabolism 
Sirtuin activity is linked to multiple metabolic pathways for two reasons. First, sirtuin 
catalyzed reactions require NAD+, which is a cofactor of various enzymes involved in metabolic 
pathways in cells (131). Second, many substrates of sirtuins are themselves metabolic enzymes 
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(Table 1.2.) Indeed, sirtuins are involved in a number of different metabolic pathways, 
including lipid, glucose and glutamine metabolism, ketone body synthesis, and urea cycle. 
Specifically, most sirtuins play roles in regulating metabolism and energy homeostasis to help 
the cell adapt to low-energy conditions like fasting and CR environment (132).   
(a) Glucose metabolism 
Glucose is a primary resource for cell survival and proliferation, so its level is strictly 
regulated via a number of different biological processes. Sirtuins have been found to modulate 
some of these processes, including glycolysis, gluconeogenesis and insulin secretion (133). 
SIRT1 modulates both glycolysis and gluconeogenesis by regulating several important 
metabolic factors. PGC1 is a key regulator of mitochondria biogenesis in vertebrates (134). 
Activation of PGC1 by SIRT1 induces gluconeogetic genes and represses glycolytic genes 
during fasting, thereby inducing glucose production (134). On the other hand, Liu et al. 
demonstrated that in liver during late fasting, SIRT1 could also suppress glucose production by 
deacetylating CRTC2 and promoting its ubiquitin-dependent degradation (135). SIRT2, SIRT3 
and SIRT4 are also involved in regulating gluconeogenesis, which plays an important role when 
energy level is limited. SIRT2 deacetylates and stabilizes PEPCK, the rate-limiting enzyme of 
glucogenesis, to promote glucose production during fasting. SIRT3 and SIRT4 regulate the 
activity of GDH a mitochondria enzyme that converts glutamate to α-ketoglutamate in the TCA 
(tricarboxylic acid) cycle, in an opposite manner (71, 120). SIRT3 deacetylates GDH in vivo 
and the activity of GDH is found to be increased in the presence of SIRT3 in vitro, although the 
physiological role of GDH acetylation has not been conclusively established.  SRIT4 ADP-
ribosylates and inhibits GDH, leading to reduced insulin secretion in response to amino acids. 
SIRT5 has regulatory effects on glucose metabolism by desuccinylating and inhibiting pyruvate 
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dehydrogenase (PDH), succinate dehydrogenase (SDH), leading to decreased mitochondrial 
respiration in mouse liver and embryonic fibroblasts. Recently, SIRT6 is also found to assist 
maintain glucose homeostasis through deacetylation of histone H3K9 which control the 
expression of multiple glycolytic genes, such as PFK1 and GLUT1 (136). SIRT6 deficiency 
causes a pronounced increase in glucose uptake both in muscle and brown adipose tissues.  
(b) Lipid metabolism 
Lipid metabolism, compromising of lipids synthesis, storage and expenditure, is tightly 
regulated in the cells. The role SIRT1 plays in lipid metabolism is complicated.  It has been 
elegantly demonstrated that SIRT1 plays an important role in regulating lipid metabolism under 
extreme conditions, such as fasting or high fat diet. SIRT1 activation in high fat fed mice 
enhances fat oxidation and protects the mice against metabolic disorders (137, 138). 
Hepatocyte-specific deletion of SIRT1 increases susceptibility to body weight gain upon high 
fat feeding, while the whole-body SIRT1 knock out mice fed on high fat diet impairs 
glycerolipid/free fatty acid cycle (139, 140). It has also been suggested that SIRT1 inhibits lipid 
synthesis and simulates fatty-acid oxidation in response to fasting (141). SIRT1 deacetylates 
and activates PGC1α, which upregulates the expression of several enzymes involved in fatty 
acid oxidation, including medium chain acyl-CoA dehydrogenase (MCAD) and carnitine 
palmitoyltransferase-1a (CPT-1a) (109, 141). During fasting, SIRT1helps in maintaining the 
energy balance via sequential induction of CRTC2 and FOXO1(135). For example, it induces 
the expression of the rate-limiting lipolytic enzyme adipose triglyceride lipase (ATGL) via 
deacetylating FOXO1(142). SIRT1 also deacetylates and inhibits sterol regulatory element-
binding protein (SREBP), a transfactor that is a critical regulator of lipid and sterol homeostasis 
in eukaryotes, resulting in decreased expression of lipogenic genes, lipid synthesis and fat 
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storage (143, 144). The above studies seem to show clear evidence of SIRT1’s role in lipid 
metabolism. However, some studies yield contradictory conclusions. For example, Pfluger et al. 
showed that SIRT1-overexpressing mice were protected from hepatic steatosis under high-fat 
diet (145), while Qiang et al. found the opposite result, attributing the outcome to SIRT1 
inhibition of cAMP-responsive element-binding protein, a transcription factor that normally 
activates fatty acid metabolism and gluconeogenesis (115). Moreover, overexpression of SIRT1 
in the forebrain of female mice increased fat mass and increased expression of adipogenic genes 
in white adipose tissue, leading to increased fat accumulation and decreased physical activity 
(146). Based on these contradicted results, it has been proposed that SIRT1 mediated 
decomposition or adipogenesis may be tissue specific and dependent on expression the level of 
the enzyme (132).  
The expression of SIRT3 is upregulated during fasting in liver and brown adipose 
tissues. It has been demonstrated that SIRT3 deacetylates and activates long-chain acyl 
Coenzyme A dehydrogenase (LCAD) under fasting condition, leading to the upregulation of 
long-chain fatty acids oxidation (126). SIRT3-deficient mice exhibits reduced ATP levels and 
intolerance to cold exposure during fasting, suggesting that SIRT3 also plays an important role 
in regulation of fatty acid oxidation (147). By contrast, SIRT4 seems to negatively regulate 
fatty-acid oxidation in liver and muscle cells (148). SIRT6 is implicated in both lipid synthesis 
and fatty acid oxidation. Liver-specific deletion of SIRT6 in mice leads to reduced fatty-acid 
oxidation and triglyceride synthesis (149). 
(c) Other metabolism 
Sirtuins are also involved in other metabolism that specifically associates with fasting 
and limited nutrient supply. For example, SIRT3 upregulates the electron transport chain via 
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deacetylating succinate dehydrogenase A (SDHA) (150). During fasting, SIRT3 deacetylates 
and activates mitochondria 3-hydroxy-3-methylglutarl-CoA synthase 2(HMGCS2), the rate-
limiting enzyme in ketone body synthesis (151). It also deacetylates and stimulates ornithine 
transcarbamoylase (OTC), promoting the urea cycle during calorie restriction (CR). SIRT3 
knockout mice exhibits a failure to reduce orotic acid levels, a known outcome of OTC 
deficiency (152). SIRT5 deacetylates and activates CPS1, the rate-limiting enzyme of the urea 
cycle (95). As mentioned in the previous section, SIRT5 has recently been defined as a lysine 
demalonylase, desuccinylase and deglutarylase, and further studies suggest that the above 
activities are involved in the deacylation of CPS1 (10, 11).  
1.5.3.3. DNA repair 
Our cells are susceptible for environmental conditions which often lead to the DNA 
damages via single (SSB) and double-strand breaks (DSB). Eukaryotes have evolved to 
circumvent/repair DNA damage via four major pathways: (1) homologous recombination (HR), 
(2) non-homologous end joining (NHEJ), (3) base-excision repair (BER), and (4) nucleotide-
excision repair (NER). Studies in model organisms suggest that some members of sirtuin family 
(SIRT1-SIRT3, SIRT4 and SIRT6) play important roles in maintaining genomic integrity by 
regulating DNA repair (153, 154). Some of them regulate DNA repair factors directly via  their 
deacetylation, whereas the other influence DNA repair by preventing DNA damage indirectly 
via modulating the cell cycle and preventing oxidative stress (154).  
SIRT1 plays a pivotal role in DNA repair via regulating different pathways. SIRT1 null 
embryos exhibits impaired DNA damage response and reduced the ability to repair the DNA 
damage (155). It has been demonstrated that SIRT1 regulates a number of proteins important 
for HR repair, such as NBS (156), Rad51 (157), and the DSB sensing protein WRN (158). 
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SIRT1 regulates NHEJ via cooperative action with ataxia telangiectasia mutated (ATM) and 
HDAC1 in the neuronal DSB response (159). In postmitotic neurons, after being recruited to 
DSBs, SIRT1 stimulates the activity of ATM, which primes the cellular DSB signaling cascade 
for DNA repair. On the other hand, SIRT1 also deacetylates and stimulates HDAC1, which is 
crucial for DSB repair through NHEJ. SIRT1 also plays key roles in NER by deacetylating 
xeroderma pigmentosum group A and C (XPA and XPC) and recruiting them to the sites of 
DNA damage (160, 161).  
SIRT2 links to DNA repair mainly via its regulatory roles in cell cycle and replication 
stress response. During G2/M phase of mitosis, SIRT2 enters nuclei and deacetylates histone 
H4K16Ac (85), facilitating H4K20 methylation and regulating mitotic entrance (162). The loss 
of SIRT2 is associated with greater genome instability and DNA damage. The replication stress 
response is one of the DNA damage response (DDR) pathways that recognizes challenges to 
DNA replication and mobilizes diverse DNA repair and cell cycle checkpoint pathways (163). 
SIRT2 is found to promote the replication stress response by deacetylating and activating the 
activity of cyclin-dependent kinase 9 (CDK9) (117).  
The mitochondria sirtuins, SIRT3, 4 and 5 are not involved directly in DNA repair. 
However, their roles in regulating metabolism and preventing the accumulation of reactive 
oxygen species (ROS) enable them to regulate DNA repair indirectly. Failure to activate 
MnSOD by SIRT3 leads to high level of ROS (164). SIRT4 inhibits glutamine metabolism by 
deacacetylation induced inhibition of GDH, leading to the cell cycle arrest which provides 
sufficient time for cells to repair their DNA. Cells lacking SIRT4 continue to proliferate 
following the DNA damage and thus promoting genomic instability (165, 166). 
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Accumulative studies have demonstrated the role for SIRT6 in numerous DNA repair 
pathways, even before the discoveries of its substrates. SIRT6 knockout cells exhibit 
hypersensitivity to genotoxic agents and genomic instability (167). It has been demonstrated 
that SIRT6 is required to stabilize DNA-dependent protein kinase in response to induced DSB 
to promote NHEJ repair (168). Moreover, SIRT6 protects telomeric regions of chromatin by 
deacetylation of H3K9 and H3K56 (96, 169).  CtIP, which is recently identified as a SIRT6 
substrate, is a DNA damage response protein which facilitates the resection of DSBs and DNA 
repair by HR (97). SIRT6 ADP-ribosylates PARP, resulting in an enhanced DSB repair by both 
NHEJ and HR (170). SIRT6 promotes chromatin remodeling which also plays a crucial role in 
DSB repair (171).  
1.5.4. Pathological roles of human sirtuins 
Since sirtuins are involved in controlling multiple biological processes, especially in 
DNA repair and metabolism, it is not surprising that they are associated with a number of 
human diseases such as metabolic disorders, inflammation, type 2 diabetes, cardiovascular 
disease, Alzheimer’s disease, and cancers. Most of the above diseases are age-related, and they 
are intimately correlated with the sirtuin activities. For example, chronic inflammation impairs 
metabolic homeostasis, which in turn leads to the the pathogenesis of type 2 diabetes. The 
implication of sirtuins in various human diseases has led to the identification of sirtuins as 
potential therapeutic targets.   
1.5.4.1. Inflammation 
Inflammation is an important factor in the pathogenesis of several metabolic and age-
related degenerative diseases. Emerging studies have demonstrated that there is a close 
molecular coordination between different phases of inflammation and the energy metabolism 
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(172). Since sirtuins play regulatory roles in metabolism, it is not surprising that they are linked 
to inflammation. Indeed, SIRT1, SIRT2, SIRT3, and SIRT6 have shown anti-inflammation 
effect. 
Several studies have suggested that SIRT1 protects organisms against inflammation via 
inhibiting the effects of inflammatory factors, such as NF-κB and tumor necrosis factor TNF-
α(173, 174). NF-κB, which governs an ancient signaling pathway in insects and vertebrates, is 
the master regulator of innate immunity (175). NF-κB is a heterodimeric complex of p50 and 
p65 (RelA) and it controls several genes involved in inflammation, and its activity increase with 
age in many mammalian tissues and stem cells. The NF-κB signaling pathway in conjunction 
with  SIRT1 integrate energy metabolism to immune responses, contributing to the maintenance 
of cellular homeostasis (175). SIRT1 deacetylates the p65 subunit of NF-κB and inhibits its 
signaling pathway, which stimulate glycolytic energy flux during acute inflammation. 
Macrophages play an important role in initiating obesity-related tissue inflammatory responses 
(176). It has been demonstrated that SIRT1 represses the inflammatory pathway activity and 
release of TNFα from LPS-stimulated macrophages (174). Moreover, SIRT1 stimulates 
oxidative energy production via the activation of AMPK, PPARα and PGC1-α, which also 
inhibit NF-κB signaling and suppress inflammation. During inflammation, the transcription of 
SIRT1 is also suppressed by the pro-inflammatory cytokine IFN- (177), whereas SIRT1 
activator resveratrol restores this decline (178).  
NF-κB is also regulated by other sirtuins, including SIRT2 and SIRT6. SIRT2 
deacetylates NF-κB subunit p65 at Lys-310, leading to the suppression of NF-κB level and 
inflammation(179). In SIRT2 knock-out mouse embryonic fibroblasts, Lys310 of p65 
isacetylated, leading to an increased expression of NF-κB target genes. In mouse models, SIRT6 
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is found to bind to NF-κB subunit RelA and destabilize it via deacetylation of H3K9, possibly 
leading to anti-inflammatory features of SIRT1 and SIRT2 (180, 181).  Another study by Van 
Gool et al. suggests that TNF-α translation is enhanced by increased intracellular NAD+ in a 
SIRT6 dependent manner (182). However, the molecular mechanism underlying this opposite 
effect is not yet clear. Finally, SIRT7-deficient mice develop inflammatory cardiomyopathy, 
indicating that it also has an anti-inflammatory role (99). 
1.5.4.2. Cardiovascular disease 
Cardiovascular disease is one of the most life threatening diseases of human beings. 
SIRT1, SIRT3, SIRT6 and SIRT7 have been reported as regulators of cardiac hypertrophy 
(abnormal enlargement or thickening of heart muscle), which is one of the main causes of heart 
failure.  
Early studies demonstrated that SIRT1 play a protective role against cardiac hypertrophy 
by deacetylating and modulating p53 activity (ref). Recently, the protective role of SIRT1 has 
been extended to its ability to regulate fatty acid oxidation (as discussed in the previous section). 
Cardiac hypertrophy is accompanied by a metabolic shift to glycolysis and impaired fatty acid 
oxidation. Thus, SIRT1 alleviates cardiac hypertrophy by inhibiting glycolysis and promoting 
fatty acid oxidation. However, some other studies suggest that SIRT1 might play a detrimental 
role in cardiac function. For example, Kawashima et al. found that moderate overexpression of 
SIRT1 impaired cardiac diastolic function without causing heart failure in mice (183). 
Sundareen et al. demonstrated that the overexpression of SIRT1 in mice heart led to an 
increased phosphorylation and deacetylation of Akt and consequently caused cardiac 
hypertrophy, as well as increased the extent  of Akt deacetylation leading to  reduction in tumor 
development (184). Studies by Alcendor et al. might provide some explanation for such oppose 
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results. Their findings suggest that low (2.5 fold) to moderate (7.5 fold) overexpression of heart-
specific SIRT1attenuates age-dependent increases in cardiac hypertrophy and cardiac 
dysfunction, while high level (12.5 fold) of SIRT1 overexpression increases hypertrophy and 
decreases cardiac function (185). 
SIRT3 is involved in preventing cardiovascular diseases due to its mitochondrial 
localization and ability to regulate reactive oxygen species (ROS). SIRT3 deficient mice 
develop cardiac hypertrophy, whereas transgenic animals with overexpression of SIRT3 in the 
heart are protected against agonist-mediated cardiac hypertrophy (186). SIRT3 also deacetylates 
and activates LKB1, which in turn activates AMP-activated kinase, leading to the deactivation 
of Akt after its phosphorylation is suppressed (187). 
SIRT6 deficient mice exhibit cardiac hypertrophy and heart failure, whereas transgenic 
overexpression of SIRT6 in mice heart blocks agonist-induced hypertrophy, suggesting its 
importance in protecting organisms from cardiovascular disease. More interestingly, enhanced 
NAD+ biosynthesis via overexpression of nicotinamide mononucleotide adenylyltransferase 
(Nmnat2) blocks agonist-induced hypertrophy in neonatal rat cardiomyocytes, and the latter 
influence is due to  the activation of SIRT6(188).  It has been demonstrated that SIRT6 blocks 
IGF-Akt signaling pathway and development of cardiac hypertrophy by targeting c-Jun (189). 
Very recent studies suggest that SIRT6 attenuate phenylephrine-induced cardiomyocytes 
hypertrophy in cultured neonatal rat cardiomyocytes at least partially via regulation of the p300 
acetytransferase and subsequent suppression of NF-B (190). 
1.5.4.3. Alzheimer’s disease 
In the field of neurodegeneration, Resveratrol and SIRT1 have been proven to 
bebeneficial in vitro and in vivo models of Alzheimer’s disease by reducing amyloid-beta 
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protein accumulation. SIRT1 increases the level of α-secretase through activation of the α-
secretase gene ADAM10. Because α-secretase is the enzyme responsible for non-amyloidogenic 
cleavage of amyloid precursor protein (APP), up regulation of α-secretase shifts APP processing 
to reduce the pathological accumulation of the presumptive toxic amyloid β (138).  
1.5.4.4. Cancer 
All members of the sirtuin family have been involved in cancer. Since these enzymes are 
involved in a variety of different cellular functions, they have very complex and sometimes 
controversial roles in both promoting and/or suppressing tumorigenesis (191).  
All members of the sirtuin family have been involved in cancer. Since these enzymes are 
involved in a variety of different cellular functions, they have very complex and sometimes 
controversial roles in both promoting and/or suppressing tumorigenesis(191).  
The role of human SIRT1 in cancer is mostly debated. On one hand, SIRT1 plays an 
important role in DNA repair and genome integrity, thereby acting as a tumor suppressor to 
protect the cells from tumorigenesis. On the other hand, SIRT1 regulate DNA repair and 
promote cell survival with properties of oncogenes (192). It seems that the ability of SIRT1 to 
promote or suppress tumorigenesis is dependent on the specific tumor type, cellular context, and 
signaling pathway affected.  
The roles of the other sirtuins in cancer development have just started to emerge. SIRT2 
has been proposed to be a tumor suppressor protein due to its role in preventing chromosomal 
instability during mitosis. SIRT2-deficient mice develop gender-specific tumors. Females 
primarily develop mammary tumors, whereas males develop hepatocellular carcinomas (94). 
Mitochondrial sirtuins have been ascribed to play critical roles in cancer progression via 
metabolic reprogramming. Indeed, SIRT3 expression is down-regulated in human breast 
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cancers, and SIRT3 knock-out mice have a higher incidence of mammary tumors (193). SIRT6 
has been recently demonstrated as a tumor suppressor that regulates cancer metabolism (194). 
SIRT6 expression is down-regulated in human pancreatic and colorectal cancers, and Sirt6 
deletion promotes intestinal tumorigenesis in vivo. Finally, SIRT7 depletion has been reported 
to reduce tumorigenesis  of cancer cells, suggesting that SIRT7 may have oncogenic properties 
in cancer development (98). 
1.5.4.5. Calorie restriction, aging, and lifespan extension 
Calorie restriction (CR) is the most robust environmental intervention that attenuates 
aging and increases life span in many species. The correlation between calorie restriction (CR) 
and lifespan extension was first discovered by McCay et al. in 1935 on  rodents (195). 
Subsequently,  such lifespan extension effect has also been observed in other species, including 
yeast, fruit flies, fish, rats, mice and even primates (196-198). Extensive studies have led to the 
suggestion that lifespan extension and health benefits of caloric restriction are mediated by 
pathways involving sirtuins. Sir2, the first sirtuin enzyme identified in budding yeast, was found 
to increase the life span of yeast (23). Similar results found in fruit flies and mice provided 
evidence that the associated gene products (sirtuins) were responsible for promoting longevity, 
and these findings created enormous interest on anti-aging research. A number of independent 
studies provide evidences that CR dependent life extension requires the presence of sirtuins 
(199). First, a lot of protein substrates targeted by sirtuins (Table 1.2.) are involved in 
metabolism and pathways induced by CR. Second, the expression levels of several sirtuins 
could be elevated by CR. Third, knockout of sirtuins diminished CR effect on lifespan extestion. 
Mostoslavsky et al observed genomic instability and aging-like phenotypes in the absence of 
mammalian SIRT6 (167). Fourth, elevation of sirtuins, either by overexpression of sirtuins or by 
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sirtuin activating compounds (STACs), protects organisms from non CR diet. Kanfi et al. 
reported that SIRT6 regulates lifespan in male mice (200). In recent past there has been a 
controversy whether lifespan expansion has been due to activation and/or overexpression of 
sirtuins (201). But such controversy has been fading way in the light of new experimental 
evidence (199, 202). However, the molecular basis of sirtuin and/or CR mediated enhancement 
in longevity and attenuation of age related diseases still remain to be fully elucidated. 
1.6. Activators of Sirtuins 
As mentioned in the previous section, sirtuins play positive role in DNA repair, cell 
survival, inflammation, metabolism and ultimately, aging. Therefore, members of sirtuin family 
are considered as attractive therapeutical targets for treating age-related diseases, such as 
metabolic disorders, inflammatory disorders, and Alzheimer’s disease. Circumstantial evidence 
that one of ingredients of red wine, resveratrol, activates sirtuins as well as elicits health 
benefits, the link between sirtuin activation, human health and longevity, and calorie restriction 
was anticipated, which initiated studies on designing sirtuin activators as anti-aging drugs.  
1.6.1. Sirtuin activators and their physiological effects 
The first potent sirtuin activating compounds (STACs) were identified in a high-
throughput screening using SIRT1(203). Among these native activators identified, resveratrol 
(3,5,4’-trihydroxy-trans-stilbene ) exhibited  the maxium potency in enhancing the SIRT1-
mediated deacetylation of  AMC-conjugated fluorogenic substrate. Subsequently, several 
synthetic STACs were identified by tetramethylrhodamine-based (TAMRA-based) fluorescence 
polarization assay of SIRT1, and such results were verified by the mass spectrometric analysis 
(204, 205).  
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Resveratrol is a naturally occurring phytoalexin synthesized by certain plants in 
response to injury or fungal attack. Acting as an antioxidant, it has been linked to a variety of 
health benefits in humans and rodent, such as prevention of human cardiovascular diseases(206). 
Importantly, it has been demonstrated that resveratrol and other STACs extend the lifespan of 
numerous organisms including yeasts, worms, fish and bees (203, 207-209). Resveratrol also 
prevents the deleterious effects in mice fed with high-fat diet (HFD), including fatty liver, 
insulin resistance, and inflammation. STACs also increased the lifespan of HFD mice compared 
to controls. Many of the above preventative effects overlap those triggered by overexpression of 
SIRT1 or by CR diet and numerous reports have shown that the STACs effects are dependent 
on the presence of SIRT1. For example, SIRT1-null mice develop skin tumors at normal rate 
even in the presence of resveratrol (210). SIRT1 is also required for the beneficial effects of 
resveratrol on mitochondrial biogenesis and function (211). Similarly, the synthetic compound 
SRT1720 improves metabolism and extends both mean and maximum lifespan of mice fed with 
high-fat diet, but does not show the effects on SIRT1 knockout mice (212).  
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Figure 1.14. Structures of SIRT1-activating compounds (STACs). Figure is adapted from 
reference (213). 
 
1.6.2. Controversy over the STACs 
Although several biological effects of STACs have been studied and verified, the 
legitimacy of STACs as direct SIRT1 activators has been widely debated, mainly due to the 
nature of the fluorescent assays. It has been suggested that STACs increased SIRT1 activity in 
the presence of fluorophore-tagged substrates but not with  untagged peptide substrates, leading 
to the suggestion that SIRT1 activation is  an in vitro artifact of the assay system (214, 215). In 
the meantime, a series of studies have revealed that resveratrol directly targets other proteins 
instead of SIRT1 in vivo, but consequently indirectly upregulates SIRT1 to elicit its 
physiological effects. For example, Dasgupta et al. demonstrated that resveratrol activates 
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AMPK, which enhances the SIRT1 activity by activating the gene encoding the NAD+ synthetic 
enzyme,  nicotinamide phosphoribosyltransferase (NAMPT) (216).  
Recently, the legitimacy of STACs as direct SIRT1 activators has received renewed 
support the fluorophoric moieties of the substrates  mimic the  requirement of aromatic amino 
acids which must present at the deacetylation site for efficient catalysis by the enzyme (217). 
The biochemical studies of  Dai et al. suggest that the fluorescent moiety of the substrates is 
dispensable for activation if replaced by hydrophobic amino acids, such as Phe and Trp (205). 
The latter study further demonstrated that certain synthetic STACs interact directly with SIRT1 
and activate the deacetylation reaction by an allosteric mechanism. Another study identified two 
native peptide substrates (PGC1-α and FOXO3a),  containing hydrophobic residues at the +1 
and +6 positions relative to the acetylated lysine, in the presence of which SIRT1 showed  
activation by resveratrol and other synthetic STACs (218). It was further demonstrated that the 
amino acid Glu230, located in the N-terminal domain of SIRT1, is critical for SIRT1 activation 
(55); SIRT1 E230K mutation blocks both STAC binding and activation of SIRT1. In SIRT1 
knockout myoblasts with mouse SIRT1-E222K mutation (the murine equivalent of human 
SIRT1-E230K), the ability of STACs in increasing the mitochondrial mass, ATP concentration, 
and the mitochondrial DNA copy number has been found to be blocked. The mechanism for the 
role of E230 in the activation of SIRT1 has not been demonstrated. It has been proposed  that 
E230K impairs the coupling between STAC and substrate due to electrostatic interaction 
between E230 and the positively charged residue (R446) in the catalytic domain of the substrate 
(55). 
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1.6.3. Other sirtuin activators 
Besides small molecule STACs, two endogenous protein activators of SIRT1 have been 
discovered in mammals, namely AROS (active regulator of SIRT1) and lamin A (219, 220). 
AROS was identified as a direct regulator of SIRT1 by yeast two-hybrid screening (219). It 
enhances the deacetylation of p53 by SIRT1, leading to the repression of p53-mediated 
transcriptional activity. Lamin A, a major component of the nuclear matrix, was also found to 
interact with recombinant SIRT1 and activate it under in vitro condition.  More interestingly, 
resveratrol activates SIRT1 toward the native substrate p53 by enhancing the binding SIRT1 to 
lamin A (220). Ghosh et al. demonstrated that resveratrol activates SIRT1 by increasing its 
binding with lamin A, adding heat to the debate over the role of resveratrol in SIRT1 activation 
(221). 
Isonicotinamide has been reported to serve as an activator of yeast sir2 both under in 
vitro and in vivo conditions, and the origin of its activating effect has been ascribed to the 
alleviation of the nicotinamide assisted reverse (base-exchange) reaction (222). However, the 
effective iNAM concentration needs to be at the millimolar range in the cell, limiting its 
pharmacological value.  
In summary, STACs have anti-aging, anti-carcinogenic, anti-inflammatory properties 
that could be useful for treating or preventing age-related diseases. Currently, resveratrol and 
the other synthetic STACs are in clinical trials for evaluation of their pharmacokinetics, safety 
and toxicity (223-225). Although the previous progress seems promising, many questions 
regarding the mechanism of activation both in vitro and in vivo remain to be addressed. 
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1.7. Inhibitors of Sirtuins 
While focus on activation of sirtuins has traditionally been dominating the drug 
discovery efforts in the field, the ability to inhibit these enzymes will still be important to clarify 
the roles of sirtuins as either antitumor targets or tumor suppressors. Concurrently, a number of 
small molecule sirtuin inhibitors have been developed either through the high throughput 
screening or via the mechanism-based design. 
1.7.1. Mechanism-based sirtuin inhibitors 
Sirtuins possess a unique catalytic mechanism which couples NAD+ hydrolysis to 
deacetylation of the protein substrates. This unique mechanism has been utilized for the 
mechanism-based design and synthesis of sirtuin inhibitors. Several studies have employed 
acetyl-lysine analogs to probe the mechanistic differences among protein deacetylases (both 
sirtuins and HDACs). This work has led to the identification of thioacetyl lysine and trifluoro-
acetyl lysine containing peptides as potent sirtuin inhibitors. 
1.7.1.1. Nicotinamide  
Nicotinamide is the product of sirtuin catalyzed reaction and also works as the 
physiological inhibitor of sirtuins. It has been proposed that the inhibition of several isoforms of 
sirtuins by nicotinamide is  manifested via the “base-exchange” mechanism (i.e., the reversal of 
the step involved in the formation of nicotinamide during the enzyme catalysis; see Figure 1.15), 
and such event gives rise to the noncompetitive inhibition of sirtuins  (68, 226, 227). It inhibits 
SIRT5’s desuccinylase activity (IC50 = 21 ± 4 µM), but is insensitive toward SIRT5’s 
deacetylase activity (228). Recently it has been proposed that with certain sirtuins (e.g., mouse 
SIRT2 and human SIRT3)  the nicotinamide inhibition is mixed type with increasing 
component of the competitive inhibition (229). 
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1.7.1.2. Carbanicotinamide adenine dinucleotide (carba-NAD+) 
The NAD+ analog carba-NAD+ (1 and 2 in Figure 1.16), in which a 2,3-
dihydroxyclclopentane ring replaces the -D-ribotide ring of the nicotinamide riboside moiety 
of NAD+, and its diastereoisomer pseudocarba-NAD+ were designed as inhibitors of enzymes 
that involved in ADP-ribosyl transfer, namely, NAD+ glycohydrolases and ADP-ribosyl 
transferases (230). In these compounds, the structure of the dinucleotide is modified to prevent 
the cleavage of the glycosidic bond. Since sirtuin catalyzed deacylation reaction involves such 
cleavage, these NAD+ analogs served the competive inhibitors against  NAD+ (39). The X-ray 
crystal structures of several sirtuins bound with substrates and carba-NAD+ have provided the 
structural basis of ligand binding and catalysis in sirtuins (39, 231). 
1.7.1.3. Thioacetyllysine peptides 
Several studies have employed acetyl-lysine analogs to probe the mechanistic 
differences among protein deacetylases (both sirtuins and HDACs). This work has led to the 
identification of thioacetyl lysine and trifluoro-acetyl lysine containing peptides as potent 
inhibitors. It has been proposed that the thioacetyl analogs follow the same reaction coordinate 
as their acetyl counterparts but the former analog  is trapped at the thioimidate intermediate 
stage after the glycosidic bond cleavage and the acetyl group transfer step (Figure 1.9) (66). 
Thioacetyllysine derived from human acetyl-coenzyme A synthetase 2 inhibits SIRT1 with an 
IC50 value of 0.9 M (232). A thioacetyllysine peptide derived from H3 histone exhibits potent 
inhibition of SIRT1, SRIT2, SIRT3 and Hst2 with IC50 values of 2.0, 5.6, 2.3, and 1.02 M, 
respectively (66). The most potent compound derived from p53 (Figure 1.14) inhibits SIRT1 
with an IC50 of 180 nM and 20-fold selectivity over SIRT2 (233). Fluoroacetyllysine peptides 
also inhibit sirtuin activity by competing against acetyllysine peptide substrate, but less potently 
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than thioacetyllyinse peptide (66). Trifluoroacetyllysine peptide dervided from H3 inhibits Hst2 
with an IC50 value of 61 M. Similarly, since SIRT5 uses the same mechanism as the 
deacetylases to remove malonyl and succinyl groups, thiosuccinyl and thiomalonyl peptides 
could be mechanism-based, and isoform selective inhibitors for SIRT5. He et al. synthesized a 
H3K9 thiosuccinyl peptide, KGTAR(SuK)STGGKA, which competes against the peptide 
substrate and selectively inhibits SIRT5 with an IC50 value of 5 µM (234). Such inhibitors are 
expected to serve as valuable tools for investing the dsuccinylation/dmalonylation reactions of 
physiological substrates. 
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Figure 1.15. Mechanism-based sirtuin inhibitors. 
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1.7.2. Sirtuins inhibitors discovered through high-throughput screening 
High-throughput screening is a common and robust approach in drug discovery. A 
variety of sirtuins inhibitors have been discovered by high-throughput screening, including 
suramin derivatives (34), indole, sirtinol, cambinol, indoles, splitomicin and thiobarbiturates. Of 
these inhibitors identified, suramin and indole derivatives have been crystalized with selected 
suirtuins and their structures have been solved. The structural data have provided insights into 
the binding and inhibitory mechanisms of sirtuins. 
1.7.2.1. Suramin and analogs 
Suramin, a polysulfonated naphylurea compound (8,8′-[carbonylbis [imino-3,1-
phenylenecarbonylimino (4-methyl-3,1-phenylene) carbonylimino] bis-1,3,5-
naphtalenetrisulfonic acid hexasodium salt), was one of the oldest synthetic therapeutics and has 
been used clinically for the treatment of African trypanosomiasis and onchocerciasis since 1920. 
Later on, it has also shown several other therapeutic potentials such as treatment of several 
cancers and the inhibition of HIV infection, presumable as result of its inhibition of growth 
factor/receptor interactions, inhibition of angiogenesis, and inhibition and activation of protein-
tyrosine phosphatases (235-237). It was discovered as SIRT1/SIRT2 inhibitors via a large scale 
screening for sirtuin activators (203). The binding affinity (Kd) determined from isothermal 
titration calorimetry is 5.5 µM, whereas the IC50 value is 22 µM. Crystallization data suggest 
that suramin binds to the NAD+ binding pocket B, C and the peptide-binding site of SIRT5, 
thereby has been assumed of competing with both the peptide subtrates and the cosubstrate 
NAD+ (34). In the crystal structure of the SIRT5-suramin complex, the binding of the 
symmetric suramin bridges two SIRT5 molecules together to form a dimer (Figure 1.16). More 
interestingly, in the active pocket, Y102 and R105, which are responsible for SIRT5’s unique 
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desuccinylase activity, formed hydrogen bonds with the trisulfonylnaphyl groups of suramin. 
But whether this unique binding pattern correlates to the inhibition mechanism has not been 
studied. Although suramin has been demonstrated as regulators in diverse pathways and 
exhibits side effect during clinical trials, a comprehensive understanding of its binding and 
inhibition mechanism on sirtuins will still provide important information for understanding the 
mechanism of sirtuin catalysis, and could be used as a lead chemical compound for designing 
more potent and selective inhibitors of sirtuins. Trapp et al. developed several suramin analogs 
and performed structure-activity studies and developed several suramin analogs as selective 
SIRT1 and SIRT2 inhibitors with nanomolar potency (238). The aminoanthranilic acid 
derivative NF675 (7 in Figure 1.17) inhibits SIRT1 with an IC50 of 93 nM and displays 24-fold 
higher selectivity for SIRT1 over SIRT2. 
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Figure 1.16. Overall structure of the SIRT5 suramin complex. Two monomers (pink and yellow) 
are linked by one molecule of suramin 
 
1.7.2.2. Indole derivatives 
Indole-based SIRT1 inhibitors were also discovered by in vitro HST screening(239). 
EX527 (6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide; 9 in Figure 1.17.) is one of 
few compounds for which both initial mechanistic and structural data are available and that 
combine high inhibitory potency with significant isoform selectivity (239). EX527 inhibits 
SIRT1 with an  IC50 value of 120 nM and displays around 100-fold selectivity over SIRT2 and 
SIRT3, but shows  no effect on either  deacetylase or desuccinylase activities of SIRT5 (45). 
Kinetic analysis revealed noncompetitive inhibition against peptide substrate, and 
uncompetitive inhibition of deacetylation with respect to NAD+, suggesting that EX527 binds to 
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the enzyme after the binding of NAD+(45). Crystal structure of SIRT1/NAD+/EX527 analog (10) 
complex suggests that binds deep in the catalytic cleft, displacing the NAD+ nicotinamide and 
forcing the cofactor into an extended conformation which seems to sterically prevent substrate 
binding(44). However, a more recent structural study on several sirtuin inhibitor complexes 
suggests that EX527 could also bind to the enzyme-intermediate and enzyme-product 
complexes (45). These crystal structures show that EX527 occupies the nicotinamide biding site 
and a neighboring pocket and contacts the ribose of NAD+ or of the coproduct 2’-O-AADPr. 
Kinetic data also suggest that sirtuin intermediate can exist for seconds, allowing the 
nicotinamide cleavage and EX527 binding. Complex structures with native alkylimidate and 
thio-analog suggest steric incompatibility between inhibitor and intermediate. Based on the 
above information, the authors conclude that EX527 stabilizes the closed enzyme conformation 
to prevent product release. A possible explanation about the discrepancy between these two 
studies could be that EX527 inhibits SIRT1 in multiple ways. It could bind to the active pocket 
with NAD+ to stabilize the non-active conformation of the enzyme, preventing the binding of 
peptide substrate, while it could bind to the active Michaelis-Mention complex but prevent the 
release of product. Detailed mechanistic studies are crucial to resolve this controversy. 
1.7.2.3. Other inhibitors 
Other high-thoughput screening assays have identified a number of compounds that 
display low M to nM potency, including but not limited to sirtinol, cambinol, and 
triobarbiturates. Recently some analogues based on the structural frameworks of these inhibitors 
showed improved potency. 
 Sirtinol (11) was discovered through forward chemical genetics, cell-based phenotypic 
screening of 1600 unbiased compounds (240). It inhibits yeast Sir2p, SIRT1 and SIRT2 with 
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IC50 values of 66, 131, and 38 M, respectively. Structure-activity relationship analysis 
suggests that the hydroxyl-napthaldehyde moiety is necessary and sufficient for inhibitory 
activity (240). A series of sirtinol analogues were assayed against yeast Sir2, SIRT1 and SIRT2, 
among which para-sirtinol (11, Figure 1.17) showed 10-fold more potency than sirtinol against 
SIRT1 and SIRT2(241).  
Cambinol (13 in Figure 1.18) exhibits micromolar potency against SIRT1 and SIRT2, 
but is insensitive against SIRT3 and SIRT5 (242, 243). Steady-state kinetic studies demonstrate 
that cambinol is competitive with histone H4 peptide substrate and noncompetitive with NAD+. 
Docking analysis using SIRT2 crystal structure suggests that the binding is stabilized by - 
stacking interactions between the -naphthol and two aromatic residues in the C pocket of the 
enzyme (244). The N1-substituents show increase in both activity and selectivity against SIRT2 
with IC50 values ranging from 1 (14 in Figure 1.18) to 22 M (244). Antitumor activity of 
cambinol has been observed in lung cancer cells and Hela cells as a result of hyperacetylation of 
key stress response proteins (p53, Ku70, FOXO3a and -tubulin) and cell cycle arrest (242).  
Thiobarbiturates were discovered as potential sirtuin inhibitors through a virtual 
screening of approximately 328,000 compounds (245). The most potent compound 15 inhibits 
SIRT1 and SIRT2 with IC50 values of 13.2 and 9.1 M, respectively. Based on molecular 
dynamic simulation data, several novel thiobarbiturates with modified hydrophobic substituents 
were synthesized. For example, biphenyl derivative 16 shows selectivity on SIRT2 with an 
IC50 value of 8.7 M, while indole derivative 17 has SIRT1 selectivity with an IC50 of 5.9 M 
(245). Recently a series of thiobarbiturates were identified as SIRT5 inhibitors in the low 
micromolar range and are selective over SIRT3 (243). Compound 18 inhibits SIRT5 with an 
IC50 value of 2.3 M. 
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Splitomicin (19) was discovered as yeast Sir2 and Hst1 inhibitor through a yeast cell-
based screening for inhibition of sirtuin-mediated telomeric silencing (246). Structure-activity 
studies on splitomicin derivatives suggest that the acetyllysine binding pocket is the site of 
interaction between splitomicin and Sir2, and structural differences in this hydrophobic cleft 
were accounted for inhibitor selectivity (247). Splitomicin derivative HR73 (20) has been 
identified as effective inhibitor of human SIRT1 with an IC50 value of 5 M. Elevated level of 
acetylation of p53 and suppression of HIV transcription were observed upon treatment of H473 
in vivo (114). 
In summary, a variety of small molecule inhibitors for sirtuins have been identified, 
some of which have been tested in physiological systems. However, identification of sirtuin 
isoform selective inhibitors still remains bottleneck for structural-functional studies of sirtuin 
enzymes. X-ray crystallographic studies with sirtuins and the above inhibitors will be beneficial 
for understanding the inhibition mechanism and designing of more potent inhibitors. 
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Figure 1.17. Sirtuin inhibitors discovered through high-throughput screening (suramin and 
indole analogs). 
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Figure 1.18. Sirtuin inhibitors discovered through high-throughput screening (continued, other 
inhibitors). 
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Table 1.3. Summary of representative sirtuin inhibitorsa 
Inhibitor IC50 (µM) Reference 
SIRT1 SIRT2 SIRT3 SIRT5 Others 
1 (carba-NAD+) NAb NA NA NA 300 (Hst2) (39) 
2 (pseudocarba-NAD+) NA NA NA NA NA (39) 
3 (nicotinamide) 25 100 30 21 130 (Hst2) (228) 
4 (thioacetyl peptides) 0.18-2.0 3.6-5.6 2 NA 1.02 
(Hst2) 
(66, 232, 
233) 
5 (trifluoroacetyl 
peptide) 
NA NA NA NA 61 (Hst2) (66) 
6 (thiosuccinyl 
peptides) 
NA NA NA 5-100c  (248) 
7 (suramin) 0.297 1.15 NA 22  NA (238, 249) 
8 (NF675) 0.093 2.26 NA NA NA (238) 
9 (EX-527) 0.098 19.6 48.7 NA NA (239) 
10 (EX-527 analogue) 0.124 277 >100d NA NA (239) 
11(sirtinol) 37-131 38-58 24% at 
50 M 
48.9 NA (249) 
12  13 25.9 NA NA NA (241) 
13 (cambinol) 56 59 NA 42.5c NA (249) 
14 16.9 1 NA NA NA (244) 
15  13.2  9.1  NA NA NA (245) 
16 50.5 8.7 NA NA NA (245) 
17 5.9 20.3 NA NA NA (245) 
18 5.3 9.7 41%  at 
50 M 
2.3c NA (243) 
19 (splitomicin) NA NA NA NA 86 (sir2p) (246) 
20 (HR73) 5 NA NA NA NA (247) 
a The schematic structures of the inhibitors in the table are presented in Figures 1.18 to 1.20. 
b Data is not available 
c Result was obtained by testing SIRT5 desuccinylase activity 
d No inhibition at 100 M 
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2. STATEMENT OF PROBLEM 
Sirtuins are emerging as the key regulators of metabolism and aging, and their potential 
activators and inhibitors are being explored as therapeutics for improving health and treating 
diseases. However, there has been limited success in identifying highly potent sirtuin isoform 
selective activators and inhibitors. Despite the global structural-functional similarity among 
different isoforms of sirtuins, there are noticeable differences in their catalytic as well as 
modulatory features, which have not been elucidated at the molecular level. The goal of this 
dissertation is to contribute to the effort in comprehending mechanistic aspects of the SIRT1 and 
SIRT5 catalyzed reactions to facilitate designing isozyme selective activators and inhibitors as 
potential drugs. In particular, the investigation was carried out with the following four specific 
aims: 
1. To discover novel inhibitors for sirtuins via  high-throughput screening of the 
in-house library of small molecules 
2. To determine the contributions of two critical amino acid residues, namely 
Y102 and R105 in SIRT5 (vis a vis the corresponding residues of  SIRT1) on 
substrate selectivity and inhibition of the enzymes 
3.  To elucidate the ligand and mutation induced changes in the structural 
features of SIRT1 and SIRT5 variants.  
4. To investigate the steady-state and transient kinetics as well as 
thermodynamics for the ligand binding to SIRT1 and SIRT5 isozymes.
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3. MATERIALS 
The plasmid containing the coding sequence of human SIRT1 (pCMV-SPORT6) and 
SIRT5 (pCMV-SPORT6) was obtained from Open Biosystems (Huntsville, AL). The ligation 
independent cloning (LIC) compatible E. coli expression vector pLIC-His was a kind gift from 
Dr. Stephen P. Bottomley (Monash University, Australia). The primers used for subcloning 
SIRT1, SIRT2, SIRT5 as well as site-directed mutagenesis of SIRT5 were synthesized by 
Integrated DNA Technologies (Coralville, IA). SacII restriction endonuclease and T4 DNA 
polymerase were obtained from New England Biolabs (Ipswich, MA). QuikChange II site-
directed mutagenesis kit was purchased from Agilent Technologies (Santa Clara, CA). 
Polycarbonate membrane filters and syringe filtration devices were from Pall Life Sciences (Ann 
Arbor, MI). Dialysis membranes were from Spectrum Laboratories, Inc. (Rancho Dominguez, 
CA). 40% polyacrylamide solution, Bradford reagent and protein standards were purchased from 
BioRad (Hercules, CA). Suramin, Fluor-de-Lys® (KI-104), deacetylated lysine-coumarin adduct 
(BML-KI142) and Met-7-aminio-4-methylcoumarin, were purchased from Enzo Life Sciences 
Inc (Plymouth Meeting, PA). Trypsin from bovine pancreas, bovine serum albumin (BSA), 
ammonium per sulfate, 2-mecaptoethenol, imidazole, magnesium chloride, nicotinamide and 
isonicotinamide were purchased from Sigma (St. Louis, MO). EX527 was purchased from 
Cayman Chemical Company (Ann Arbor, MI). The succinylated substrate (Ac-SucLys-AMC) 
was synthesized following the protocol described by Andreas et al (250). 
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4. METHODS 
4.1. Cloning, Expression and Purification of Recombinant Human Sirtuin Isoforms 
4.1.1. Sub-cloning of human SIRT1 and SIRT5 
SIRT1 (193-747) and SIRT5 (51-301) were cloned into the pLIC-His expression vector 
provided by Dr. Stephen Bottomley and the overall process was accomplished via the ligation 
independent cloning methods as described by Cabrita et al.(251). The LIC vector has been 
designed to overexpress the recombinant protein under the control of the T7 promoter system. As 
shown in Figure 4.1, the vector encodes a hexa-histidine peptide followed by a TEV (Tobacco 
Etch Virus) protease recognition sequence and an LIC site. The clones containing the coding 
sequence of human SIRT1 (clone ID: 4518906; accession number: BC012449) and SIRT5 (clone 
ID: 3352592; accession number: BC000126) was obtained from Open Biosystems (Huntsville, 
AL) as live cultures. The plasmids DNA were extracted using QIAprep® miniprep DNA isolation 
kit and used as templates for the cloning. SIRT1 sequence (193-747) was amplified by PCR 
using the oligonucleotides 5’-CCAGGGAGCAGCCTCGATGATTGGCACAGATCCTCGA-3’ 
and 5’-GCAAAGCACCGGCCTCGTTATGATTTGTTTGATGGATAGTTCATGTC-3’ as the 
forward and reverse primers, respectively. The reagents used for 50 µL of PCR reaction were as 
follows: 5 µL of 10X cloned Pfu DNA polymerase buffer, 1.25 µL of dNTPs mixture 
(containing 10 mM of each dNTP), 1.0 µL of template (50-100 ng/µL), 2 µL of the primer mix 
(containing 250 ng/µL of each primer), 1.5 µL of cloned Pfu DNA polymerase and 5 µL glycerol.  
The PCR was performed on the MiniCycler ™ (MJ research) for 25 cycles under the following 
experimental conditions: initial denaturation at 94 °C for 50 sec, denaturation at 94 °C for 45 sec, 
annealing at 61 °C for 50 sec, extension at 72 °C for 90 sec. The PCR amplified DNA was gel 
purified using QIAquick gel extraction kit and treated with T4 DNA polymerase (1U/0.1 pmol) 
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and 2.5 mM dATP at 22 °C for 1 hour, followed by heat inactivation at 72 °C for 20 min. The 
pLIC vector was similarly treated but with 2.5 mM dTTP. To anneal the vector with the 
amplified DNA, 2 µL of the vector was mixed with 4 µL of the PCR product. The reaction 
mixture was incubated for one hour at 22 0C, and then stopped by the addition of 1 µL of 25 mM 
EDTA solution in water, pH 8.0 (adjusted with NaOH).   The annealed vector was transformed 
into DH5 competent cells using standard molecular biology protocol. The cells were plated on 
LB (Luria Bertani) agar plates containing 0.1 mg/mL ampicillin and the plasmids DNA was 
extracted from the resulting colonies using QIAprep® miniprep DNA isolation kit.  
SIRT5 (encoding 51-301) was amplified by PCR using the oligonucleotides 5’-
CCAGGGAGCAGCCTCGGCTCGGCCAAGTTCAAGTATGGC-3’ and 5’-
GCAAAGCACCGGCCTCGTTAGGCAAGGGCTTCAGGAGTCG-3’ as forward and reverse 
primers respectively. The cloning procedure was the same as that of SIRT1.  
The clones containing SIRT1 and SIRT5 genes in the pLIC-His vectors were confirmed 
by sequencing of the resulting plasmid (Mclab, San Francisco, CA). 
 
 68 
 
 
Figure 4.1. The ligation independent cloning strategy for the sub-cloning of the human SIRT1 
and SIRT5 gene. The LIC compatible primers were used to amplify the SIRT1/SIRT5 gene. The 
PCR product was treated with the T4 DNA polymerase in the presence of dATP. The pLIC –His 
vector was digested with the SacII restriction enzyme prior to the T4 DNA polymerase treatment 
in the presence of dTTP. The T4 treatment of the PCR product, as well as the digested vector, in 
the presence of the respective dNTP generated the cohesive ends which could anneal with each 
other on mixing. The annealed product was transformed into DH5α E. coli cells. The nicks left in 
the recombinant plasmids were sealed by bacterial DNA ligase. TEV protease could be used to 
remove the His-tag from the fusion proteins, leaving the four extra amino acids (GAAS) at the 
N-terminal of the recombinant protein. Figure is adapted from reference (251). 
 
4.1.2. Site-directed mutagenesis of SIRT5 
The wild type SIRT5 plasmid was used as a template for the site-directed mutagenesis, 
using the QuikChange II site-directed mutagenesis kit (Agilent Technologies) to create three 
SIRT5 mutants, Y102A, R105I and Y102A/R105I.  
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The forward and reverse primers for creating the three mutants are listed as follows: 
SIRT5 Y102A  
Forward: 5’-GGGTGTGGGAGTTCGCCCACTACCGGCGGG-3’ 
Reverse: 5’-CCCGCCGGTAGTGGGCGAACTCCCACACCC-3’ 
SIRT5 R105I  
Forward: 5’-GGGAGTTCTACCACTACATTCGGGAGGTCATGGGGAG-3’  
Revers: 5’-CTCCCCATGACCTCCCGAATGTAGTGGTAGAACTCCC-3’.  
SIRT5 Y102A/R105I  
Forward: 5’-CCGGGTGTGGGAGTTCGCCCACTACATTCGGGAG-3’ 
Reverse 5’-CTCCCGAATGTAGTGGGCGAACTCCCACACCCGG-3’.  
The PCR were set up with the following condition: initial denaturation for 30s at 95°C 
followed by 16 cycles of 30s at 95°C, 1 min at 55°C for annealing and 14 min at 68°C for extension. 
After PCR, the amplified DNA in the reaction mixtures were treated with 1 μl of Dpn1 restriction 
enzyme (10 U/ μl) and incubated at 37°C for 2 hours to digest the parental SIRT5 template DNA. 
The reaction was stopped by placing the reaction tubes on ice. The amplified products were then 
transformed into TOP10 chemically competent cells. Plasmids were extracted from the transformed 
cells and sent for sequencing to confirm the results.  
4.1.3. Expression and purification of SIRT1 
The plasmids containing SIRT1 were transformed into BL21(DE3) Star® (Invitrogen), 
expressed and purified as described by Milne et al with slight modification (204). Starter cultures 
were prepared by inoculating a single colony into 5 mL stetile LB medium containing 0.1 
mg/mL of ampicillin. After incubation at 37 °C for 16 hours, the culture was used for inoculating 
1 L of media containing ampicillin at 37 °C for 4 to 6 hours until the OD600 reached 0.6 to 0.8. 
 70 
 
The expression of the enzyme was induced by adding 0.5 mM IPTG and the cell continued to 
grow overnight at 18°C. The cells were then pelleted out by centrifugation at 6,000 g and 4 °C 
for 20 min. The pellets were resuspended in lysis buffer (50 mM Tris, pH 8, containing 250 mM 
NaCl, 2-mercaptoethanol 0.25% Triton X-100 and 0.1mg/ml PMSF) and lysed by sonication 
(power level 4, 50% duty cycle) in an ice-bath for 20 minute, in 30 sec steps. The lysate was 
centrifuged at 15,000 g and 4 °C for 30 min and resulting supernatant containing soluble proteins 
in the cell lysate were purified by immobilized metal affinity chromatography (IMAC) using a 5 
mL Histrap HP (GE Healthcare). The HisTrap column was made up of the highly cross-linked 
agrose containing IDA (Iminodiacetic Acid) as an immobilized chelating group. Due to the 
presence of the imidazole ring of the histidine, the His-tagged protein specifically bound to the 
metal chelating sites, facilitating the specific binding of the recombinant protein. The non-
specific and weak binding of the contaminating proteins was prevented by the addition of 50 mM 
imidazole in the SIRT1 cell lysis buffer. A linear gradient of 50-375 mM imidazole in 
purification buffer was used to elute sirt1 from the HisTrap column in different fractions. The 
purified enzymes were dialyzed into storage buffer (50 mM HEPES, pH 7.5, containing 100 mM 
NaCl, 10 % glycerol and 1 mM TCEP) and stored at -70 °C. 
4.1.4. Expression and purification of SIRT5 wild type and mutants 
The plasmids containing SIRT5 or SIRT5 mutants were transformed into BL21(DE3) 
Star® (Invitrogen), expressed and purified as described by Milne et al. with slight modification 
(204). Starter cultures were prepared by inoculating a single colony into 5 mL stetile LB medium 
containing 0.1 mg/mL of ampicillin. After incubation at 37 °C for 16 hours, the culture was used 
for inoculating 1 L of media containing ampicillin at 37 °C for 4 to 6 hours until the OD600 
reached 0.6 to 0.8. The expression of the enzyme was induced by adding 0.5 mM IPTG and 
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continued overnight at room temperature. The cells were then pelleted out by centrifugation at 
6,000 g and 4 °C for 30 min. The pellets were resuspended in lysis buffer (50 mM Tris, pH 8, 
containing 250 mM NaCl, 2-mercaptoethanol 0.25% Triton X-100 and 0.1mg/ml PMSF) and 
lysed by sonication (power level 4, 50% duty cycle) in an ice-bath for 20 minute, in 30 sec steps. 
The lysate was centrifuged at 15,000 g and 4 °C for 30 min and resulting supernatant containing 
soluble proteins in the cell lysate were purified by immobilized metal affinity chromatography 
(IMAC)  using a 5 mL Histrap HP column (GE Healthcare). The non-specific and weak binding 
of the contaminating proteins was prevented by the addition of 40 mM imidazole in the cell lysis 
buffer. A linear gradient of 40-375 mM imidazole in purification buffer was used to elute SIRT5 
from the HisTrap column in different fractions. The purified enzymes were subjected to the 
SDS-PAGE analysis and stored in 50 mM HEPES (pH 7.5), 100 mM NaCl, 10 % glycerol and 1 
mM TCEP at -70 °C. 
4.1.5. Purity of proteins 
During the course of purification, the expression level of each of the above proteins 
during each stage of purification was qualitatively determined by SDS-PAGE analysis as 
described in Current Protocols in Molecular Biology. A resolving gel of 12% acrylamide 
prepared in 1.5 M Tris, pH 8.8 and a stacking gel of 4% prepared in 0.5 M tris, pH 6.8 were 
utilized, both containing 0.1% SDS. Samples were dissolved in loading dye (300 mM Tris, pH 
6.8, 10% SDS, 25% glycerol, 5 mM β-mercaptoethanol, and 0.015% bromophenol blue) and 
heated in a boiling water bath for 5 min before loading. The gels were run at 200 V in tris-
glycine buffer (0.1% SDS, 25 mM tris, 190 mM glycine, pH 8.3), and then stained with 0.1% 
coomassie blue in 10% acetic acid and 10% methanol for 15 min followed by destaining with 10% 
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acetic acid and 40% methanol.  Purity of the enzymes was qualitatively judged by the number 
and intensity of other protein bands relative to that of the protein of interest.   
4.1.6. Estimation of protein concentrations 
The concentration of enzyme was estimated by Bradford assay using BSA as a standard 
protein. The assay was performed using absorption micro plate reader (Spectra Max PLUS, 
Molecular Devices). A mixture of 1:1 diluted HDAC8 in storage buffer was mixed with 1:4 
diluted Bradford reagent. The mixture was incubated for 5 minutes at room temperature and then 
the absorbance was measured at 595 nm. The molar concentration was calculated taking the 
molecular weight of SIRT1 as 62 kDa and SIRT5 as 31 kDa. 
4.2. Electronic Spectroscopic Methods 
4.2.1. Spectrophotometric studies 
All the absorption studies were performed on an absorption multi-mode microplate reader 
(Spectra Max PLUS, Molecular Devices). The absorbance spectra of 1 μM enzymes were 
obtained at room temperature using a 1 cm path-length cuvette in 25 mM Tris-Cl, pH 7.5, 
containing 100 mM NaCl, 10 % glycerol and1 mM TCEP. The spectrum MH5-75 was measured 
under the same condition. The Absorption change of MH5-75 in the presence of SIRT5 were 
measured by incubating 10 µM MH5-75 with 70 µM SIRT5 in a 1 cm path-length cuvette and 
taking the absorption spectra at different time intervals (immediately, after 2 hours, 3 hours and 
5.5 hours, respectively).  
4.2.2. Measurements of protein emission spectra 
Steady state spectrofluorometric studies were performed on a Perkin Elmer lambda 50-B 
spectrofluorometer, equipped with a magnetic stirrer and thermostated water bath. The emission 
spectra of SIRT1 and SIRT5 were acquired by fixing the excitation wavelength at 280 nm while 
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maintaining both excitation and emission slits at 5 mm without any cut-off filter. All 
measurements were performed in a standard quartz cuvette at room temperature.  
4.2.3. Measurements of time-resolved fluorescence spectra 
Fluorescence lifetime measurements were performed on a custom designed 
QuantaMaster 30™ (Photon Technology International, Birmingham, NJ).  The Light Emitting 
Diode (LED) was used as the excitation source for measuring the time resolved fluorescence 
decay of proteins, with maximum power output at 280 nm. The start and end delays were set up 
at 70 ns and 120 ns, respectively. The data were collected in 200 channels. 30 repeated data were 
averaged to reduce the noise to signal ratio. To correct for the instrument response, a 
corresponding instrument response function (IRF) was generated by a coffee mate solution using 
the identical experimental instrumental parameters. The fluorescence decay curves was analyzed 
using the Felix32™ software (Photon Technology International, Birmingham, NJ), using the single 
or double exponential rate equations of the following format (Eq. 4.1) 
𝐼(𝑡) =  ∑ 𝑎i𝑛𝑖=1 𝑒
−𝑡 𝜏i⁄                                                          Eq. 4.1 
where i and τi are amplitude and fluorescence lifetime for the ith component, 
respectively. The relative contribution of component i (fi) was calculated from the following 
equation (Eq. 4.2) 
𝑓i = (
𝛼i𝜏i
∑ 𝛼i𝜏i𝑛𝑖−1
) × 100%                                                   Eq. 4.2 
The goodness of the exponential fit of fluorescence curves was determined by the 
reduced chi-square, the Durbin Watson, and Z values. 
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4.2.4. Measurements of circular dichroism (CD) spectra 
Far-UV CD spectra (190-250 nm) were collected on a J-710 spectropolarimeter (Jasco, 
Tokyo, Japan) equipped with a Peltier temperature controller. The enzyme stocks were diluted to 
10 µM in 5 mM Tris-HCl  buffer, pH 8.0, containing 0.5 % glycerol, 0.1 mM TCEP and 15 mM 
KCl, and transferred to a 1 mm path-length quartz cuvette for obtaining the CD spectra.  The 
samples were subjected to the CD spectral acquisitions from 190 nm to 250 nm in triplicates and 
the spectra were averaged. The CD signals were converted to the mean residue ellipticity (MRE; 
𝜃) using Equation 4.3.  
𝜃 =  
𝑠𝑖𝑔𝑛𝑎𝑙
10∙𝑙∙𝑐
∙
1
𝑟
                                                            Eq. 4.3 
where “signal” is the amplitude of the raw CD signal; l is the path length (mm) of the cuvette; c 
is the protein concentration, and r is the number of amino acid residues in the protein.  
4.3.  Steady-state Kinetic Methods 
4.3.1. Trypsin-coupled enzyme activity assay 
The sirtuin catalyzed deacetylase and desuccinylase reactions were measured via the 
trypsin coupled assay system. Acetylaced-Lys (Fluor-de-lys®) and succinylated-Lys (Ac-Suclys-
AMC) were used as the substrates for the deacetylation and descuccinylation reactions While the 
former substrate was obtained commercially, the succinylated substrate (Ac-Suclys-AMC) was 
synthesized according to the procedure described by Madsen et al. (250). As shown in  
Figure 4.2, the substrates contain the acetylated/succinylated lysine residue which is attached to 
an amino methyl coumarin moiety (AMC) via an amide linkage. Removal of the acetyl group 
from the substrates by sirtuin catalyzed reaction produces a deacetylated or desuccinylated 
product, which is hydrolyzed by trypsin liberating free AMC. The free AMC which is highly 
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fluorogenic (ex = 365 nm and em = 500 nm) could be easily detected using spectrofluorometer.  
The enzymatic reactions were carried out at 25 °C in 50 mM Tris-HCl assay buffer, pH 8.0, 
containing 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, and 1 mg/mL bovine serum albumin. The 
initial velocity of the enzyme catalyzed reaction was determined by monitoring the time 
dependent increase in the fluorescence intensity at 460 nm (λex = 365 nm) using a fluorescence 
microplate reader (SpectraMax Gemini, Molecular Devices). Since trypsin was used as a 
coupling enzyme, its concentration was optimized to ensure the emergence of minimal or 
negligible lag-phase prior to the onset of the steady state phase. 
 
Figure 4.2. Schematic representation of the trypsin-coupled assay to measure the initial rate of 
the sirtuin catalyzed reaction. 
 
4.3.2. Bi-substrate kinetic analysis of the sirtuin catalyzed reactions 
The bi-substrate kinetic experiments were performed by varying the concentrations of 
NAD+ (from 100 to 500 µmM) and Ac-SucLys-AMC or Fluor-de-lys® substrates (from 100 µM 
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to 1200 µM) and 0.8 µM trypsin. The steady state rates of the enzyme catalyzed reactions were 
derived from the time dependent changes in the fluorescence signal, and the data were analyzed 
by the sequential kinetic mechanism (Eq 4.4) via Grafit 4 software. 
 𝑣 = (
𝑉max[𝐴][𝐵]
𝐾a𝐾mb+𝐾ma[𝐵]+𝐾mb[𝐴]+[𝐴][𝐵]
)                                    Eq. 4.4 
Where Vmax is the maximum reaction velocity, Ka is the dissociation constant for the 
acylated substrates (A), and Kma and Kmb are the Michaelis-Menten constants for acylated 
substrates and NAD+ (B), respectively. 
4.3.3. Screening of sirtuin effectors 
In pursuit of developing novel inhibitors/activators (effectors) of sirtuins, a series of 
small molecules were synthesized in the laboratories of Dr. Greg Cook and Dr. Sanku Mallik 
from Department of Chemistry and Biochemistry and Department of Pharmaceutical Sciences at 
North Dakota State University, respectively. To evaluate their effectiveness on SIRT1/ SIRT5 
catalyzed reaction, the initial screening was performed by measuring the change in SIRT1/SIRT5 
activity in the presence of 10 µM of the potential effectors using the coupled assay described in 
section §4.2.1. The assays were conducted in 96-well plates, and the reactions were initiated 
(simultaneously in each plate column) by addition of the enzyme using a multi-channel pipette. 
The small molecules inhibiting the SIRT1/SIRT5 activity > 30% were selected for further 
confirmation and characterization. 
4.3.4. Ki measurement 
The inhibition constants of half and fullsuramin on wild-type SIRT1 and SIRT5 catalyzed 
reactions and that of full-suramin on SIRT5 Y102A mutant enzyme were determined by 
performing the steady state kinetic studies using  fixed concentrations of substrates and NAD+. 
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For the inhibition studies of half suramin on SIRT1 catalysis, the experiment was performed in 
the presence of 100 µM Fluor-de-lys® substrate, 500 µM NAD+, and varying concentration 
(from 0 µM to 100 µM) of half-sruamin.  For the inhibition studies of SIRT5 catalyzed reactions 
by half suramin, the experiments were carried in the presence of 100 µM Ac-Suclys-AMC 
substrate, 100 µM NAD+, and varying concentrations (from 0 µM to 7 mM) of half-suramin. 
Other reaction conditions were the same as described above. Since the enzyme concentration was 
much lower than the concentration of suramin, the data were analyzed using the quadratic 
equation describing the competitive steady state model for the inhibitors (Eq. 4.5) with Grafit 4.0. 
𝑣 =
𝑣0×𝐾i
𝐾i+([𝐼]t−0.5([𝐼]t+[𝐸]t+𝐾i−√([𝐼]t+[𝐸]t+𝐾i)2−4×[𝐼]t×[𝐸]t))
                            Eq. 4.5 
where v0 is the initial velocity of HDAC8 catalyzed reaction without any inhibitor, [I]t is total 
concentrations of the inhibitor, [E]t is the total concentration of enzyme used in the assay. 
4.3.5. IC50 measurement 
The IC50 values of EX527 for the sirtuin catalyzed reactions were measured using the 
fixed concentrations of substrates and NAD+. For the inhibition studies of SIRT1 catalysis, the 
experiment was performed in the presence of 100 µM Fluor-de-lys® substrate, 500 µM NAD+, 
and varying concentration (from 0 µM to 40 µM) of EX527.  For the inhibition studies of wild-
type and SIRT5 mutants catalyzed reactions by EX527, the experiments were carried in the 
presence of 100 µM Ac-Suclys-AMC substrate, 500 µM NAD+, and varying concentrations 
(from 0 µM to 200 µM) of EX527. Other reaction conditions were the same as described above.  
The IC50 values of MH5-75 for SIRT5 catalyzed reactions were measured in the presence 
of 50 µM Ac-Suclys-AMC, 50 µM NAD+, and increasing concentration of MH5-75 (from 0 to 
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400 µM). Other reaction conditions were the same as described above. All the data were fitted by 
equation (Eq. 4.6) by Grafit 4.0.  
𝑦 =  
𝑅𝑎𝑛𝑔𝑒
1+(
𝑥
𝐼𝐶50
)𝑠
+ Background                                                      Eq. 4.6 
Where the Range  is the fitted uninhibited value minus the Background, and s is the slope 
factor. The parameters x and y are the concentrations of the inhibitor (EX527 or MH5-75)  and 
initial rates of the enzyme catalysis. 
4.3.6. Inhibition mode 
4.3.6.1. Inhibition analysis of SIRT5 by suramin 
The trypsin-coupled desuccinylase assay was performed as described previously (250). 
The reactions were carried out at 25 °C in an assay buffer (50 mM Tris, pH 8.0, 137 mM NaCl, 
2.7 mM KCl, 1mM MgCl2, and 1 mg/mL bovine serum albumin). Trypsin was used as the 
coupled enzyme and its concentration was optimized to ensure the emergence of negligible lag-
phase prior to the steady state phase. For determining the inhibition type with respect to the 
succinylated lysine-AMC substrate, the concentration of NAD+ was kept constant (and 50 M, 
respectively), and the concentration of suramin was varied from 0 M to 100 M. For 
determining the inhibition type with respect to NAD+, the concentration of succinylated lysine-
AMC was kept constant at 120 M. The initial velocities at different concentrations of 
succinylated lysine-AMC, NAD+ and suramin were fitted to three possible inhibition 
mechanisms, competitive (Eq. 4.7), mixed inhibition (Eq. 4.8) and uncompetitive inhibition (Eq. 
4.9) using Grafit 4.0 (Erithacus software). 
  𝑣o =
Vmax [S]
Km(1+
[I]
Ki
)+[S]
                                                            Eq. 4.7 
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𝑣o =
Vmax [S]
Km(1+
[I]
Ki
)+[S](1+
[I]
Ki'
)
                                                    Eq. 4.8 
𝑣o =
Vmax [S]
Km+[S](1+
[I]
Ki
)
                                                        Eq. 4.9 
4.3.6.2. Inhibition analysis of SIRT1 and SIRT5 variants by nicotinamide 
The nicotinamide inhibition of sirtuin catalyzed reactions was determined by performing 
the steady-state kinetic experiments in the absence and presence of nicotinamide as described 
above. The experiments were performed in the presence of either 100 µM Fluor-de-lys® or Ac-
SucLys-AMC substrate with varying concentration of NAD+ and nicotinamide. The steady-state 
kinetic data were fitted globally by the competitive, mixed, and noncompetitive inhibition 
models using the DYNAFIT software based on the rapid-equilibrium approximation (252). All 
the parameters were allowed to float except for the enzyme concentration. The software utilizes 
several model-discrimination criteria, including the second order Akaike Information Criterion 
(AIC) (253, 254), so that the best model out of the three different candidates could be identified.  
4.4. Transient Kinetic Methods 
To determine the rate constants of binding of suramin to SIRT5, transient kinetic 
experiments were performed using an Applied Photophysics SX-18MV stopped-flow system.  
The stopped-flow system (dead time = 1.3 ms) was operated in the fluorescence mode with an 
emission path length of 2 mm. The time-dependent change in the tryptophan fluorescence was 
monitored by exciting the reaction at 280 nm. The change in protein fluorescence signal was 
detected using a cut-off filter of 320 nm. All the transient kinetic experiments were performed at 
least ten times in 25 mM Tris buffer, pH 7.5, containing 100 mM NaCl, 1 mM TCEP and the 
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resultant kinetic traces were averaged and analyzed by Origin 8.5.1 using either a single (Eq. 
4.10) or double exponential rate equation (Eq. 4.11)  
𝐹𝑙𝑢𝑡 = 𝐴𝑚𝑝 × 𝑒(−
1
𝜏
) + 𝑜𝑓𝑓𝑠𝑒𝑡                                              Eq. 4.10 
where Flut is the fluorescence at a given time. Amp and 1/τ are the total amplitude and relaxation 
rate constant, respectively.  
𝐹𝑙𝑢𝑡 = 𝐴𝑚𝑝1 × 𝑒(−
1
𝜏1
) + 𝐴𝑚𝑝2 × 𝑒(−
1
𝜏2
) + 𝑜𝑓𝑓𝑠𝑒𝑡                        Eq. 4.11 
where Flut  is the fluorescence at a given time. Amp1 and Amp 2 are the respective amplitudes 
associated with relaxation rate constants (1/τ1 and 1/τ2). Relaxation rate constants were measured 
as a function of the ligand concentration and data were analyzed using appropriate kinetic 
models as described in the results section. 
4.5. Thermodynamic Studies 
4.5.1. Binding isotherms of suramin to SIRT1 and SIRT5 
All the steady-state spectrofluorometric studies were performed in sirtuin storage buffer 
on a Perkin-Elmer lambda 50-B spectrofluorometer, equipped with a magnetic stirrer and 
thermostated water bath using a 4 × 4 mm2 square quartz cuvette. The change in intrinsic 
fluorescence signal of the enzyme upon of ligand was used for the titration of fixed concentration 
of SIRT1 or SIRT5 with increasing concentration of suramin to obtain the overall binding 
isotherms. The fluorescence emission spectrum of SIRT1 or SIRT5 was monitored in the range 
of 330–500 nm after excitation at 280 nm. The excitation and the emission slit width in these 
experiments were 10 and 8 respectively with PMT (photo multiplier tube) voltage of 800. The 
resulting binding isotherms for the enzyme-ligand complex were analyzed via the complete 
solution of the quadratic equation modified for the decreasing signal (Eq.4.12) 
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𝐹 = 𝐹max − 𝐶 ∗ (𝐿t + 𝐾d + 𝑛 ∗ 𝐸t) − √(𝐿t + 𝑛 ∗ 𝐸t + 𝐾d)2 − 4 ∗ 𝐿t ∗ 𝐸t/2        Eq. 4.12 
where F is fluorescence signal of protein/ligand after the addition of other interacting partner; 
Fmax is the fluorescence signal of protein in the absence of the interacting partner, Et, and Lt are 
the total enzyme and total ligand concentration, respectively; Kd  is the dissociation constant of 
the enzyme-ligand complex, n is stoichiometry of the enzyme-ligand complex and C is the 
change in amplitude of the signal. 
4.5.2. Isothermal titration calorimetry 
Isothermal titration calorimetric (ITC) experiments were performed on a VP-ITC 
microcalorimeter (GE Healthcare). All experiments were performed in duplicate or triplicate 
using the same stock solutions of the ligands and the enzyme. The mean values of the ITC-
derived thermodynamic parameters and the associated standard deviations are reported in the 
Results section. 
4.5.2.1. EX527 
The sample cell was filled with 1.8 mL (effective volume = 1.4 mL) of 20 µM  
Y102A/R105I mutant SIRT5 and  0 or 10 mM NAD+ in 50 mM HEPES buffer, pH 7.5, 
containing 100 mM NaCl, 10 % glycerol and 1 mM TCEP. The content of the sample cell was 
titrated with 45 aliquots (4 µl each) of EX527 containing either 0 or 10 mM NAD+, prepared in 
the same buffer. 
4.5.2.2. Nicotinamide 
The thermodynamic parameters for the binding of nicotinamide to SIRT5 was obtained 
by titration of of 40 µM SIRT5 by 45 injections (5 µl each) of 2 mM nicotinamide in the 
presence of 1 mM Ac-Suclys-AMC substrate. The sample cell of VP-ITC was filled with 1.8 mL 
(effective volume = 1.4 mL) of 40 µM SIRT5 premixed with 0 or 1 mM Ac-Suclys-AMC 
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substrate in 50 mM HEPES buffer, pH 7.5, containing 100 mM NaCl, 10 % glycerol, 2% DMSO 
and 1 mM TCEP. The content of the sample cell was titrated with 40 aliquots (5 µl each) of 2 
Mm nicotinamide prepared in the same buffer. 
4.5.2.3. Suramin and half-suramin 
The thermodynamic parameters for the binding of suramin to low concentration of SIRT5 
were obtained by titration of 10 µM SIRT5 with 45 aliquots (4 µL each) of 300 µM suramin in 
50 mM Tris-HCl, pH 7.5, containing 100 mM NaCl, 10 % glycerol and 1 mM TCEP at 25 °C. 
The thermodynamic parameters for the binding of suramin to high concentration of SIRT5 were 
obtained by titration of 80 µM SIRT5 with 45 aliquots (3 µL each for the first 10 titrations and 5 
µL for the remaining 35 titrations) of 700 µM or 1 mM suramin in the above buffer. The 
thermodynamic parameters for the binding of half suramin to SIRT5 were obtained by titration 
of 80 µM of SIRT5 with 45 aliquots (4 µl each) of 5 mM half suramin in the above buffer 
without TCEP. The experimental data were analyzed by appropriate binding models using the 
Origin® software package, which yielded the association constant (Ka) and enthalpic (ΔHº) 
Changes. 
4.5.3. Size exclusion chromatographic studies 
The molecular weights of SIRT5 in the presence of different molar raios of enzyme to 
Suramin were determined by size exclusion chromatography using a Superdex 200 column (16 
mm × 600 mm) on an AKTAdesign purifier (GE Healthcare). The superdex 200 column was 
packed using a packing reservoir (XK16/70 column) on the AKTAdesign pump P-901 following 
the protocol provided by GE Healthcare. The void volume of the column was determined by 
running a sample of 2mg/mL blue dextran dissolved in equilibration buffer (50 M HEPES, pH 
7.5 with 100 M NaCl) containing 5% glycerol. The column was calibrated by detetmining the 
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elution volumes (Ve) of five molecular weight standards, namely cytochrome C (12.4 kDa), 
carbonic anhydrase (29 kDa), BSA (66 kDa), yeast ADH (150 kDa) and -amylase (200 kDa) 
(Sigma-Aldrich). SIRT5 (60 M) was mixed with varying concentration of suramin (0, 0.5 M, 
1M, 1,5 M, 5M, 10 M, and 20 M) on ice in 25 mM HEPES buffer, pH 7.5, containing 100 
mM NaCl and 1 mM TCEP. The mixture was loaded on to the Superdex 200 column and washed 
it with the above buffer containing the corresponding concentration of suramin. 1 mL sample 
was loaded to a 2 mL sample loop that was also pre-filled with the same concentration of 
suramin. After loading, the protein concentration was approximately diluted to 30 M while the 
concentration of suramin remained unchanged. The elution profile was monitored at 280 nm and 
recorded for different chromatographic runs.  The peak deconvolution was performed by the 
peak analysis module of Origin 8.5.1 (OriginLab) using the Guassion function. (Eq. 4.13)  
  𝑦 = 𝑦o +
𝐴
𝑤√𝜋/2
𝑒
−2
(𝑥−𝑥c)2
𝑤2                                                 Eq. 4.13 
where yo, xc and A are the offset, center, and the area of the peak, w is the width derived from the 
“Full Width at Half Maximum” (FWHM) using the equation 
𝐹𝑊𝐻𝑀 = √2𝑙𝑛2 × 𝑤                                                      Eq. 4.14 
The molar ratio of dimer versus monomer was calculated based on the peak areas (A) 
derived from the fitting results. 
4.5.4. Thermal stabilities 
The thermal unfolding of the enzymes was performed by monitoring the changes in the 
CD signal at 208 nm as a function of increasing temperature (maintained via the Peltier 
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controller) from 12 to 95 °C at a rate of 1° C min-1. The data were analyzed either by a single 
(Equation 4.14) or double (Equation 4.15) Boltzmann equations,  
𝜃 =  
𝐴1−𝐴2
1+𝑒(𝑥−𝑥0)/𝑑𝑥
+ 𝐴2                                                                                 Eq 4.15 
Where x is the temperature, A1 and A2 are the initial (base line) and final (upon completion of 
unfolding) ellipticities, respectively; x0 is the melting temperature (Tm), and dx is the width of the 
thermal transition, 
𝜃 =  
𝐴0−𝐴1
1+𝑒(𝑥−𝑥01)/𝑑𝑥1
+
𝐴1−𝐴2
1+𝑒(𝑥−𝑥02)/𝑑𝑥2
+ 𝐴2                                                   Eq 4.16 
Where x is the temperature, A0, A1 and A2 are the initial, intermediate, and final baseline 
ellipticities for the two sequential (independent) thermal transitions, respectively, with  x01 and 
x02 being the  melting temperatures (Tm) and dx1 and dx2 being the widths of the first and second 
thermal transitions, respectively.  
4.6. Atomic Force Microscope Size Measurements 
The size distributions of SIRT5 in the presence of various concentrations of suramin were 
measured by AFM in collaboration with Dr. Yongki Choi from Department of Physics at North 
Dakota State University. The SIRT5 sample was prepared by premixing 10 µM SIRT5 solutions 
with suramin at the following four different concentrations; SIRT5 in the absence of suramin, 
and the mixtures of SIRT5 and suramin at the molar ratios of 1:1, 4:1, and 1:10. The solution 
was dropped on top of a freshly cleaned mica surface and incubated for 10 minutes at room 
temperature. The mica surface was rinsed and dried prior to the AFM imaging. AFM was used to 
measure the height of individual SIRT5 proteins on a mica flat surface.  AFM measurements 
were carried out in non-contact mode at a scanning rate of 1.3 Hz and a resonance frequency at 
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145 kHz using a NT-MDT NTEGRA (NT-MDT America, Tempe, AZ). The cantilever was 
made of silicon nitride and was 100 m long. The scanning area was 5 × 5 µm at the resolution 
of 1024 points per line. The images were flattened by a first-order line correction to remove a 
vertical offset between scan lines and a first-order plane subtraction to level a tip-sample tilt. To 
measure protein’s height, the ImageJ software was used to locate the proteins using a peak 
pointing tool. The peak locations of proteins were retrieved as x and y coordinates in each image, 
and a height profile was individually generated for all proteins to determine their heights using a 
LabVIEW program. The height distribution of proteins was obtained from a histogram analysis 
by dividing the entire range of heights into small intervals of equal width, sorting the proteins 
into a series of height intervals, and counting their numbers fallen into each interval. A log-
normal function was found to be useful to examine a skewed distribution especially if the 
logarithm of the heights, log(x), is Gaussian.  The function to find the most peak in the 
distribution is given by Eq. 4.17 
𝑓(𝑥) ∝ exp [− (
ln(𝑥/𝑥0)
𝑤0
)
2
]                                            Eq. 4.17 
where two parameters, x0 and w0, are the peak position and its width, respectively. 
4.7. Molecular Modeling 
Molecular Operating Environment (MOE-2014) by Chemical computing group (CCG) 
was used for the molecular modeling of SIRT5-suramin interaction (255). The protein 
preparation step involved 3D protonation, energy minimization and active site identification. The 
crystal structure of the protein was retrieved from protein data bank (PDB code: 2NRY).  Protein 
was energy minimized and 3-D protonated by using the structure preparation module of MOE. 
Since the protein contains the co-crystallized ligand, the active site was identified around the co-
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crystallized ligand by using the LigX module of the MOE. The pocket was found to be a deep 
cavity lined with the key residues including both hydrophobic and hydrophilic amino acids. The 
ligand for the molecular docking studies were prepared using MOE and were followed by energy 
optimization at a standard MMFF94 force field level, with a 0.0001 kcal/mol energy gradient 
convergence criterion (256).The optimized geometry was saved in a molecular data base file for 
further studies. The optimized ligand was docked with the protein (PDB code:  2NRY) using the 
MOE-Dock program. For docking, the default MOE docking parameters were utilized to 
generate 50 poses of compound in each docking run.  As a result of docking computations mdb 
output files were generated enclosing all docking results with scoring and multiple 
conformations of ligand. All the docked conformations were analyzed and the best scored pose 
from each docking run was retained for further studies of interaction evaluation. The 2D ligand-
protein interactions were visualized using the MOE’s ligand interactions program. 
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5. RESULTS 
5.1.  Cloning, Expression, Purification, and Physiochemical Properties Characterization of 
Recombinant Human SIRT1 and SIRT5 
5.1.1. Cloning, expression, purification of SIRT1, SIRT2 and SIRT5 
5.1.1.1. Cloning, expression and purification of SIRT1 
As elaborated in the previous chapter (§4.1.1), the coding sequence of human sirtuin 1 
(SIRT1) from its parent plasmid pOTB7 was amplified by the PCR method and cloned into the 
pLIC-His vector (251). Besides containing a ligand independent cloning (LIC) site, the pLIC-His 
vector encodes for an N-terminal hexa-histidine peptide followed by a TEV (Tobacco Etch Virus) 
protease recognition sequence (Figure 5.1). The SIRT1 gene was cloned within the LIC site, 
located downstream of the TEV recognition site. The hexa-histidine peptide (His-tag) serves as a 
purification tag for Immobilized Metal Affinity Chromatography. As shown in Figure 5.2, the 
size of the PCR product was approximately 1.7 kb (between 1.5 and 2 kb), as expected for a 
1665 base pair  coding sequence of SIRT1 (193-747) with an additional 36 base pairs derived 
from the primers. The resultant plasmid was sequenced with the forward and reverse primers to 
confirm the SIRT1 coding region of the catalytic domain of SIRT1 (amino acid sequence 193-
747) in the plasmid. The analysis of the sequence data by nucleotide BLAST revealed 100% 
identity with SIRT1 (193-747). 
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Figure 5.1. The vector map of the pLIC-His vector used for cloning human SIRT5 gene. The 
pLIC-His has a T7 promoter based system (Panel B) and has been derived from the pET921b (+) 
(Panel A). The SIRT1/SIRT5 gene was cloned at the LIC site. 
 
 
A 
B 
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Figure 5.2. The agarose gel electrophoresis showing the PCR amplified SIRT1 gene using the 
pLIC compatible forward and reverse primers. The left lane shows the O’GeneRule™ 1 kb Plus 
DNA ladder. 
     
The pLIC-His plasmid was transformed into the BL-21 Star (DE3) E. coli host cells. The 
expression of SIRT1 was induced by 0.5 M IPTG, serving as an inducer of the T7 promoter-lac 
operator system. After induction, the cells were further grown at 18 °C with constant shaking 
overnight to produce SIRT1 in the soluble (native) form. The cells were lysed by sonication, and 
the enzyme was purified from the soluble fraction of the crude lysate via the Immobilized Metal 
Affinity Chromatography (IMAC) using a HisTrap column as described in the Method section 
(§4.1.3). A linear gradient of 20-375 mM imidazole in purification buffer was applied to elute 
the enzyme from the column. The purity of the enzyme was confirmed by the SDS-PAGE 
analysis. Figure 5.3 shows the SDS-PAGE profile of SIRT1 (from 6 L culture) in different 
fractions of the eluants from Ni2+-IDA affinity chromatography. The major bands corresponded 
to the expected molecular mass of SIRT1 (62 kDa). When no imidazole was added to the lysis 
and the equilibration buffers, the fractions eluted from the column contained multiple bands 
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(Figure 5.3 A). On the other hand, when 50 mM imidazole was added to both the lysis and 
equilibration buffers, the fractions eluted from the column had lower contaminations of other 
proteins (Figure 5.3 B). Apparently, the presence of 50 mM imidazole efficiently reduced the 
non-specific binding of proteins to the column. The fractions containing pure SIRT1 were pooled 
and dialyzed against the storage buffer (25 mM HEPES, pH 7.5 containing 150 mM NaCl, 10% 
glycerol and 1 mM TECP). The protein concentration of the purified enzyme was estimated by 
the Bradford method using BSA as the standard (section §4.1.6). The yield of the purified SIRT1 
obtained from six liters of the bacterial culture was approximately 15 mg. 
 
Figure 5.3. SDS-PAGE analysis of purified SIRT1 by Ni2+-IDA affinity chromatography. (A) the 
Histrap column was equilibrated in the absence of imidazole. The bands in lane 1 represent the 
protein standards with the molecular weights given in kDa. The bands from lane 2 to lane 8 
represent SIRT1 eluted from the Histrap column. (B) Elution profile of SIRT1 from the column 
equilibrated with 50 mM imidazole. The bands in lane 1 represent the protein standards with the 
molecular weights given in kDa. The bands in lane 2 and 3 represent the crude proteins before 
loading and after loading to the Histrap column. The bands from lane 4 to lane 7 represent 
SIRT1eluted from the Histrap column. 
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5.1.1.2. Cloning, expression and purification of SIRT5 
The coding sequence of human sirtuin 5 (SIRT5) from its parent plasmid pOTB7 was 
amplified by PCR and cloned into the pLIC-His vector using the ligation independent cloning 
(LIC) strategy. The resulting plasmid was  sequenced using  the forward and reverse primers 
(Mclab, San Francisco, CA) to confirm the presence of coding region of  the catalytic domain of 
SIRT5 (amino acid sequence 51-301) . Analysis of the sequencing data by nucleotide BLAST 
revealed 100% identity with SIRT5 (51-301). The pLIC-His-SIRT5 plasmid was transformed in 
the BL-21 Star (DE3) E. coli host cells and the expression was induced by 0.5 M IPTG. After 
induction, the cells were further grown at 18 °C with constant shaking overnight to enhance the 
expression of SIRT5 in  soluble (native) form. The cells were then lysed by sonication, and the 
enzyme was purified from the soluble fraction of the crude lysate via the Immobilized Metal 
Affinity Chromatography (IMAC) using a HisTrap column as described in the Method section 
(§4.1.4). The non-specific and weak binding of the contaminating proteins was prevented by 
addition of 40 mM imidazole in the SIRT5 cell lysis buffer. 
The purity of the enzyme was confirmed by the SDS-PAGE analysis (Figure 5.2). The 
band of SIRT5, which eluted between 200 to 300 M imidazole gradient, corresponding  to the 
expected  molecular mass of  SIRT5 (31 kDa). The fractions containing pure SIRT5 were pooled 
and dialyzed against the storage buffer (25 mM HEPES, pH 7.5 containing 150 mM NaCl, 10% 
glycerol and 1 mM TECP). The protein concentration of the purified enzyme was estimated by 
the Bradford method using BSA as the standard. The yield of the purified SIRT5 obtained from 
one liter of the bacterial culture was proximately 34 mg. 
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Figure 5.4. SDS-PAGE analysis of SIRT5 fractions eluted from the Ni2+-IDA affinity column. 
The bands in lane 1 represent the protein standards with the molecular weights given in kDa. The 
bands from lane 2 to lane 7 represent SIRT5 eluted from the Histrap column. 
 
5.1.2. Cloning, expression and purification of SIRT5 mutants 
Du et al. demonstrated that the presence of two amino acids, viz., Y102 and R105, at the 
active site pocket of SIRT5 changes the substrate specificity of the enzyme from carrying out 
normal deacetylation to desuccinylation/demalonylase reaction (257). The structural alignment 
between SIRT5 and SIRT1 (Figure 5.5) reveals that the above amino acids are substituted by Ala 
and Ile in SIRT1, respectively. To ascertain whether the above difference in the amino acid 
substitutions is exclusively responsible for the difference in the substrate specificity between 
SIRT1 and SIRT5, two single (Y102A and R105I) and one double mutation (Y102A/R105I) in 
SIRT5 were created by site-directed mutagenesis as described in section §4.1.2. After 
verification of the mutation sites in the coding sequence of SIRT5 , the mutant plasmids were 
transformed into E. coli BL21 Star (DE3) cells, and the expression was induced by 0.5 M IPTG. 
After induction, the cells were further grown at 18 °C with constant shaking overnight to enhance 
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the expression of mutant SIRT5 in the soluble (native) form. The cells were lysed by sonication, 
and the mutant enzymes were  purified from the soluble fractions of the crude lysates via the 
Immobilized Metal Affinity Chromatography (IMAC) using  HisTrap columns as described in 
the Method section (§4.1.4). The purities of the enzymes were confirmed by the SDS-PAGE 
analysis (Figure 5.5 to 5.7). All of the SIRT5 mutant bands corresponded to the expected 
molecular mass of 31 kDa. . The protein concentration of the purified enzyme was estimated by 
the Bradford method using BSA as the standard. The expression levels of all three mutant 
enzymes were comparable to that of the wild type SIRT5. The yield of the purified SIRT5 
Y102A, R105I, and Y102A/R105I obtained from the one liter of the bacterial culture was 
approximately 27 mg, 32 mg, and 37 mg, respectively. 
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Figure 5.5. Comparative structural features in the catalytic domains of SIRT5 and SIRT1. (A) 
The superimposition (ribbon diagrams) of the catalytic domains of human SIRT5 (blue) and 
SIRT1 (tan). (B) A close view at the active site pockets of SIRT5 and SIRT1. The side chains of 
Y102 and R105I (yellow) in SIRT5 and of A313 and I316 (pink) in SIRT1 are presented as ball-
and-stick models. 
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Figure 5.6. SDS-PAGE analysis of SIRT5 Y102A fractions eluted from the Ni2+-IDA affinity 
column. The bands in lane 1 represent the protein standards with the molecular weights given in 
kDa. The bands from lane 2 to lane 6 represent SIRT5 Y102A eluted from the Histrap column. 
 
 
 
 
 
    1          2          3            4             5          6         
SIRT5 Y102A 
250 kD 
150 kD 
100 kD 
  75 kD   
` 
 50 kD 
 
 37 kD 
   
 
 
25 kD 
20 kD 
 
 96 
 
 
Figure 5.7. SDS-PAGE analysis of SIRT5 R105I fractions by Ni2+-IDA affinity column. The 
bands in lane 1 represent the protein standards with the molecular weights given in kDa. The 
bands from lane 2 to 4 represent the unbound proteins washed from the Histrap column. The 
bands from lane 5 to 10 represent SIRT5 R105I eluted from the column. 
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Figure 5.8. SDS-PAGE analysis of SIRT5 Y102A/R105I fractions by Ni2+-IDA affinity column. 
The bands in lane 1 represent the protein standards with the molecular weights given in kDa. The 
bands in lane 2 represent the unbound proteins washed from the Histrap column. The bands in 
lanes from 3 to lane 7 represent SIRT5 Y102A/R105I eluted from the Histrap column. 
 
5.1.3. Physiochemical properties characterization of SIRT1, SIRT2 and SIRT5 
5.1.3.1. UV-Visible spectra of recombinant human SIRT1 and SIRT5 
Proteins absorb in the UV range t primarily because of the presence of peptide groups as 
well as the aromatic amino acids (Phe, Try, Trp). The molar extinction coefficients () of 
proteins (expressed as M-1cm-1) are dependent on the relative abundance of  above aromatic 
amino acids as well as their molecular microenvironment in  protein structures. Hence, the molar 
concentrations of protein in aqueous solutions are often determined from their absorbance at 280 
nm. Figure 5.8 and 5.9 show the UV-visible spectra of the recombinant form of the human 
SIRT1 and SIRT5 in 10 mM Tris-Cl, pH 7.5 containing 100 mM NaCl, 10 % glycerol and 1 mM 
TCEP. SIRT1 (193-747) contains 18 phenylalanine, 12 tyrosine and 2 tryptophan residues which 
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serve as the chromophores. As shown in the absorption spectrum of SIRT1 (Figure 5.8), the 
absorbance of 2 µM SIRT1 at 280 nm measured in a 1 cm path length quartz cuvette was 0.069. 
On the other hand, SRIT5 (33-302) contains 13 phenylalanine, 5 tyrosine and 4 tryptophan 
residues. The absorbance of 1 µM SIRT5 at 280 nm was 0.035 (Figure 5.9). Based on the 
absorbance values, the molar extinction coefficients of SIRT1 and SIRT5 were calculated as 
being equal to 34500 M-1 cm-1 and 34900 M-1 cm-1, respectively. These values are  in close 
agreement with values estimated by the method of Gill and von Hippel based on their amino acid 
sequences (258), which are 28980 M-1 cm- 1 and 29640 M-1 cm- 1 for SIRT1 and SIRT5, 
respectively. 
 
Figure 5.9. UV-visible spectrum of the recombinant human SIRT1. The spectrum of 2 μM 
SIRT1 was obtained in the storage buffer (25 mM Tris-Cl, pH 7.5, 100 mM NaCl, 10 % glycerol 
and1 mM TCEP) using a 1 cm path length quartz cuvette.  
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Figure 5.10. UV-visible spectrum of the recombinant human SIRT5. The spectrum was obtained 
using 1 μM SIRT5 in the storage buffer (25 mM Tris-Cl, pH 7.5, 100 mM NaCl, 10 % glycerol 
and1 mM TCEP). 
 
5.1.3.2. Circular dichroism (CD) spectral features in the far-UV region of 
recombinant human SIRT1and SIRT5 variants 
In typical circular dichroism (CD) spectra of proteins, in the far-UV region are primarily  
contributed by their secondary structural features. In order to determine whether Y102A, R105I, 
and Y102A/R105I mutations in SIRT5 alter the secondary structural features of the wild-type 
SIRT5, the CD spectra of the native and mutant SIRT5 as well as SIRT1 were recorded. Figure 
5.11 shows the changes in the mean residue ellipticities (θ) of the enzymes as a function of 
wavelength. Note that except for SIRT1, the wild-type and mutant SIRT5 enzymes exhibit 
double minima at 208 and 222 nm, which suggest the predominance of  helices with minor 
(masked) contribution of  sheet structures. Although the elliptical features of both wild-type and 
mutant SIRT5 are qualitatively similar, there are noteworthy differences in the shapes as well as 
the amplitudes of the elliptical peaks among the above enzymes. Such differences are more 
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apparent with SIRT5 containing the R105 mutation. In contrast, the CD spectrum of SIRT1 is 
dominated by the random coil structural features, presumably due to its extended N-terminal and 
C-terminal segments which are not highly organized.  
 
Figure 5.11. CD spectra of SIRT1and SIRT5 variants. The mean residue ellipticities of 10 µM 
enzymes as a function of wavelength are shown. The experiments were performed using a quartz 
cuvette of 1 mm path length in 5 mM Tris-HCl buffer, pH 7.5, containing 0.5 % glycerol, 5 mM 
TCEP and 15 mM KCl. 
 
5.1.3.3. Steady state fluorescence spectra of recombinant human SIRT1 and 
SIRT5 
In proteins, three aromatic amino acids, phenylalanine, tyrosine and tryptophan, 
contribute to the intrinsic fluorescence.  Although both tryptophan and tyrosine residues could be 
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excited at 280 nm to obtain their fluorescence spectra, tryptophan exhibits marked selectively 
when excited at 295-305 nm.  Emission spectra, anisotropy, and quenching of tryptophan 
residues in proteins are frequently utilized to investigate their structural-functional features. For 
instance,  changes the protein fluorescence  upon binding of  ligands have been widely used to 
study ligand-protein interactions (259).  Unfortunately, prior to this study, no fluorescence 
studies to discern the ligand induced conformational changes in SIRT1 and SIRT5 had been 
performed. To determine signals that could be utilized for the characterization of recombinant 
sirtuins, the intrinsic fluorescence properties of the enzymes were investigated. The recombinant 
form of human SIRT1 (193-747) possesses two tryptophan (W232 and W624) and twelve 
tyrosine (Y280, Y301, Y317, Y343, Y376, Y428, Y497, Y523, Y650, Y642, Y658, Y699 and 
Y742) residues.  However, of two available crystal structures of truncated SIRT1, none of the 
above tryptophan residues are present, and thus their precise locations as well as 
microenvironments are unclear. Figure 5.12 is the ribbon diagram of SIRT1 catalytic core 
(residues 241-516) showing seven tyrosine residues. The steady-state fluorescence emission 
spectrum of SIRT1 was obtained by setting the excitation monochromator at 280 nm, and 
scanning the emission profile from 320 to 500 nm (Figure 5.13). Note that the spectrum exhibits 
a maximum at 337 nm.  SIRT5 harbors five tyrosine (Y76, Y102, Y104, Y176 and Y255) and 
four tryptophan residues (W77, W80, W99, and W222). In view of the structural data, all of the 
four tryptophan residues are present in the small domain and appear to be buried in the interior 
core of the enzyme. Figure 5.15 shows the steady-state fluorescence emission spectrum of SIRT5, 
obtained by setting excitation monochrmator at 295 nm, and scanning the emission profile from 
320 to 500. The fluorescence spectrum has the emission maximum at nearly 334 nm.  Based on 
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these spectral features, it is apparent that the tryptophan residues of SIRT1 are present in more 
hydrophilic environment than those of SIRT5. 
 
Figure 5.12. Ribbon Diagram of SIRT1 Catalytic Core Showing Seven Tyrosine Residues 
(Pink).  
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Figure 5.13. Steady-state fluorescence emission spectra (black color traces) of 1μM SIRT1 in 25 
mM Tris-Cl, pH 7.5, 100 mM NaCl, 10 % glycerol and 1 mM TCEP) upon excitation at 280 nm.  
 
 103 
 
   
 
Figure 5.14. Ribbon diagram of SIRT5 showing the tryptophan (red) and tyrosine residues 
(blue). 
 
Figure 5.15.  Steady-state fluorescence emission spectra of 1 μM SIRT5 in 25 mM Tris-Cl, pH 
7.5, 100 mM NaCl, 10 % glycerol and 1 mM TCEP) upon excitation at 280 nm.  
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5.1.3.4. Fluorescence lifetimes of SIRT1 and SIRT5 
In addition to the steady-state emission properties of SIRT1 and SIRT5, the fluorescence 
lifetime properties of the tryptophan residues in both SIRT1 and SIRT5 were investigated. The 
time-resolved fluorescence spectroscopy sheds light on the ligand induced conformation changes 
in the protein structures  (260). Notably, the above measurement is free from any inner filter 
effect often encountered in the steady state fluorescence spectroscopic measurements. 
To determine the lifetime of tryptophan residues in SIRT1 and SIRT5, the fluorescence 
lifetime decay curves of the enzymes were recorded (λex = 280 nm, λem = 340 nm for SIRT1, and 
λex = 280 nm, λem = 336 nm for SIRT5). Figure 5.15 shows the tryptophan fluorescence decay 
curve of SIRT1 in 25 mM Tris-Cl, pH 7.5, 100 mM NaCl, 10 % glycerol and 1 mM TCEP. The 
solid smooth lines are the best fit of the data for the double exponential rate equation with short 
(1) and long (2) lifetimes of 0.95 ns and 4.13 ns, respectively. The associated amplitudes of the 
two lifetimes are 11 and 89 fluorescence units, respectively. Figure 5.16 shows the tryptophan 
fluorescence decay curve of SIRT5 in the same buffer. The solid smooth lines are the best fit of 
the data for the double exponential rate equation with short (1) and long (2) lifetimes of 0.78 ns 
and 4.09 ns, and their associated amplitude of 34 and 66 fluorescence units, respectively.  A 
comparative account of the above lifetimes of SIRT1 versus SIRT5 further reveals that the 
tryptophan residues of the enzyme are confined in different microenvironments. 
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Figure 5.16. Fluorescence lifetime decay of SIRT1. The fluorescence lifetime decay profile of 6 
µM SIRT1 ( λex = 280 nm, λem = 340 nm) in 25 mM Tris-Cl, pH 7.5, 100 mM NaCl, 10 % 
glycerol and 1 mM TCEP. The solid smooth lines are the best fit of the data for the double 
exponential rate equation with short (1) and long (2) lifetimes of 0.95 ns (fixed) and 4.13 ± 0.23 
ns, respectively. The bottom panel shows the residuals of the fit of the lifetime trace. 
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Figure 5.17. Fluorescence lifetime decay of SIRT5. The fluorescence lifetime decay profile of 5 
M SIRT5 ( λex = 280 nm, λem = 336 nm) in 25 mM Tris-Cl, pH 7.5, 100 mM NaCl, 10 % 
glycerol and 1 mM TCEP. The solid smooth lines are the best fit of the data for the double 
exponential rate equation with short (1) and long (2) lifetimes of 0.51 ± 0.09 ns and 3.05 ns 
(fixed value), respectively. The bottom panel shows the residuals of the fit of the lifetime trace. 
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5.2. Steady-state Kinetics of SIRT1 and SIRT5 Variants 
It has been noted that except for SIRT6, most of the sirtuin catalyzed reactions follow a 
compulsory order mechanism, involving the binding of acylated substrates followed by the 
binding of NAD+ (33, 261, 262). To ascertain the influence of mutations on the kinetic 
parameters of the enzyme catalyzed reaction, steady-state kinetic studies were performed on 
SIRT1 and SIRT5. 
5.2.1. Trypsin coupled enzyme reaction of sirtuins 
As elaborated in section § 1.8, several in vitro enzyme assays for sirtuins have been 
developed to determine the steady-state rates of the enzyme catalyzed reactions Since the 
determination of  the steady-state kinetic parameters of enzyme catalyzed reactions requires 
precise measurements  of the initial rates of the enzyme catalysis, the trypsin coupled continuous 
assay system (250) was employed using acetylated-Lys (Fluor-de-lys®) and succinylated-Lys 
(Ac-Suclys)-AMC conjugates  as the substrates for the deacetylation and descuccinylation 
reactions, respectively. While the former substrate was obtained commercially, we synthesized 
the succinylated substrate (Ac-Suclys-AMC) according to the procedure described by Madsen et 
al. (263).  
In the sirtuin catalyzed assay system, trypsin cleaves the lysine-coumarin bond during the 
deacylation reaction, resulting in a time dependent increase in fluorescence. In order to optimize 
the signal to noise ratio of the overall reaction traces of the trypsin coupled sirtuin catalysis, the 
excitation and emission wavelengths were fine tuned. In that pursuit, the excitation and emission 
spectra of the substrate and the final product of the trypsin-coupled enzyme assay were obtained. 
As shown in Figure 5.18, these spectra have a significant overlapping region. In order to reduce 
the inner filter effect produced by high concentration of Fluor-de-lys® (150 µM), used in sirtuin 
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activity measurement while obtaining reasonable signal of the product, the excitation and 
emission wavelengths were determined as being equal to 360 nm and 460 nm, respectively. The 
excitation and the emission spectra of Fluoro-de-Lys® substrate and the final product of the 
trypsin-coupled assay have minimal overlap at the above wavelengths (Figure 5.18), and thus 
eliminates any spectroscopic artifacts during the fluorescence based enzymatic assay. 
The enzymatic assay conditions were optimized at different experimental settings on the 
microplate reader (SpectraMax Gemini, Molecular Devices). Figure 5.20 shows the 
representative time courses of the SIRT5 catalyzed reaction in the presence 100 µM Ac-Suclys-
AMC substrate, 50 M NAD+, 0.8 µM enzyme, and increasing concentrations of  trypsin. Since 
trypsin also degrades (albeit slowly) the enzyme protein, the assay condition was optimized (with 
respect to the trypsin concentration) such that the initial rate of the enzyme catalyzed reaction 
could be reliably determined (264). Note that at low concentration of trypsin (0.4 µM; Figure 
5.20.), the reaction proceeds with a finite lag phase. As the concentration of trypsin increases, the 
amplitude of the lag phase decreases and the initial steady-state rate reaches its maximum value 
at 0.8 µM trypsin (Figure 5.20, trace 4). Further increase in trypsin concentration to 0.9 µM did 
not affect the initial rate of the enzyme catalysis (Figure 5.20, trace 5) but slightly shortened the 
steady-state phase, suggesting that 0.8 µM trypsin was adequate to satisfy the coupled reaction 
system. In the presence of latter concentration of trypsin, the steady-state rates could be reliably 
determined at time regimes significantly higher than those of the preceding lag phases as 
elaborated by Cleland (264). Since the objective had been to delineate the contributions of Y102 
and R105 residues of SIRT5 in substrate selectivity, the acylated lysine-coumarin conjugates 
were chosen as the fluorogenic substrates instead of using physiologically relevant peptide 
substrates. 
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Figure 5.18. The excitation and the emission spectra of the fluorogenic substrate (Fluoro-de-
Lys®) and the final product of the trypsin-coupled assay. The excitation spectra were obtained at 
the emission wavelength of 500 nm. To obtain the emission spectra, the fluorophores were 
excited at 365 nm. Due to significant overlap in the excitation and the emission spectra of the 
substrate and the product, the specific wavelengths i.e., ex = 360 nm, em = 460 nm, were 
chosen where the interference from the substrate was minimal, significantly reducing the inner 
filter effect.  
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Figure 5.19. Real-time progress curve for SIRT5-catalyzed desuccinylation reaction. The time 
courses of the SIRT5 catalyzed reaction using the fixed concentrations of Ac-Suclys-AMC 
substrate and NAD+, and varying concentrations of trypsin as the coupling enzyme are shown. 
The dashed curves represent the time dependent increase in fluorescence at 460 nm (ex = 350 
nm) due to release of 7-hydroxyl-4-methylcoumarin (AMC) from the substrate after the cleavage 
of trypsin. The solid lines indicate the linear regression analysis of the data after the initial lag 
phases.  
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parameters for the deacetylation/desuccinylation reactions catalyzed by the wild-type and mutant 
enzymes (SIRT1, SIRT5, SIRT5 Y102A, SIRT5 R105I, SIRT5 Y102A/R105I), the initial 
velocities of the wild-type and mutant enzyme catalyzed reactions were determined with 
increasing concentrations of Fluor-de-lys® and Ac-Suclys-AMC substrates and changing fixed 
concentrations of NAD+. To determine the kcat values of sirtuins, their corresponding Vmax values 
(obtained as relative fluorescence unit, RFU, per second from the trypsin-coupled assays) were 
converted to the concentration units and divided by the enzyme concentrations. The raw initial 
rates (RFU/s) were converted to µM/s by measuring the increase in fluorescence of the reaction 
products (either AMC or the fluorophore of the Fluor-de-lys® substrate) of the sirtuin assays as 
function of the fluorophore concentration. Note that the fluorophore Fluor-de-lys® of was 
prepared by treatment of  Fluor-de-lys® deactylated standard (available from the Enzo Life 
Sciences) with 100 µM of trypsin for 10 minutes. Figure 5.21 shows the kinetic data for the 
SIRT5 catalyzed reaction as a function of Ac-Suclys-AMC substrate and NAD+ concentrations. 
Since all sirtuin (with exception of SIRT6) catalyzed reactions conform to the bi-substrate 
compulsory order mechanism (261), the product inhibition studies were not performed to 
substantiate the above mechanism. Instead, we analyzed the data of Figure 5.6 by the ternary 
complex kinetic mechanism (Eq 4.4 in section §4.3.2). The solid smooth lines are the best fit of 
the data for the Km,sub and Km,NAD values as being equal to 290 ± 29 µM and 69 ± 9 µM, 
respectively. The kcat value of the enzyme was determined to be (3.83 ± 0.38) ×10
-3 s-1. Similar 
studies were performed with Y102A, R105I, and Y102A/R015I double mutants of SIRT5 as well 
as with wild-type SIRT1 using both Fluor-de-lys® and Ac-Suclys-AMC substrates, and 
determined their Km and kcat values. It should be pointed out that although other groups (228, 257) 
have created mutations in the R105 residue of  SIRT5 (to either Met or  Leu)  to assess its role in 
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modulating the substrate specificity and nicotinamide inhibition of the enzyme, no systematic 
studies on the influences of Y102 and R105 mutations in SIRT5 (to mimic the amino acid 
residues found in SIRT1) on the structural-functional features of the enzymes have been 
performed prior to our studies presented herein. These data are shown in Figures 5.22 to 5.25, 
and the derived parameters are summarized in Table 5.1. Consistent with the previous reports 
(106, 265), SIRT1 possesses strong deacetylase activity with Km,sub = 356 ± 56 M and Km,NAD = 
388 ± 73 µM, respectively, but no detectable desuccinylase activity. On the other hand, SIRT5 
showed a strong desuccinylase activity but only weak deacetylase activity, which could not be 
further pursued to determine its Km and kcat values. The data of Table 5.1 unravels the fact that 
the Km,NAD for SIRT5 of desuccinylase reaction (69 µM) is about 5 fold lower than that obtained 
for the SIRT1 catalyzed deacetylation reaction. It should be pointed out that Madsen et al. 
reported the Km,NAD for SIRT5 reaction using the same succinylated substrate as being equal to 
150 ± 45 µM (250). But since the above authors used only a fixed substrate concentration, the 
Km,NAD can, at the best, be taken as its apparent value. To our further interest, we noted that 
Y102A mutation exhibits both deacetylase and desuccinylase activity with comparable efficiency. 
On the other hand, both R105I and R015/Y102A mutant enzymes were devoid of the 
desuccinylase activity but both these enzymes exhibited the deacetylase activity. Upon 
quantitative comparison, the Km,NAD for SIRT5 Y102A mutant was about 5 fold higher than that 
for the wild-type enzyme in case of the descuccinylation reaction, but the above discrepancy was 
about 20 fold in case of the  deacetylase reaction. Clearly, the Km,NAD
  is considerably higher 
when SIRT5 catalyzes the deacetylation versus the desuccinylation reaction. It is further 
noteworthy that R105I and Y102A/R105I double mutants of SIRT5 exhibit higher deacetylase 
activity, with kcat values of (12.2 ± 1.0) × 10
-5 s-1, and (2.6 ± 0.1) × 10-5 s-1, respectively, than that 
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determined for the Y102A mutant enzyme. Although Y102A/R105I double mutant of SIRT5 
mimics the active site pocket of SIRT1, the Km,sub for the double mutant (388 ± 12 M) is 
comparable to that obtained for  SIRT1 (356 ± 56 M), but the  kcat value of the former enzyme 
((2.6 ± 0.1) × 10-5 s-1)  was about 22 fold lower than that obtained for the latter enzyme ((5.8 ± 
0.9) × 10-4 s-1). Hence, the specificity constant (kcat/Km) of Y102A/R105I double mutant SIRT5 
is about 40 fold lower than that of SIRT5, suggesting that the Y102 and R105 are not exclusive 
determinant of the substrate specificity between SIRT1 and SIRT5. A cumulative account of 
these steady-state kinetic data leads to the conclusion that there is a mutual cooperation between 
Y102 and R105 residues in modulating the deacetylase versus desuccinylase activity of SIRT5. 
Table 5.1. Steady-state kinetic parameters of SIRT5 variants and SIRT1 on acetyl and succinyl 
substrates 
  Km,sub (µM) Km,NAD (µM) kcat (×10
-5 s
-1
) 
k
cat
/K
m
 
(M
-1
s
-1
) 
SIRT5 
deacetylation NDa NDa NDa 0.006 
desuccinylation 290 ± 29 69 ± 9 383.2 ± 38.3 13.207 
SIRT5 Y102A 
deacetylation 720 ± 144 1605 ± 321 6.6 ± 1.3 0.091 
desuccinylation 300 ± 54 321 ± 49 27.4 ± 4.9 0.409 
SIRT5 R105I 
deacetylation 1658 ± 140 609 ± 120 12.2 ± 1.0 0.073 
desuccinylation NDa NDa NDa 0.006 
SIRT5 Y102A 
R105I 
deacetylation 388 ± 12 1194 ± 667 2.6 ± 0.1 0.065 
desuccinylation N/A N/A N/A 0.002 
SIRT1 deacetylation 356 ± 56 388 ± 73 57.9 ± 9.1  1.626 
desuccinylation NAb N/Ab N/Ab N/Ab 
a Km and kcat values could not be independently determined due to the experimental limitation of 
using high substrate concentration; kcat/Km was estimated from the linear first order region of the 
Michaelis-Menten plot at low concentrations of the substrates. 
b N/A: no activity was observed. 
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Figure 5.20. Standard plot the increase in fluorescence (RFU; λex = 360 nm, λem = 460 nm) as a 
function of fluorophore concentration. (A) Standard plot for the assay using Ac-suclys-AMC as 
substrate. The fluorescence intensity was plotted against increasing concentration of AMC and 
the solid smooth line represents the linear fit of the data. (B) Standard plot for the assay using 
Fluor-de-lys® as substrate. The curve was prepared from the fluorescence end point reading of 
the known concentration of the fluorophore, which was generated upon the treatment of different 
concentrations of deacetylated standard with 100 M trypsin. 
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Figure 5.21. Two substrates reactions of SIRT1. The two substrate SIRT1 catalyzed reactions 
were performed under the steady-state conditions with varying concentrations of NAD+ (400, 
600, 800, 1000, 1500 and 4000 µM) and Fluor-de-lys® substrate (100, 200, 400, 600, 800 and 
1000 µM). The data were fitted to sequential mechanism using the Grafit software with varying 
concentration of Fluor-de-lys® substrate at various fixed concentration of NAD+ (A), and with varying 
concentration of NAD+ at various fixed concentration of Fluor-de-lys® substrate (B). The double-
reciprocal plot of 1/𝑣 vs 1/[NAD+] at increasing concentration of  Fluor-de-lys® substrate (C), 
and the double-reciprocal plot of 1/v vs 1/[Fluor-de-lys] at increasing concentration of  NAD+ (D) 
are also shown. 
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Figure 5.22. Two substrates reactions of SIRT5. The two substrate SIRT5 catalyzed reaction was 
performed under the steady-state condition with varying concentrations of Ac-SucLys-AMC 
substrate (25, 50, 100, 200, and 500 µM) and NAD+ (50, 70, 100, 150, 250, 350, 500, and 700 
µM). The data were fitted to the sequential kinetic mechanism for the binding of the substrate 
and NAD+ using the Grafit software with varying concentration of Ac-SucLys-AMC substrate at 
various fixed concentration of NAD+ (A), and with varying concentration of NAD+ at various fixed 
concentration of Ac-SucLys-AMC substrate (B). The double-reciprocal plot of 1/v vs 1/[NAD+] at 
increasing concentration of  Ac-Suclys-AMC substrate (C), and the double-reciprocal plot of 1/v 
vs 1/[Ac-Suclys-AMC] at increasing concentration of  NAD+ (D) are also shown. 
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Figure 5.23. Two substrates sesuccinylation reactions of SIRT5 Y102A. The two substrate 
SIRT5 catalyzed reactions were performed under the steady-state conditions with varying 
concentrations of NAD+ (400, 600, 800, 1000, 1500 and 4000 µM) and Ac-SucLys-AMC 
substrate (100, 200, 400, 600, 800 and 1000 µM). The data were fitted to sequential mechanism 
using the Grafit software with varying concentration of Ac-SucLys-AMC substrate at various fixed 
concentration of NAD+ (A), and varying concentration of NAD+ at various fixed concentration of Ac-
SucLys-AMC substrate (B). The double-reciprocal plot of 1/v vs 1/[NAD+] at increasing 
concentration of  Ac-Suclys-AMC substrate (C), and the double-reciprocal plot of 1/v vs 1/[Ac-
Suclys-AMC] at increasing concentration of  NAD+ (D) are also shown. 
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Figure 5.24. Two substrates deacetylation reactions of SIRT5 Y102A. The two substrate SIRT5 
Y102A catalyzed reactions were performed under the steady-state conditions with varying 
concentrations of NAD+ (400, 600, 800, 1000, 1500 and 4000 µM) and Fluor-de-lys® substrate 
(100, 200, 400, 600, 800 and 1200 µM). The data were fitted to sequential mechanism using the 
Grafit software with varying concentration of Fluor-de-lys® substrate at various fixed 
concentration of NAD+ (A), and with varying concentration of NAD+ at various fixed 
concentration of Fluor-de-lys® substrate (B). The double-reciprocal plot of 1/v vs 1/[NAD+] at 
increasing concentration of  Fluor-de-lys® substrate (C), and the double-reciprocal plot of 1/v vs 
1/[Fluor-de-lys] at increasing concentration of  NAD+ (D) are also shown. 
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Figure 5.25. Two substrates reactions of SIRT5 R105I. The two substrate SIRT5 R105I 
catalyzed reactions were performed under the steady-state conditions with varying 
concentrations of NAD+ (400, 600, 800, 1000, 1500 and 4000 µM) and Fluor-de-lys® substrate 
(100, 200, 400, 600, 800 and 1200 µM). The data were fitted to sequential mechanism using the 
Grafit software with varying concentration of Fluor-de-lys® substrate at various fixed 
concentration of NAD+ (A), and with varying concentration of NAD+ at various fixed 
concentration of Fluor-de-lys® substrate (B). The double-reciprocal plot of 1/v vs 1/[NAD+] at 
increasing concentration of Fluor-de-lys® substrate (C), and the double-reciprocal plot of 1/v vs 
1/[Fluor-de-lys] at increasing concentration of  NAD+ (D) are also shown. 
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Figure 5.26. Two substrates reactions of SIRT5 Y102A/R105I. The two substrate SIRT5 
Y102A/R105I catalyzed reactions were performed under the steady-state conditions with varying 
concentrations of NAD+ (400, 600, 800, 1000, 1500 and 4000 µM) and Fluor-de-lys® substrate 
(100, 200, 400, 600, 800 and 1000 µM). The data were fitted to sequential mechanism using the 
Grafit software with varying concentration of Fluor-de-lys® substrate at various fixed 
concentration of NAD+ (A), and with varying concentration of NAD+ at various fixed 
concentration of Fluor-de-lys® substrate (B). The double-reciprocal plot of 1/v vs 1/[NAD+] at 
increasing concentration of Fluor-de-lys® substrate (C), and the double-reciprocal plot of 1/v vs 
1/[Fluor-de-lys] at increasing concentration of NAD+ (D) are also shown. 
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lymphoma phase I clinical trial, validating sirtuins as antilymphoma drug targets (266). However, 
most known sirtuin inhibitors are either poorly potent, or suffer from poor physiochochemical 
properties. Hence, there is an urgent need to develop novel sirtuin inhibitors/activators as 
therapeutic agents. In a preliminary attempt to identify compounds with pharmaceutical potential, 
various small organic compounds were tested for their inhibition/activation potencies against 
SIRT1 and SIRT5. The screening of in house as well as commercially available compounds (10 
µM) was performed in a 96-well format via the trypsin-coupled assay using a microplate reader 
(SpectraMax Gemini, Molecular Devices) using 10 µM of the effector. While SIRT1 catalyzed 
deacetylation reaction was monitored in the presence of  100 M Fluor-de-lys® substrate 500 
M NAD+,  SIRT5 catalyzed desuccinylation reaction was  performed using 100 M Ac-Suclys-
AMC and 50 M NAD+. Tables 5.2 to 5.7 show the summary of screening results, which were 
categorized into 5 groups based on the chemical structures of the compounds. The latter included 
thiolated compounds (Table 5.2), thiourea derivatives (Table 5.3), hydroxybezoic, 
hydroxypicolinic and nicotinatic group containing compounds (Table 5.4), hydrazine/hydrazide 
derivatives (Table 5.5), barbiturate/thiobarbiturate derivatives (Table 5.6), and other 
miscellaneous compounds (Table 5.7). The compounds which inhibit the SIRT1 or SIRT5 
catalyzed reaction >30 % at 10 µM concentration were selected to determine their inhibition 
potency (IC50) as described in the Methods section (section §4.3.5). 
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Table 5.2. Summary of screening of thiolated compounds for SIRT1 and SIRT5 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
BNG-2-74 
 
NI/NA NI/NA 
BNG-2-73 
 
NI/NA NI/NA 
TM-1-186 
 
NI/NA NI/NA 
DP-180 N
SH  
NI/NA NI/NA 
DP-178 
 
NI/NA NI/NA 
MT-105 
 
23.5 23.5 
VYU-2-15 
 
NI/NA NI/NA 
VYU-2-59 
 
NI/NA NI/NA 
VYU-2-14 
 
NI/NA NI/NA 
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Table 5.2. Summary of screening of thiolated compounds for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
VYU-2-58 
 
NI/NA NI/NA 
VYU-2-17 
HS COOH 
NI/NA NI/NA 
VYU-2-16 
HS
O
O
 
NI/NA NI/NA 
JES-1-21 
 
NI/NA NI/NA 
VYU-2-19 
HS
COOH
 
NI/NA NI/NA 
VYU-2-57 
 
NI/NA NI/NA 
VYU-2-56 
 
NI/NA NI/NA 
VYU-2-26 
 
NI/NA NI/NA 
VYU-2-28 
 
NI/NA NI/NA 
VYU-2-64 
 
NI/NA NI/NA 
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Table 5.2. Summary of screening of thiolated compounds for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
VYU-2-30 
 
NI/NA NI/NA 
VYU-2-136 
 
NI/NA NI/NA 
VYU-2-204 
 
NI/NA NI/NA 
VYU-2-152 
 
NI/NA NI/NA 
MT-114 
 
NI/NA NI/NA 
VYU-3-42 
 
NI/NA NI/NA 
MT-106 
 
NI/NA NI/NA 
VYU-2-246 
 
NI/NA NI/NA 
VYU-2-72 
 
NI/NA NI/NA 
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Table 5.2. Summary of screening of thiolated compounds for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
TM-2-195 
 
NI/NA NI/NA 
VYU-2-134 
 
NI/NA NI/NA 
VYU-2-154 
 
NI/NA NI/NA 
VYU-2-156 
 
NI/NA NI/NA 
MT-109 
 
NI/NA NI/NA 
MT-104 
 
NI/NA NI/NA 
MT-111 
 
NI/NA NI/NA 
VYU-2-166 
 
NI/NA NI/NA 
BNG-2-148 
 
NI/NA NI/NA 
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Table 5.2. Summary of screening of thiolated compounds for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
BNG-167 
 
NI/NA NI/NA 
VYU-2-270 
 
NI/NA NI/NA 
VYU-2-272 
 
NI/NA NI/NA 
VYU-2-296 
 
NI/NA NI/NA 
VYU-2-219 
 
NI/NA NI/NA 
VYU-2-221 
 
NI/NA NI/NA 
VYU-2-264 
 
NI/NA NI/NA 
VYU-2-266 
 
NI/NA NI/NA 
VYU-3-54 
 
NI/NA NI/NA 
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Table 5.2. Summary of screening of thiolated compounds for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
VYU-3-56 
 
NI/NA NI/NA 
BNG-3-36 
 
NI/NA NI/NA 
M-263 
 
NI/NA NI/NA 
NI = No Inhibition  
NI = No Activation 
% = represents the % inhibition of SIRT1 enzyme activity at 10 M of the inhibitor 
 
Table 5.3. Summary of screening of thiourea derivatives for SIRT1 and SIRT5 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
TM-1-197 
 
NI/NA NI/NA 
TM-1-202 
 
NI/NA NI/NA 
TM-1-204 
 
NI/NA NI/NA 
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Table 5.3. Summary of screening of thiourea derivatives for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
TM-1-149 
 
NI/NA NI/NA 
TM-1-155 
 
NI/NA NI/NA 
TM-1-236 
 
NI/NA NI/NA 
TM-1-235 
 
NI/NA NI/NA 
TM-1-236 
 
NI/NA NI/NA 
TM-1-185 
 
NI/NA NI/NA 
TM-1-183 
 
NI/NA NI/NA 
TM-1-155 
 
NI/NA NI/NA 
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Table 5.3. Summary of screening of thiourea derivatives for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
TM-1-114 
 
NI/NA NI/NA 
TM-1-113 
 
NI/NA NI/NA 
TM-2-87 
 
NI/NA NI/NA 
TM-1-261 
 
NI/NA NI/NA 
TM-1-267 
 
NI/NA NI/NA 
TM-1-274 
 
NI/NA NI/NA 
TM-1-278 
 
NI/NA NI/NA 
TM-1-288 
 
NI/NA NI/NA 
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Table 5.3. Summary of screening of thiourea derivatives for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
TM-2-4 
 
NI/NA NI/NA 
BNG-2-119 
 
NI/NA NI/NA 
TM-2-7 
 
NI/NA NI/NA 
TM-2-8 
 
NI/NA NI/NA 
TM-2-16 
 
NI/NA NI/NA 
TM-2-32 
 
NI/NA NI/NA 
TM-II-48 
 
NI/NA NI/NA 
TM-2-57 
 
NI/NA NI/NA 
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Table 5.3. Summary of screening of thiourea derivatives for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
TM-2-60 
 
NI/NA NI/NA 
TM-2-51 
 
NI/NA NI/NA 
TM-2-87 
 
NI/NA NI/NA 
TM-2-88 
 
NI/NA NI/NA 
TM-2-90 
 
NI/NA NI/NA 
TM-2-97 
 
NI/NA NI/NA 
TM-2-101 
 
NI/NA NI/NA 
TM-2-104 
 
NI/NA NI/NA 
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Table 5.3. Summary of screening of thiourea derivatives for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
TM-2-105 
 
NI/NA NI/NA 
TM-2-107 
 
NI/NA NI/NA 
TM-2-125 
 
NI/NA NI/NA 
TM-2-126 
 
NI/NA NI/NA 
TM-2-130 
 
NI/NA NI/NA 
TM-2-131 
 
NI/NA NI/NA 
TM-2-138 
 
NI/NA NI/NA 
TM-2-139 
 
NI/NA NI/NA 
TV-1-90 
 
NI/NA NI/NA 
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Table 5.3. Summary of screening of thiourea derivatives for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
TV-1-91 
 
NI/NA NI/NA 
TV-1-92 
 
NI/NA NI/NA 
TV-1-93 
 
NI/NA NI/NA 
TV-1-106 
 
NI/NA NI/NA 
TV-1-114 
 
NI/NA NI/NA 
NI = No Inhibition  
NI = No Activation 
% = represents the % inhibition of SIRT1 enzyme activity at 10 M of the inhibitor 
 
Table 5.4. Summary of screening of hydroxybenzoic, hydroxypicolinic and nicotinatic group 
containing compounds for SIRT1 and SIRT5 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
VYU-2-11 
 
NI/NA NI/NA 
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Table 5.4. Summary of screening of hydroxybenzoic, hydroxypicolinic and nicotinatic group 
containing compounds for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
VYU-2-10 
 
NI/NA NI/NA 
VYU-2-23 
 
NI/NA NI/NA 
VYU-2-13 
 
NI/NA NI/NA 
VYU-2-20 
 
NI/NA NI/NA 
VYU-2-22 
 
NI/NA NI/NA 
VYU-2-62-1 
 
NI/NA NI/NA 
VYU-2-62-2 
 
NI/NA NI/NA 
VYU-2-48 
 
NI/NA NI/NA 
VYU-2-46 
 
NI/NA NI/NA 
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Table 5.4. Summary of screening of hydroxybenzoic, hydroxypicolinic and nicotinatic group 
containing compounds for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
BNG-2-39 
 
NI/NA NI/NA 
VYU-2-44 
 
NI/NA NI/NA 
VYU-2-98 
 
NI/NA NI/NA 
VYU-2-114 
 
NI/NA NI/NA 
VYU-2-181 
 
NI/NA NI/NA 
VYU-2-122 
 
NI/NA NI/NA 
TV-1-33 
 
NI/NA NI/NA 
APB-177 
 
NI/NA NI/NA 
TM-1-291 
 
NI/NA NI/NA 
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Table 5.4. Summary of screening of hydroxybenzoic, hydroxypicolinic and nicotinatic group 
containing compounds for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
APB-178 
 
NI/NA NI/NA 
VYU-2-94 
 
NI/NA NI/NA 
VYU-2-197 
 
NI/NA NI/NA 
VYU-2-224 
 
NI/NA NI/NA 
VYU-2-169 
 
NI/NA NI/NA 
VYU-2-276 
 
NI/NA NI/NA 
VYU-2-274 
 
NI/NA NI/NA 
VYU-2-278 
 
NI/NA NI/NA 
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Table 5.4. Summary of screening of hydroxybenzoic, hydroxypicolinic and nicotinatic group 
containing compounds for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
VYU-2-234 
 
NI/NA NI/NA 
VYU-2-195 
 
NI/NA NI/NA 
VYU-2-212 
 
NI/NA NI/NA 
VYU-2-280 
 
NI/NA NI/NA 
VYU-2-110 
 
NI/NA NI/NA 
VYU-2-124 
 
NI/NA NI/NA 
VYU-2-126 
 
NI/NA NI/NA 
OK-1-16 
 
NI/NA NI/NA 
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Table 5.4. Summary of screening of hydroxybenzoic, hydroxypicolinic and nicotinatic group 
containing compounds for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
VYU-2-208 
 
NI/NA NI/NA 
OK-1-15 
 
NI/NA NI/NA 
VYU-2-210 
 
NI/NA NI/NA 
BNG-2-147 
 
NI/NA NI/NA 
BNG-2-182 
 
NI/NA NI/NA 
BNG-2-151 
 
NI/NA NI/NA 
APB-1-181 
 
NI/NA NI/NA 
BNG-2-117 
 
NI/NA NI/NA 
BNG-2-152 
 
NI/NA NI/NA 
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Table 5.4. Summary of screening of hydroxybenzoic, hydroxypicolinic and nicotinatic group 
containing compounds for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
VYU-3-45 
 
NI/NA NI/NA 
JES-1-16 
 
NI/NA NI/NA 
JES-1-45 
 
NI/NA NI/NA 
VYU-2-189 
 
NI/NA NI/NA 
VYU-2-191 
 
NI/NA NI/NA 
APB-185 
 
NI/NA NI/NA 
MJD-171 
 
NI/NA NI/NA 
MJD-169 
 
NI/NA NI/NA 
VYU-2-193 
 
NI/NA NI/NA 
 
 140 
 
Table 5.4. Summary of screening of hydroxybenzoic, hydroxypicolinic and nicotinatic group 
containing compounds for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition or fold activation 
SIRT1 SIRT5 
VYU-2-226 
 
NI/NA NI/NA 
VYU-2-228 
 
NI/NA NI/NA 
VYU-3-40 
 
NI/NA NI/NA 
VYU-3-38 
 
NI/NA NI/NA 
BNG-2-175 
 
NI/NA NI/NA 
BNG-3-33 
 
NI/NA NI/NA 
NI = No Inhibition  
NI = No Activation 
% = represents the % inhibition of SIRT1 enzyme activity at 10 M of the inhibitor 
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Table 5.5. Summary of screening of hydrazine/hydrazide derivatives as potential 
inhibitors/activators for SIRT1  
ID Structure 
% Inhibition 
SIRT1 SIRT5 
TM-1-121 
 
NI/NA NI/NA 
TM-1-254 
 
NI/NA NI/NA 
TM-1-243 
 
NI/NA NI/NA 
TM-1-259 
 
NI/NA NI/NA 
TM-1-144 
 
NI/NA NI/NA 
TM-1-170 
 
NI/NA NI/NA 
TM-1-182 
 
NI/NA NI/NA 
TM-1-234 
 
NI/NA NI/NA 
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Table 5.5. Summary of screening of hydrazine/hydrazide derivatives as potential 
inhibitors/activators for SIRT1 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
TM-1-272 
 
NI/NA NI/NA 
TM-1-268 
 
NI/NA NI/NA 
TM-1-246 
 
NI/NA NI/NA 
TM-1-187 
 
NI/NA NI/NA 
TM-1-248 
 
NI/NA NI/NA 
TM-1-108 
 
NI/NA NI/NA 
TM-1-255 
 
NI/NA NI/NA 
TM-2-6 
 
NI/NA NI/NA 
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Table 5.5. Summary of screening of hydrazine/hydrazide derivatives as potential 
inhibitors/activators for SIRT1 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
TM-2-19 
 
NI/NA NI/NA 
TM-1-257 
 
NI/NA NI/NA 
TM-1-288 
 
NI/NA NI/NA 
TM-1-231 
 
NI/NA NI/NA 
TM-1-245 
 
NI/NA NI/NA 
TM-1-256 
 
NI/NA NI/NA 
TM-2-21 
 
NI/NA NI/NA 
TM-2-14 
 
NI/NA NI/NA 
TM-1-293 
 
NI/NA NI/NA 
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Table 5.5. Summary of screening of hydrazine/hydrazide derivatives as potential 
inhibitors/activators for SIRT1 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
TM-2-31 
 
NI/NA NI/NA 
TM-1-258 
 
NI/NA NI/NA 
TM-1-265 
 
NI/NA NI/NA 
TM-1-253 
 
NI/NA NI/NA 
TM-2-55 
 
NI/NA NI/NA 
TM-II-46 
 
NI/NA NI/NA 
NI = No Inhibition  
NI = No Activation 
% = represents the % inhibition of SIRT1 enzyme activity at 10 M of the inhibitor 
 
 
 
 
 
 
 
 
 
 145 
 
Table 5.6. Summary of screening of barbiturate/thiobarbiturate derivatives as potential 
inhibitors/activators for SIRT1 and SIRT5 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
MDS-2-9 
 
NI/NA NI/NA 
MDS-2-10 
 
NI/NA NI/NA 
MDS-2-18 
 
NI/NA NI/NA 
MDS-2-22 
 
NI/NA NI/NA 
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Table 5.6. Summary of screening of barbiturate/thiobarbiturate derivatives as potential 
inhibitors/activators for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
MDS-01-03 
 
NI/NA NI/NA 
MDS-01-04 
 
NI/NA NI/NA 
MDS-01-05 
 
NI/NA NI/NA 
MDS-01-06 
 
NI/NA NI/NA 
 
 
 
 
 147 
 
Table 5.6. Summary of screening of barbiturate/thiobarbiturate derivatives as potential 
Inhibitors/Activators for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
MDS-01-07 
 
NI/NA NI/NA 
MDS-01-08 
 
NI/NA NI/NA 
MDS-01-09 
 
NI/NA NI/NA 
MDS-01-10 
 
NI/NA NI/NA 
MDS-01-11 
 
NI/NA NI/NA 
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Table 5.6. Summary of screening of barbiturate/thiobarbiturate derivatives as potential 
Inhibitors/Activators for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
MDS-01-13 
 
NI/NA NI/NA 
MDS-01-14 
 
NI/NA NI/NA 
MDS-01-16 
 
NI/NA NI/NA 
MDS-01-17 
 
NI/NA NI/NA 
MDS-1-19 
 
NI/NA NI/NA 
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Table 5.6. Summary of screening of barbiturate/thiobarbiturate derivatives as potential 
inhibitors/activators for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
MDS-1-20 
 
NI/NA NI/NA 
MDS-1-22 
 
NI/NA NI/NA 
MDS-1-23 
 
NI/NA NI/NA 
MDS-1-27 
 
NI/NA NI/NA 
MDS-3-12 
 
NI/NA NI/NA 
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Table 5.6. Summary of screening of barbiturate/thiobarbiturate derivatives as potential 
inhibitors/activators for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
MDS-3-16 
 
NI/NA 23 
MDS-3-19 
 
NI/NA NI/NA 
MDS-3-38 
 
NI/NA NI/NA 
MDS-04-06 
 
NI/NA NI/NA 
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Table 5.6. Summary of screening of barbiturate/thiobarbiturate derivatives as potential 
inhibitors/activators for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
MDS-4-9 
 
NI/NA NI/NA 
RS-IV-46 
 
NI/NA NI/NA 
RS-V-46 
 
NI/NA NI/NA 
RS-V-48 
 
NI/NA NI/NA 
RS-V-50 
 
NI/NA NI/NA 
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Table 5.6. Summary of screening of barbiturate/thiobarbiturate derivatives as potential 
inhibitors/activators for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
RS-V-53 
 
NI/NA NI/NA 
RS-V-75 
 
NI/NA NI/NA 
MH-5-51b 
 
NI/NA NI/NA 
MH-5-52 
 
NI/NA NI/NA 
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Table 5.6. Summary of screening of barbiturate/thiobarbiturate derivatives as potential 
inhibitors/activators for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
MH-5-53 
 
NI/NA NI/NA 
MH-5-54 
 
NI/NA NI/NA 
MH-5-68 
 
NI/NA NI/NA 
MH-5-69 
 
NI/NA NI/NA 
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Table 5.6. Summary of screening of barbiturate/thiobarbiturate derivatives as potential 
inhibitors/activators for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
MH-5-75 
 
20.1 40 
MH-5-76 
 
NI/NA NI/NA 
NI = No Inhibition  
NI = No Activation 
% = represents the % inhibition of SIRT1 enzyme activity at 10 M of the inhibitor 
 
Table 5.7. Summary of screening of miscellaneous compounds as potential inhibitors/activators 
for SIRT1 and SIRT5 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
YT-2-212 
 
NI/NA NI/NA 
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Table 5.7. Summary of screening of miscellaneous compounds as potential inhibitors/activators 
for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
YT-2-201 
 
NI/NA NI/NA 
VYU-2-86 
 
NI/NA NI/NA 
VYU-2-87 
 
NI/NA NI/NA 
VYU-2-88 
 
NI/NA NI/NA 
VYU-2-89 
 
NI/NA NI/NA 
TM-2-37 
 
NI/NA NI/NA 
TM-2-103 
 
NI/NA NI/NA 
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Table 5.7. Summary of screening of miscellaneous compounds as potential inhibitors/activators 
for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
TM-2-3 
 
NI/NA NI/NA 
BNG-3-93 
 
NI/NA NI/NA 
BNG-3-90 
 
NI/NA NI/NA 
MT-119 
 
NI/NA NI/NA 
MT-122 
 
NI/NA NI/NA 
MT-124 
 
NI/NA NI/NA 
MT-128 
 
NI/NA NI/NA 
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Table 5.7. Summary of screening of miscellaneous compounds as potential inhibitors/activators 
for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
MT-129 
 
NI/NA NI/NA 
VYU-2-62-4 
 
NI/NA NI/NA 
VYU-2-250 
 
NI/NA NI/NA 
VYU-2-248 
 
NI/NA NI/NA 
TV-1-55 
 
NI/NA NI/NA 
VYU-2-171 
 
NI/NA NI/NA 
VYU-2-252 
 
NI/NA NI/NA 
VYU-2-204-2 
 
NI/NA NI/NA 
VYU-2-63-3 
 
NI/NA NI/NA 
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Table 5.7. Summary of screening of miscellaneous compounds as potential inhibitors/activators 
for SIRT1 and SIRT5 (continued) 
ID Structure 
% Inhibition 
SIRT1 SIRT5 
BNG-3-60 
 
NI/NA NI/NA 
TV-1-67 
 
NI/NA NI/NA 
MK-249 
 
NI/NA NI/NA 
BNG-2-23 
 
NI/NA NI/NA 
M-264 
 
NI/NA NI/NA 
BNG-4-87-1 
 
NI/NA NI/NA 
NI = No Inhibition  
NI = No Activation 
% = represents the % inhibition of SIRT1 enzyme activity at 10 M of the inhibitor 
 
Of all compounds screened, one thiolated compound (thio-quinoline, MT-105; Table 5-2) 
and two barbiturate derivatives (MDS-3-16 and MH5-75; Table 5-7) showed modest inhibitory 
potencies against SIRT1 or SIRT5. Of two barbiturate derivatives, MDS-3-16 was found to be 
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selective for SIRT5. It exhibited 30% inhibition (by 10 M compound) against SIRT5, but did 
not show any inhibition (by the same concentration of the compound) against SIRT1. On the 
other hand, 10 M concentration of MH5-75 exhibited 40% inhibition against SIRT5 but 20% 
inhibition against SRIT1. To test the efficacies of MDS-3-16 and MH5-75 on SIRT5, the IC50 
values of the compounds were determined by measuring the initial rate of the SIRT5 
desuccinylation reaction in the presence of increasing concentrations of the inhibitors. The data 
were analyzed using the equation described in section §4.3.5. As shown in Figures 5.28 and 5.29, 
the solid red lines represent the best fits of the experimental data, yielding the IC50 values of be 
76.0 ± 7.5 µM and 43.7 ± 2.5 µM for MDS-3-16 and MH-5-75, respectively. 
 
Figure 5.27. Dose-response of SIRT5 desuccinylase activity in the presence of 150 µM Ac-
Suclys-AMC, 50 µM NAD+, and increasing concentration of MD-3-16 (from 0 to 100 µM). The 
solid smooth lines represent the best fit of the data for the IC50 value as 76.0 ± 7.5 µM. 
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Figure 5.28. Dose-response of SIRT5 desuccinylase activity in the presence of 150 µM Ac-
Suclys-AMC, 50 µM NAD+, and increasing concentration of MH5-75 (from 0 to 400 µM). The 
solid smooth lines represent the best fit of the data for the IC50 value as 43.7 ± 2.5µM. 
 
5.3.2. Steady-state kinetics for the inhibition of SIRT5 by MH5-75  
Due to its highest inhibitory potency, detailed steady state kinetic studies for the 
inhibition of SIRT5 by MH-5-75 were performed. Such studies involved measuring the SIRT5 
catalyzed reaction via the continuous (trypsin coupled) assay system in the absence and presence 
of MH-5-75. In this approach, the concentration of one substrate was varied while the other 
substrate was kept constant. The initial velocities of the reactions in the above conditions were 
measured and the mode of inhibition (viz., competitive, mixed, and uncompetitive) were 
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determined by the model discrimination module of DYNAFIT software. Figure 5.29 shows the 
double reciprocal plots (1/v versus 1/[substrate]) for the SIRT5 catalyzed reaction as a function 
of the succinylated substrate Ac-Suclys-AMC (Figure 5.29 A and B) and NAD+ (Figure 5.32 C 
and D) at various fixed concentration of MH5-75. As shown in Figure 5.29A, the double-
reciprocal plots for the reactions in the presence of varying MH5-75 (0, 50, 100, 200 and 400 
µM) and succinylated lysine concentration (50 to 600 µM) conform to the  mixed inhibition 
model with the Ki and Ki’ values of 25.57 ± 3.18 µM and 48.92 ± 5.35 µM, respectively, while 
the plots for the reactions with varying MH-5-75 (0, 50, 100, 200 and 400 µM) and NAD+ (40 to 
300 µM) shows noncompetivie inhibition (Figure 5.29 D), with the Ki value of 37.0 ± 1.5) µM. 
Note that the three Ki values determined from the analysis are comparable, suggesting that the 
binding of MH5-75 is not apparently affected by the binding of the succinylated substrate and 
NAD+. The mixed inhibition of MH-5-75 against the Ac-Suclys-AMC may indicate that the 
ligand partially competes against the succinylated substrate during SIRT5 catalysis. 
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Figure 5.29. Steady-state kinetics for the inhibition of SIRT5 by compound MH5-75. (A) The 
SIRT5 catalyzed desuccinylation reactions were performed in the presence of 300 µM NAD+ and 
varying concentrations of Ac-SucLys-AMC (from 50 to 600 µM) in the presence of 0, 50, 100, 
200 and 400 µM concentrations of MH5-75. Data were fitted using DYNAFIT software yielding 
the Ki and Ki’ values of (25.6 ± 3.2) µM and (48.9 ± 5.3) µM, respectively, under the mixed 
inhibition model. The double-reciprocal plot of 1/v vs 1/[Ac-Suclys-AMC] at increasing 
concentrations of MH5-75 are shown in (B). (C) The SIRT5 catalyzed reactions were performed 
in the presence of 100 µM Ac-SucLys-AMC and varying concentrations of NAD+ (from 40 to 
300 µM) in the presence of 0, 50, 100, 200 and 400 µM concentrations of MH5-75. Data were 
fitted using DYNAFIT software yielding the Ki value of (37.0 ± 1.5) µM under the non-
competitive model. The double-reciprocal plot of 1/v vs 1/[Ac-Suclys-AMC] at increasing 
concentrations of MH5-75 are also shown in (D). 
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5.3.3. Inhibition of selected sirtuins by suramin 
As elaborated in the Introduction section (section §1.7.2), suramin has been found to 
inhibit various isoforms of sirtuins. To compare the efficacy of suramin on SIRT1 and SIRT5, 
the initial velocities of SIRT1 catalyzed deacetylation reaction and SIRT5 catalyzed 
desuccinylation reaction were measured in the presence of increasing concentrations of suramin 
and the data were analyzed by competitive inhibition model  (as detailed in the Methods section 
§4.3.4). The solid lines of the Figures 5.18 and 5.19 represent the best fit of the experimental 
data by Eq.4.5, yielding the Ki values of 1.1 ± 0.1 µM and 189 ± 14.9 µM for SIRT1 and SIRT5, 
respectively. Note that due to the low initial rate of SIRT5 catalyzed reaction with Fluor-de-lys® 
substrate, the Ki for SIRT5 with respect to deacetylation reaction could not be reliably 
determined. 
The uniqueness of SIRT5 in catalyzing the desuccinylation (as opposed to the normal 
deacetylation reaction) has been ascribed to the presence of two amino acid residues (namely 
Y102 and R105) within the active site pocket of the enzyme (10). The crystal structure of 
SIRT5-suramin complex demonstrates that Y102 and R105 coordinate with the negatively 
charged sulfonyl moieties of suramin (34). In order to probe the contributions of these two amino 
acids for the inhibition of SIRT5 by suramin, the inhibition of three SIRT5 mutants (namely, 
Y102A, R105I, and Y102A/R105I) were also investigated. It should be pointed out that while 
the Y102A mutant enzyme maintained both detectable desuccinylase and deacetylase activities, 
R105I and Y102A/R105I lost the desuccinylase activity but retained the deacetylase activity (see 
section §5.2.2). Both the deacetylase and desuccinylase activities of Y102A mutant SIRT5 were 
evaluated in the presence of suramin (Figure 5.32). The Y102A catalyzed desuccinylation 
reaction was determined in the presence of 100 µM Ac-SucLys-AMC, 50 µM NAD+, and 
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increasing concentration of suramin (from 0 to 100 µM). Figure 5.32A shows the best fit of the 
data, yielding the Ki values determined to be 3.69 ± 1.4 µM. The SIRT5 Y02A catalyzed 
deacetylation reactions were performed in the presence of 100 µM Fluor-de-lys® substrate, 500 
µM NAD+, and increasing concentration of suramin (from 0 to 100 µM), with the Ki value 
determined to be 6.8 ± 1.7 µM. 
The SIRT5 Y102A/R105I catalyzed deacetylation reactions were performed in the 
presence of 100 µM Ac-SucLys-AMC, 500 µM NAD+, and increasing concentration of suramin 
(from 0 to 50 µM). Figure 5.33 shows the best fit of the data for the Ki values as 25.7 ± 3.0 µM. 
On the contrary, only 10% of R105I mutant enzyme was inhibited by 250 µM suramin. Clearly, 
despite of the fact that Y102 and R105 coordinate with suramin in the active site, the roles these 
two residues paly are opposite. Y102 prevents the inhibition of the enzyme by suramin, while 
R105 assist the inhibition by suramin.  
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Figure 5.30. Ki determination of SIRT1 and SIRT5 by suramin. (A) SIRT1 deacetylase activity 
was measured in the presence of 100 µM Fluor-de-lys® substrate, 500 µM NAD+, and increasing 
concentration of suramin (from 0 to 5 µM). The solid smooth line represents the best fit of the 
data for the Ki values as 1.1 ± 0.1 µM. (B) Ki determination of SIRT5 by suramin. The SIRT5 
catalyzed reactions were performed in the presence of 100 µM Ac-SucLys-AMC, 50 µM NAD+, 
and increasing concentration of suramin (from 0 to 700 µM). The solid smooth line represents 
the best fit of the data for the Ki values as 189.1 ± 14.9 µM. 
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Figure 5.31. Ki determination of SIRT5 Y102A by suramin. (A) The SIRT5 Y102A catalyzed 
desuccinylation reactions were performed in the presence of 100 µM Ac-SucLys-AMC, 50 µM 
NAD+, and increasing concentration of suramin (from 0 to 100 µM). The solid smooth lines 
represent the best fit of the data for the Ki values as 3.7 ± 1.4 µM. (B) The SIRT5 Y02A 
catalyzed deacetylation reactions were performed in the presence of 100 µM Fluor-de-lys® 
substrate, 500 µM NAD+, and increasing concentration of suramin (from 0 to 100 µM). The solid 
smooth lines represent the best fit of the data for the Ki values as 6.8 ± 1.7 µM. 
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Figure 5.32. Ki determination of SIRT5 Y102A/R105I by suramin. The SIRT5 Y102A/R105I 
catalyzed deacetylation reactions were performed in the presence of 100 µM Ac-SucLys-AMC, 
500 µM NAD+, and increasing concentration of suramin (from 0 to 50 µM). The solid smooth 
lines represent the best fit of the data for the Ki values as 25.7 ± 3.0 µM. 
 
Table 5.8 Inhibition potency of suramin against SIRT1 and SIRT5 variants 
Enzyme Activity Ki or % inhibition 
SIRT1 deacetylase 1.14 ± 0.1 µM 
SIRT5 desuccinylase 189.1 ± 14.9 µM 
SIRT5 Y102A 
deacetylase 6.8 ± 1.7 µM 
desuccinylase 3.7 ± 1.4 µM 
SIRT5 R105I deacetylase 10% by 250 µM suramin 
SIRT5 Y102A/R105I deacetylase 25.7 ± 3.0 µM 
 
5.3.4. Inhibition mode of SIRT5 desuccinylase activity by suramin 
The X-ray crystallographic data of SIRT5-suramin complex revealed that the inhibitor 
binds at the NAD+ binding pockets B and  C, as well as  the peptide-binding pocket of the 
enzyme, suggesting that it has the potential to compete against both NAD+ and the peptide 
substrates (34). To investigate the inhibition mode of SIRT5 desuccinylase activity by suramin, 
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steady-state kinetic studies of SIRT5 catalyzed desuccinylation reaction were performed in the 
presence of suramin,  using the continuous assay as described in section §4.3.1. The 
concentrations of one substrate and suramin were varied while the other substrate was kept 
constant. The initial velocities of the reactions in the above conditions were measured, and the 
double reciprocal plots of 1/v versus 1/[substrate] were fitted to the competitive, mixed, and 
uncompetitive inhibition models to distinguish the mode of inhibition. Figure 5.34 shows the 
steady-state rates and the corresponding double-reciprocal plots for the SIRT5 catalyzed reaction 
as a function of NAD+ (Figure 5.34A and B) or succinylated substrate (Figure 5.34C and D) at 
various fixed concentration of suramin. As shown in Figure 5.34B, the double-reciprocal plots 
for the reactions in the presence of varying suramin (0, 100 µM, 200 µM) and succinylated 
lysine concentrations (90 to 700 µM) conform to the  competitive inhibition model with the Ki 
determined to be 46.9 ± 3.2 M, while the plots for the reactions with varying suramin (0, 100 
µM, 200 µM) and NAD+ (40 to 300 µM) show mixed inhibition (Figure 5.34 C and D), with the 
Ki and Ki’ values determined to be 90.5 ± 13.4 M and 270.7 ± 36.2 M, respectively. The 
above results indicate that besides being fully competitive against succinylated substrate, 
suramin also partially competes against NAD+ during SIRT5 catalyzed reaction. Such inhibition 
modes are consistent with the model of binding of suramin in the crystal structure of SIRT5-
suramin complex (34). 
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Figure 5.33. Steady-state kinetics for the inhibition of SIRT5 desuccinylase activity by suramin. 
(A) The wild-type SIRT5 catalyzed reactions were performed in the presence of 50 µM NAD+ 
and varying concentrations of Ac-SucLys-AMC (from 50 to 700 µM) in the presence of 0, 50 
and 100 µM suramin. The double-reciprocal plot of 1/v vs 1/[Ac-SucLys-AMC] at increasing 
concentration of suramin (B) are also shown. Data were fitted using Grafit software with the 
mixed inhibition model. (C) The wild-type SIRT5 catalyzed reactions were performed in the 
presence of 100 µM Ac-SucLys-AMC and varying concentrations of NAD+ (from 40 to 300 µM) 
in the presence of 0, 50 and 100 µM concentrations of suramin. The double-reciprocal plot of 1/v 
vs 1/[NAD+] at increasing concentration of suramin (D) are also shown. Data were fitted using 
Grafit software with the mixed inhibition model. 
 
5.3.5. Inhibition of sirtuins by nicotinamide 
It has been proposed that the inhibition of several isoforms of sirtuins by nicotinamide is  
manifested via the “base-exchange” mechanism (i.e., the reversal of the step involved in the 
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formation of nicotinamide during the enzyme catalysis as elaborated in section §1.3.2; see Figure 
5.34), and such event gives rise to the noncompetitive inhibition of the enzyme  (68, 226, 227). 
Recently it has been proposed that with certain sirtuins (e.g., mouse SIRT2 and human SIRT3)  
the nicotinamide inhibition is mixed type with increasing component of the competitive 
inhibition (229). To ascertain the effect of nicotinamide on human SIRT1 and SIRT5 as well as 
its mutants in the presence of different substrates, detailed steady-state kinetic studies were 
performed via the same continuous (trypsin coupled) assay system as described in the previous 
sections. Figure 5.35 shows the steady-state rates and the corresponding double reciprocal plot 
for the SIRT5 catalyzed desuccinylation reaction as a function of succinylated substrate 
concentration (in the presence of 50 M NAD+) at various fixed concentrations of nicotinamide. 
The double-reciprocal plots for the reactions in the presence of varying suramin (0, 100 µM, 200 
µM) and succinylated lysine concentration (90 to 700 µM) conform to the mixed inhibition 
model, with the Ki and Ki’ values determined to be 15.8 ± 0.7 M and 71.2 ± 7.7 M, 
respectively. The higher Ki’ value suggests that the inhibition potency of nicotinamide is reduced 
by approximately 5 folds after the binding of the succinylated substrate. The double-reciprocal 
plots for the reactions in the presence of varying suramin (0, 100 µM, 200 µM) and succinylated 
lysine concentration (90 to 700 µM) conform to the mixed inhibition model, with the Ki and Ki’ 
values determined to be 15.8 ± 0.7 M and 71.2 ± 7.7 M, respectively. The higher Ki’ value 
suggests that the inhibition potency of nicotinamide is reduced by approximately 5 folds after the 
binding of the succinylated substrate. Figure 5.36 shows the steady-state rates and the 
corresponding double reciprocal plot for the SIRT5 catalyzed desuccinylation reaction as a 
function of NAD+ concentration (in the presence of 100 M succinylated substrate) at various 
fixed concentrations of nicotinamide. Although the double reciprocal plot of Fig 5.36B appeared 
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to be competitive in nature, to ensure its validity, the data were analyzed by the model 
discrimination analysis protocol of the DYNAFIT software (252-254). The above analysis 
confirmed that the nicotinamide inhibition data of Figure 5.36 adheres to the “pure” competitive 
inhibition model; the data could not be reliably fitted either by non-competitive, uncompetitive, 
or mixed inhibition model. As will be discussed in the later section (§5.3.6), the competitive 
inhibition of nicotinamide (against NAD+) is unlikely to be contributed by the base-exchange 
mechanism. When similar studies were performed for the inhibition of nicotinamide (against 
NAD+) with other mutant enzymes, it is notable that Y102A also showed the competitive 
inhibition (Figure 5.38). However, SIRT1 and SIRT5 Y102A/R105I double mutant showed the 
mixed type of inhibition (Figure 5.37 and 5.39), and such inhibition could either be partly or 
entirely contributed by the base-exchange mechanism.  
Based on their findings on different sirtuins,  Sauve and Shramm concluded  that while 
the  base-exchange inhibition of nicotinamide for bacterial and yeast enzymes partially impaired 
their catalytic activities, it resulted in nearly 95% inhibition of  the mouse enzyme (68). The 
origin of such inhibitory potency of nicotinamide has been ascribed to the relative magnitude of 
the forward and reverse rates of formation and decay of the intermediate formed during the 
catalytic cycles of different sirtuins (Figure 5.34).  It should be mentioned that partial inhibition 
of nicotinamide was not observed with either SIRT1 or SIRT5 or its mutants. Fisher et al. 
reported that while SIRT5 deacetylase activity is insensitive to the inhibition of the enzyme by 
nicotinamide, the enzyme’s desuccinylase activity is highly sensitive (i.e., strongly inhibited) to 
nicotinamide (228). They concluded that Arg105/succinate interaction accounted for the 
differential nicotinamide sensitivities of SIRT5 activities. The above conclusion appears to be 
corroborated by our finding of the nicotinamide inhibition with the mutant enzymes (see Table 
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5.9). For example, as shown in Figure 5.39 and table 5.9, Y102A is competitively inhibited by 
nicotinamide with a Ki value of 49.1 ± 4.1 µM in the presence of the succinylated substrate, but 
the above enzyme was only weakly inhibited (about 36% inhibition at 800 µM) in the presence 
of the acetylated substrate. Interestingly, the nicotinamide inhibition in terms of the deacetylase 
activity becomes more potent and conforms to the mixed mode in the case Y102A/R105I double 
mutant enzyme (Ki = 169.3 ± 16.8 µM, Ki’ = 267.2 ± 52.4 µM). A similar mixed mode of 
inhibition was also observed with SIRT1 (Ki = 76.7 ± 12.2 µM, Ki’ = 340.5 ± 102.4 µM) in the 
presence of the acetylated substrate. Apparently, both Y102 and R105 residues of SIRT5 
coordinate with each other in modulating the sensitivity of nicotinamide inhibition during 
catalysis. Combining the aforementioned results of SIRT5 catalysis and inhibition, it is appears 
evident that the binding of succinylated substrate to SIRT5 favorably promotes the binding of 
NAD+ which is competitively displaced by nicotinamide. Whether the origin of the above 
phenomenon is kinetically or thermodynamically controlled must await further studies.  
 
Figure 5.34. Proposed nicotinamide inhibition as a result of reversible cleavage of glycosidic 
bond of NAD+.  The chemical mechanism that unites base-exchange and deacetylation reactions 
arises from a covalent O-alkalymidate intermediate that releases nicotinamide from the active 
site. This intermediate is sufficiently stable to permit regeneration of NAD+ in the presence 
ofelevated nicotinamide concentrations.  
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Figure 5.35. Inhibition of nicotinamide on SIRT5 with varying concentrations of Ac-Suclys-
AMC. The wild-type SIRT5 catalyzed reactions (A) were performed in the presence of 50 µM 
NAD+ and varying concentrations of Ac-SucLys-AMC (from 50 to 700 µM) in the presence of 0, 
25, 50 and 100 µM concentrations of nicotinamide. The double-reciprocal plot of 1/v vs 1/[Ac-
SucLys-AMC] at increasing concentration of nicotinamide (B) are also shown. Data were fitted 
using DYNAFIT software with the mixed inhibition model.  
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Figure 5.36. Inhibition of nicotinamide on SIRT5 with varying NAD+. The wild-type SIRT5 
catalyzed reactions (A) were performed in the presence of 100 µM Ac-SucLys-AMC and 
varying concentrations of NAD+ (from 40 to 300 µM) in the presence of 0, 25, 50 and 100 µM 
concentrations of nicotinamide. The double-reciprocal plot of 1/v vs 1/[NAD+] at increasing 
concentration of nicotinamide (B) are also shown. Data were fitted using DYNAFIT software 
with the competitive inhibition model and the derived Ki values are summarized in Table 5.9. 
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Figure 5.37. Inhibition of nicotinamide on SIRT1 with varying NAD+. SIRT1 reactions (A) were 
performed in the presence of 100 µM Fluo-de-lys® acetylated substrate, and varying 
concentrations of NAD+ (from 40 to 300 µM) in the presence of 0, 50, 100, and 200 µM 
nicotinamide. The double-reciprocal plot of 1/v vs 1/[NAD+] at increasing concentration of 
nicotinamide (B) are also shown. Data were fitted using DYNAFIT software with the mixed 
inhibition model and the derived Ki values are summarized in Table 5.9. 
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Figure 5.38. Inhibition of nicotinamide on SIRT5 Y102A with varying NAD+. The Y102A 
mutant catalyzed reactions (A) were performed in the presence of 500 µM Ac-SucLys-AMC and 
varying concentrations of NAD+ (from 70 to 800 µM) in the presence of 0, 50, 100 and 200 µM 
nicotinamide. The double-reciprocal plot of 1/v vs 1/[NAD+] at increasing concentration of 
nicotinamide (B) are also shown. Data were fitted using DYNAFIT software with the 
competitive inhibition model and the derived Ki values are summarized in Table 5.9. 
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Figure 5.39. Inhibition of nicotinamide on SIRT5 Y102A/R102A with varying NAD+. The 
Y102A/R105I mutant catalyzed reactions (A) were performed in the presence of 500 µM Fluo-
de-lys® acetylated substrate, and varying concentrations of NAD+ concentration (from 200 to 
1300 µM), in the presence of 0, 100, 200 and 400 µM nicotinamide. The double-reciprocal plot 
of 1/v vs 1/[NAD+] at increasing concentration of nicotinamide (B) are also shown. Data were 
fitted using DYNAFIT software with the mixed inhibition model and the derived Ki values are 
summarized in Table 5.9. 
 
 
[NAD+]  (M)
0 300 600 900 1200
R
a
te
 (
R
F
U
/s
e
c
)
0
0.2
0.4
0.6
1 / [NAD+]  (M-1)
0 0.002 0.004 0.006
1
 /
 R
a
te
 (
s
e
c
/R
F
U
)
0
5
10
15
A
B
 178 
 
Table 5.9. Nicotinamide inhibition against SIRT1 and SIRT1 variants 
  Inhibition Mode Inhibition Constant(s) 
SIRT5 
deacetylation ND ND 
desuccinylation Competitive (17.5 ± 1.1) µM 
SIRT5 Y102A 
deacetylation ND 
N/A, 36% inhibition at 
800µM 
desuccinylation Competitive (49.1 ± 4.1) µM 
SIRT5 R105I 
deacetylation ND 
N/A, 40% inhibition at 
800µM 
desuccinylation ND ND 
SIRT5 Y102A 
R105I 
deacetylation Mixed 
K
i
 = (169.3 ± 16.8) µM 
K
i’
 = (267.2 ± 52.4) µM 
desuccinylation ND ND 
SIRT1 deacetylation Mixed Ki = (76.7 ± 12.2) µM 
Ki’ = (340.5 ± 102.4) µM 
desuccinylation ND ND 
 
5.3.6. Effects of isonicotinamide on sirtuin catalysis and inhibition  
Isonicotinamide has been reported to serve as an activator of yeast sir2 both under in 
vitro and in vivo conditions, and the origin of its (activating) effect has been ascribed to the 
alleviation of the nicotinamide assisted reverse (base-exchange) reaction (222). To ascertain 
whether isonicotinamide activates SIRT1 or SIRT5, the initial rates of the enzyme catalyzed 
reactions were determined as a function of increasing concentrations of isonicotinamide. Figure 
5.39 shows the normalized rates (represented as the relative rates) of SIRT1 catalyzed 
deacetylation reactions and SIRT5 catalyzed desuccinylation reactions as a function of 
increasing concentration of isonicotinamide in the presence of low (50 µM) and high (5 mM) 
concentrations of NAD+. The data of Figure 5.39 clearly shows that under neither of the above 
reaction conditions, the rates of the enzyme catalyzed reactions decrease upon increase in 
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isonicotinamide concentration. This observation is contrary to that observed for the other sir2 
catalyzed reactions (222). The data of Figure 5.39A was analyzed by Eq. 4.6 as described in 
section §4.3.5, and obtained the magnitudes of IC50 values as being equal to 7.0 ± 2.9 mM and 
8.9 ± 3.3 mM in the presence of 50 M and 5 mM NAD+, respectively, for SIRT1. The 
corresponding IC50 values for SIRT5 under above condition were found to be 11.1 ± 2.2 mM and 
17.1 ± 4.0 mM, respectively (Figure 5.39B). Note that although the IC50 values are slightly 
higher in the presence of higher concentration of NAD+, they are not significant. To further 
confirm that isonicotinamide does not alleviate the nicotinamide inhibition, the IC50 values of 
nicotinamide for both SIRT1 (deacetylation) and SIRT5 (desuccinylation) were determined both 
in the absence and presence of 10 mM isonicotinamide (Table 5.9). The data of Table 5.9 
suggests that there is only miniscule effect of isonicotinamide on the IC50 value of nicotinamide 
inhibition in case of both SIRT1 and SIRT5. However, since the inhibitory effect of 
isonicotinamide was found to be alleviated in the presence of high concentration of NAD+ in 
case of both SIRT1 and SIRT5 catalyzed reaction (Figure 5.39), it is reasonable to surmise that 
like nicotinamide, isonicotinamide also competes (directly) against the binding of NAD+ to the 
enzyme sites. The above results are consistent with the reports of Guan et al. revealing that 
isonicotinamide weakly inhibits human SIRT3 and does not alleviate the inhibition of 
nicotinamide (267).  
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Figure 5.40. Effects of isonicotinamide on SIRT1 and SIRT5 catalyzed reactions. (A) Dose-
response of SIRT1 deacetylation activity in the presence of varying concentrations of 
isonicotinamide (from 0 to 15 mM) and NAD+ (50 µM and 5 mM). The solid smooth lines 
represent the best fit of the data for the IC50 values as 7.0 ± 2.9 mM (in the presence of 50 M 
NAD+) and 8.9 ± 3.3 mM (in the presence of 5 mM NAD+), respectively. (B) Dose-response of 
SIRT5 desuccinylation activity in the presence of varying concentrations of isonicotinamide 
(from 0 to 15 mM) and NAD+ (50 µM and 5 mM). The solid smooth lines represent the best fit 
of the data for the IC50 values as 11.1 ± 2.2 mM (in the presence of 50 M NAD+) and 17.1 ± 4.0 
mM (in the presence of 5 mM NAD+), respectively. 
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Figure 5.41. Effects of nicotinamide on SIRT1 catalyzed reaction in the absence (A) and 
presence (B) of isonicotinamide. The solid smooth lines represent the best fit of the data for the 
IC50 values as 7.0 ± 2.9 mM (in the absence of isonicotinamide) and 8.9 ± 3.3 mM (in the 
presence of 10 mM isonicotinamide), respectively. 
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Figure 5.42. Effects of nicotinamide on SIRT5 catalyzed reaction in the absence (A) and 
presence (B) of isonicotinamide. The solid smooth lines represent the best fit of the data for the 
IC50 values as 7.0 ± 2.9 mM (in the absence of isonicotinamide) and 8.9 ± 3.3 mM (in the 
presence of 10 mM isonicotinamide), respectively. 
 
 
 
 
 
[NAM] (M)
0 5 x 101 102 1.5 x 102 2 x 102
A
c
ti
v
it
y
 (
R
F
U
/S
e
c
)
0
1
2
3
4
[NAM] (M)
0 5 x 101 102 1.5 x 102 2 x 102
A
c
ti
v
it
y
 (
R
F
U
/S
e
c
)
0.6
1.2
1.8
A
B
 183 
 
Table 5.10. Isonicotinamide (iNAM) effect on the nicotinamide inhibition of SIRT1 and SIRT5 
 IC50 of Nicotinamide  
 In the absence of iNAM In the presence of 10 mM iNAM 
SIRT1 232.5 ± 52.7 µM 133.8 ± 27.2 µM 
SIRT5 26.2 ± 2.9 µM 34.7 ± 3.4 µM 
 
5.3.7. Inhibition of sirtuins by EX527 
EX527 (6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide; Figure 9A) is one of 
few compounds that possess both high inhibitory potency as well as isoform selectivity against 
sirtuins (239). This compound is also among the most studied of the published inhibitors and has 
been used as a standard inhibitor in biological studies (45, 268-270). EX527 inhibits SIRT1 but 
shows no effect on either deacetylase or desuccinylase activities of SIRT5 It has been suggested 
that the insensitivity of SIRT5 against EX527 is due to the unique Arg105 residue within the 
active site pocket of the enzyme. To date, however, there has been no experimental data to 
support or refute the above hypothesis. To probe the contributions of R105 and/or Y102 of 
SIRT5 in modulating the inhibitory potency of EX527, the initial rates of Y012A, R105I, and 
Y102A/R015I mutant catalyzed reactions were measured as a function of increasing 
concentrations of EX527. Figure 5.42 shows the relative activities of SIRT5 variants in the 
absence and presence of 50 µM EX527. The same as reported previously, neither the deacetylase 
nor the desuccinylase activity of wild-type SIRT5 was not inhibited by EX527 (45).  On the 
other hand, EX527 showed about 14% inhibition against Y102A mutant SIRT5 with the fluor-
de-lys® substrate, but showed no inhibition with succinylated substrate. R105I mutant was found 
to be inhibited by about 22% by 50 M EX527 in terms of both deacetylase and desuccinylase 
activities. The double mutant, Y102A/R105I, was inhibited by 36% and 69% by 50 M EX527 
in terms of deacetylase activity and desuccinylase activity, respectively. More interestingly, the 
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SIRT5 double mutant Y102A/R105I exhibited EX527 sensitivity comparable to that of human 
SIRT3. As shown in Figure 5.44, the IC50 value for the inhibition of the double mutant enzyme 
(21.7 ± 1.0 μM) was found to be similar to that reported (22.4 ± 2.7 µM) for the inhibition of 
SIRT3. However, the inhibitory potency of EX527 for SIRT1 (IC50 = 0.9 ± 0.1 μM; Figure 5.44) 
is still significantly higher than that accountable for the exclusive contributions of Y102 and/or 
R105 in SIRT5 (Figure 5.45). These data suggest that both Tyr102 and Arg105 mutually 
contribute to the sensitivity of inhibition by EX527 in SIRT1 versus SIRT5 enzymes during 
deacetylase reaction.  
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Figure 5.43. Effects of EX527 on SIRT5 variants catalyzed reactions. Relative activities of 
SIRT5 variants in the absence and presence of 50 µM EX527 using 100 µM  Fluor-de-lys® 
substrate and µM NAD+. 
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Figure 5.44. Steady-state kinetics for the inhibition of SIRT1 activity by EX527. Dose-response 
of SIRT1 deacetylase activity in the presence of 50 µM Fluor-de-lys® substrate, 50 µM NAD+, 
and increasing concentration EX527 (from 0 to 40 µM). The solid smooth lines represent the 
best fit of the data for the IC50 of EX527 against SIRT1 as being equal to 0.9 ± 0.2 μM. 
 
 
 
Figure 5.45. Steady-state kinetics for the inhibition of SIRT5 Y102A/R105I activity by EX527. 
Dose-response of SIRT5 Y102A/R105I deacetylase activity were tested in the presence of 50 
µM Fluor-de-lys® substrate, 50 µM NAD+, and increasing concentration of EX527 (from 0 to 
200 µM). The solid smooth lines represent the best fit of the data for the IC50 of EX527 against 
SIRT5 Y102A/R105I as being equal to 21.7 ± 1.0 μM. 
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5.4. Spectroscopic, Kinetic, and Thermodynamic Basis for the Binding of Selected Inhibitors 
to Sirtuins  
5.4.1. Binding of MH5-75 to SIRT5 
As demonstrated in section §5.3.2, MH5-75 serves as a non-competitive inhibitor against 
SIRT5 with micromolar inhibition potency. Since the compound contains a coumarin group, it is 
expected to possess specific spectroscopic properties. Figure 5.46 A shows the absorbance 
spectrum of MH5-75 in 10 mM HEPES, pH 7.5, 100 mM NaCl, 10 % glycerol and 1 mM TCEP. 
The absorbance spectrum of MH5-75 has two peaks at 264 and 410 nm. In order to determine the 
influence of SIRT5 on the absorbance of MH5-75, the absorption spectrum of MH5-75 in the 
presence of SIRT5 was recorded at different time intervals (Figure 5.46 B). Note that SIRT5 
enzyme itself possesses strong absorbance between 260 to 300 nm (see section §5.1.3.1). In 
order to assess the kinetics of SIRT5 induced changes in the electronic structure of MH5-75, the 
absorption contributions of the individual species were subtracted from their mixture (Figure 
5.46B). The data of Figure 5.46B clearly shows that while the peak at 410 nm decreased, a new 
peak at 445 nm started to emerge as a function of time, suggesting that the 410 nm peak was 
slowly red shifted to 445 nm upon binding of MH5-75 to the enzyme. Such time-dependent 
spectral changes are suggestive of the slow conformational changes in the SIRT5 structure in 
concomitance with red shift in the electronic spectra of the ligand.  
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Figure 5.46. Time-dependent changes in the UV/Vis absorption sepctra of MH5-75 in the 
presence of SIRT5. (A) 10 µM MH5-75 was prepared in 10 mM HEPES, pH 7.5, 100 mM NaCl, 
10 % glycerol and 1 mM TCEP and the absorption spectrum was measured in a quartz cuvette. 
(B)10 µM MH5-75 was incubated with 70 µM SIRT5 , and the absorption spectra was measured 
immediately (red), after 2 hours (green), 3 hours (blue) and 5.5 hours (pink) in a cuvette. The 
dash line represents the theoretical add-up of the spectra of 70 µM SIRT5 and 10 µM MH5-75. 
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5.4.2. Binding studies of SIRT1 and suramin 
5.4.2.1. Binding isotherms of suramin to SIRT5 
As mentioned in section §5.1.3, changes in intrinsic fluorescence of proteins upon 
binding of their cognate ligands are widely utilized to study protein-ligand interactions. In order 
to investigate the intrinsic fluorescence change of SIRT5 in the presence of suramin, the steady 
state fluorescence emission spectra of SIRT5 (ex = 280 nm) in the absence and presence of 
suramin were determined on a Perkin Elmer lambda 50-B spectrofluorometer in the enzyme 
storage buffer (50 mM Tris-HCl, pH 7.5, containing 100 mM NaCl, 10 % glycerol and 1 mM 
TCEP) as described in section §4.5.1, and the result is shown in Figure 5.47 A. Note that upon 
binding of 1 µM suramin, approximately 80% of the intrinsic protein fluorescence of 1 µM 
SIRT5 was quenched without any shift in the fluorescence emission peak. The binding isotherm 
of the SIRT5-suramin complex was determined by monitoring the change in the protein 
fluorescence at 334 nm (ex = 280 nm) as a function of the ligand concentration as described in 
the Methods section (section §4.5.1). Figure 5.64 B shows the fluorescence intensity of 1 µM 
SIRT5 as a function of increasing concentration of suramin. As the concentration of SIRT5 was 
comparable to that of the ligand during the course of the titration, the binding isotherm was 
analyzed by a complete solution of the quadratic equation (Eq. 4.12 in section §4.5.1). The solid 
line is the best fit of the titration data, yielding the equilibrium dissociation constant (Kd) of 
SIRT5-suramin complex as being equal to 0.13 ± 0.01 µM. Note that that the Kd value obtained 
by the above titration is about two orders of magnitude lower than the inhibition constant (50 µM) 
of suramin determined via the steady state enzyme kinetic assay. The origin of the above 
discrepancy is believed to lie in more than one binding site of suramin in SIRT5; while binding 
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of suramin with SIRT5 at one of the sites was responsible the spectral changes, that to the other 
site caused the enzyme inhibition. 
The above studies were performed for the binding of suramin to SIRT1 as well. Figure 
5.65 shows the quenching of the intrinsic fluorescence of SIRT1 in the presence of suramin 
(Figure 5.65 A), giving rise to the binding isotherm of SIRT1-suramin complex (Figure 5.65 B). 
The solid line is the best fit of the data for the Kd value of SIRT1-suramin complex as being 
equal to 0.6 ± 0.1 µM. It is noteworthy that the latter Kd  value of SIRT1-suramin complex is 
comparable to the apparent inhibition constant (1.1 µM) of suramin during SIRT1 catalyzed 
reaction, suggesting that the suramin binding site which quenches the intrinsic fluorescence of 
SIRT1 is also responsible for inhibition of the enzyme.  
 191 
 
 
Figure 5.47. Binding isotherm for the interaction of suramin with SIRT5. (A) Fluorescence 
spectra of 1 µM SIRT5 (ex = 280 nm) in the absence of suramin and presence of 1 µM suramin. 
(B) Binding affinity of the SIRT5-suramin complex. The decrease in intensity at 334 nm on 
titration of suramin into 1 µM SIRT5 is plotted as a function of suramin concentration. The 
smooth line is the best fit of the data for the Kd value of the SIRT5-suramin complex being equal 
to 0.13 ± 0.01 µM. 
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Figure 5.48. Binding isotherm for the interaction of suramin with SIRT1. (A) Fluorescence 
spectra of 1 µM SIRT1 (ex = 280 nm) in the absence of suramin and presence of 1 µM suramin. 
(B) Binding affinity of the SIRT5-suramin complex. The decrease in intensity at 334 nm on 
titration of suramin into 1 µM SIRT1 is plotted as a function of suramin concentration. The 
smooth line is the best fit of the data for the Kd value of the SIRT1-suramin complex being equal 
to 0.6 ± 0.1 µM. 
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5.4.2.2. Time-resolved fluorescence spectroscopic studies for the ligand-induced 
conformational changes in SIRT5 
To determine the mechanism of quenching of intrinsic fluorescence of SIRT5 by 
suramin, the fluorescence lifetime studies were performed. The time course of the decay of 
excited state population of 5 µM SIRT5 in the absence and presence of 1 µM suramin were 
recorded (λex = 280 nm, λem = 336 nm) via a custom designed fluorescence-lifetime instrument as 
described in section §4.2.3. Figure 5.66 shows the tryptophan fluorescence decay curves of  free 
and the ligand (suramin)-bound form of SIRT5 (the black and blue traces, respectively) in 25 
mM Tris-Cl, pH 7.5, 100 mM NaCl, 10 % glycerol and 1 mM TCEP. The experimental data 
were fitted using the double exponential rate equation (Eq. 4.1). The red smooth lines are the 
best fit of the data for the free form of SIRT5 using the double exponential rate equation, 
yielding the short  (1) and long (2) life times as being equal to  0.78 ± 0.01 ns and 4.09 ± 0.03 
ns, respectively, with their respective amplitude of 34% and 66% as calculated by Eq. 4.2. The 
corresponding lifetime values for the suramin-bound form of SIRT5 were as follows: 1 = 0.38 ± 
0.10 ns and 2 = 2.26 ± 0.16 ns with their  associated amplitudes being equal to  45% and 55 %, 
respectively Evidently, both the short and long lifetimes of SIRT5 were reduced by 
approximately two fold upon the binding of suramin, which could be attributed to the change in the 
microenvironment of the enzyme as a result of conformational modulation in the protein structure 
upon binding of  the ligand.  However, the precise deduction of the microenvironment of individual 
tryptophan moieties in SIRT5 could not be achieved due to the inherent complexity of the 
fluorescence decay curves. 
 194 
 
 
    
     
Figure 5.49. The time resolved fluorescence decay curve of the tryptophan residues of 5 µM 
SIRT5 in the absence and presence of 1 µM suramin. The red solid smooth line is the best fit of 
the data in the absence of suramin for the double exponential rate equation with short (1) and 
long (2) lifetimes of 0.50 ± 0.09 ns and 3.05 ns (fixed), respectively. The pink solid smooth line 
is the best fit of the data in the presence of 1 µM suramin for the double exponential rate 
equation with short (1) and long (2) lifetimes of 0.38 ± 0.10 ns and 2.26 ± 0.16 ns, respectively. 
The bottom panel shows the residuals of the fit of the lifetime trace. 
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5.4.2.3. Transient kinetic studies for the binding of suramin to SIRT5 
The quenching of the intrinsic protein fluorescence of SIRT5 upon binding of suramin 
served as the signal for pursuing the transient kinetic studies for their interactions via the 
stopped-flow system as described in Methods section (section §4.4).  The transient kinetic 
studies for the association of suramin with SIRT5 were conducted by mixing varying 
concentrations of the inhibitor and 1 M enzyme via the stopped-flow syringes and monitoring 
the change in the fluorescence signal using the excitation wavelength of the Xenon lamp of 280 
nm and the emission cutoff filter of 320 nm. A representative kinetic trace for the association of 
suramin with SIRT5 is shown in Figure 5.50. The data were analyzed by the double exponential 
rate equation (Eq. 4.10 in section §4.4), yielding the relaxation rate constants for the fast and the 
slow phases as being equal to  5.6 ± 0.09 s-1 and 0.21 ± 0.01 s-1, respectively. While the fast 
phase was attributed to the initial binding/encounter of the inhibitor to the active site of the 
enzyme, the slow phase was due to the isomerization of the initial encounter complex. 
The above kinetic studies were extended at increasing concentrations of suramin (from 4 
to 12 M) while maintaining a fixed concentration of the enzyme (the pseudo first-order 
condition). The resulting data conformed to the double exponential rate, and the observed rates 
increased or remained constants as a function of suramin concentration (Figure 5.68). The data of 
Figure 5.68 reveals that the fast phase showed he linear (first order) dependence on the suramin 
concentration, yielding the gradient and intercept as being equal to 7.5 ± 7.0 M-1s-1  and 468.0 ± 
59.9 s-1, respectively. The data for the slow phase showed the zero order dependence on suramin 
concentration with the Y-Axis intercept as being equal to 53 ± 8.2.  However due to technical 
difficulties in performing the transient kinetic experiments at lower concentrations of suramin 
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while maintaining the pseudo-first condition, the individual microscopic rate constants for 
SIRT5-sruamin interactions could not be reliably determined. 
 
Figure 5.50. The representative stopped flow trace for the association of SIRT5 and suramin. The 
association of the enzyme with the ligand was triggered by mixing 2 µM SIRT5 with 10 µM 
suramin in 10 mM Tris-Cl, pH 7.5, 100 mM NaCl, 10 % glycerol and 1 mM TCEP. The reaction 
was monitored at 280 nm. The solid smooth line is the best fit of the data with double 
exponential rate equation, yielding the relaxation rate constants for the fast and the slow phase as 
5.58 ± 0.09 s-1 and 0.21 ± 0.01 s-1, respectively. 
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Figure 5.51. Dependence of the observed rate constants on suramin concentrations for the 
association of suramin to SIRT5. kfast and kslow depict the fast and slow observed rate constants as 
a function of suramin concentration, respectively. The data for the fast phase were fitted with 
linear regression, yielding the gradient and intercept as 7.5 ± 7.0 s-1 M-1 and 468.0 ± 59.9 s-1, 
respectively. The data for the slow phase were fitted with horizontal line with the intercept 
determined to be 53.1 ± 8.2 s-1. 
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The X-ray crystallographic as well as the isothermal titration calorimetric (ITC) data of 
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between the trisfulfonylnaphthyl groups of suramin and amino acid residues in the active site 
pocket, the structural data of SIRT5-suramin complex also showed hydrogen bonds between the 
urea (NH-CO-NH) group (the symmetric point) and Y255 on the surface of one SIRT5 molecule 
(Figure 5.52) which seems to stabilize the dimerization. However, the above binding affinity was 
not significantly different from that observed for the binding of suramin to SIRT1, which does 
not appear form the dimeric structrure (see below). To probe the origin of the above anomaly, a 
series of ITC experiments were performed using different concentrations of SIRT5 and suramin 
in the enzyme storage buffer (50 mM Tris-HCl, pH 7.5, containing 100 mM NaCl, 10 % glycerol 
and 1 mM TCEP at 25 °C). Figure 5.53 shows the ITC profile for the titration of 50 µM SIRT5 
with 45 aliquots (3 µL each of first 10 titrants and 5 L each of the remaining 35 titrants) of 700 
µM suramin. However, in a marked contrast to the ITC binding profile of Sheutz et al. 
(conforming to the single site binding model of surmain to SIRT5), the above ITC data revealed 
that, under the above experimental condition, suramin binds to SIRT5 at least in two distinct 
modes. As apparent both from the raw (top panel of Figure 5.53) as well as the calculated ITC 
signals (bottom panel of Figure 5.53), the binding isotherm of SIRT5-suramin complex could not 
be fitted by the single site binding model. The ITC data, however, could be fitted by a minimal 
two independent binding site model (solid smooth line in the bottom panel of Figure 5.53), and 
the analytical outcome yielded the stoichiometry (n), equilibrium association constants (Ka) and 
the enthalpy changes (∆H°) for the binding of suramin to the first site as being equal to 0.2 ± 0.0, 
(6.2 ± 2.1) × 106 M-1, and 2.6 ± 0.3 kcal/mol, respectively. The corresponding parameters for 
the binding of suramin to SIRT5 at the second binding site were derived to be 0.64 ± 0.01, (2.3 ± 
0.1) × 105 M-1, and 12.5 kcal/mol, respectively. Based on these parameters, the entropic 
changes (T∆S°) for the binding of suramin to first and second binding sites of SIRT5 were found 
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to be 4.9 and -5.1 kcal/mol, respectively. Clearly, while the binding of suramin to the first site of 
SIRT5 is entropically driven, that to the second site is enthalpically driven.   
To ascertain whether the binding isotherm for the SIRT5-suramin complex invariably 
conformed to the two site binding model (Figure 5.53), the above ITC studies were performed 
under two different experimental conditions: (1) titration of 50 µM SIRT5 with 45 aliquots (5 µL 
each) of 1 mM suramin (Figure 5.54A), and (2) titration of 5 µM of SIRT5 with 45 aliquots (3 
µL each for the first 10 titrants followed by 5 L each of the remaining 35 titrants) of 200 µM 
suramin (Figure 5.54B).  Note that under both these experimental conditions, the first binding 
site peaks remain unresolved. In ITC titration of Figure 5.54A, it appears that the first site of 
SIRT5 becomes nearly saturated by the first 5 µL aliquot of 1 mM suramin, and thus it is not 
detected.  On the other hand, in Figure 5.54B, due to low stoichiometry and enthalpic values for 
the binding of suramin to the first binding site of SIRT5, it remains masked by the higher 
magnitudes of the stoichiometry and pronounced enthalpic contributions for the binding of 
suramin to the second binding site of SIRT5.  Hence, the binding isotherms of both Figures 2B 
and 2C are devoid of the first binding site and they only show one binding site. The data of 
above figures conform to the single binding site models, yielding the magnitudes of n, Ka, and 
∆H° being equal to 0.78 ± 0.01, (4.0 ± 0.4)  105 M-1 and  14.4 ± 0.3 kcal/mol (Figure 5.54A), 
and  0.84 ± 0.05, (4.5 ± 0.4)  105  M-1  and 15.3 ± 1.1 (Figure 5.54B), respectively. Note that 
these thermodynamic parameters are similar to those obtained for the binding of suramin to the 
second binding site in Figure 5.53. It is reasonable to surmise that due to lower stoichiometry and 
enthalpic changes for the binding of suramin to the first binding site of SIRT5, Sheutz et al. 
might have missed the initial data points in their ITC profiles, and thus ended up only analyzing 
the data corresponding to the second binding site 
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Figure 5.52. Crystal structure of SIRT5-suramin complex showing hydrogen bond between the 
urea (NH-CO-NH) group and Y225. 
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Figure 5.53. ITC profiles of SIRT5 titrated with suramin showing two binding sites. ITC profile 
of 35 M SIRT5 titrated with 700 M suramin in 50 mM HEPES, pH 7.5 containing 100 mM 
NaCl, 10 % glycerol and 1 mM TCEP at 25 0C. Fitted line corresponds to two-independent 
binding sites model (reference subtrated). The thermodynamic parameters determined from the 
fitting are listed in Table 5.10. 
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Figure 5.54. ITC profiles of SIRT5 titrated with suramin showing one binding sites. (A)  ITC 
profile of 35 M SIRT5 titrated with 700 M suramin in 50 mM HEPES, pH 7.5 containing 100 
mM NaCl, 10 % glycerol and 1 mM TCEP at 25 0C. Fitted line corresponds to single binding site 
model (reference subtracted).  (B) ITC profile of 10 M SIRT5 titrated with 150 M suramin at 
25℃. Fitted line corresponds to single binding site model (reference subtrated). The 
thermodynamic parameters determined from the fitting are listed in Table 5.10. 
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profile, and they could be easily fitted (solid smooth line in the bottom panel of Figure 5.55) by 
the single site binding model of SIRT1-suramin complex with stoichiometry (n), association 
constant (Ka), and the enthalpy changes (∆H°) as being equal to 1.12 ± 0.01, (3.3 ± 0.2 × 105 M-1, 
and (16.6 ± 0.3) kcal/mol respectively (Table 5.11). The latter value translates to the ∆G° of 
binding as being equal to 7.5 kcal/mol. Given the ∆H° and ∆G° values, the T∆S° was calculated 
to be 9.1 kcal/mol. Note the above thermodynamic parameters are comparable to those obtained 
from the binding of suramin to the second binding site of SIRT5.  However, due to slow 
aggregation of the enzyme at high concentration, the ITC studies for the binding of suramin at 
high concentration of SIRT5 could not be performed. Considering that SIRT1 possesses 
extended N-terminal and C-terminal regions, which might preclude the bridging of suramin 
between two protein molecules, it is reasonable to conjecture that SIRT1 would be unlikely to 
undergo the dimerization process in the presence of suramin.  
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Figure 5.55. ITC profiles of SIRT1 titrated with suramin in 50 mM HEPES, pH 7.5 containing 
100 mM NaCl, 10 % glycerol and 1 mM TCEP at 25 0C. The top panels show the raw data 
generated by titration of 10 µM SIRT1 by 45 injections (5 µl each) of 150 µM suramin. The area 
under each peak was integrated and plotted against the molar ratio of suramin to SIRT1.  
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Table 5.11. Thermodynamic parameters for binding of suramin/half suramin to SIRT5 
 Stoichiometry Ka (M-1) G° 
(kcal/mol) 
H°  
(kcal/mol) 
TS° 
(kcal/mol) 
5 M SIRT5 
with 200 M 
suramin 
0.84 ± 0.05 (4.5 ± 0.4)  105 7.7 15.3 ± 1.2 7.6 
50 M SIRT5 
with 700 M 
suramin 
Site 
1 
0.17 ± 0.01 (6.2 ± 1.1)  106 9.0 4.1 ± 0.1 4.9 
Site 
2 
0.63 ± 0.01 (2.3 ± 0.1)  105 7.4 12.5 ± 0.3 5.1 
50 M SIRT5 
with 1 mM 
suramin 
0.78 ± 0.02 (4.0 ± 0.4)  105 7.7 14.4 ± 0.3 6.7 
10 M SIRT1 
with 150 M 
suramin 
1.12 ± 0.01 (3.3 ± 0.2)  105 7.5 16.6 ± 0.3 9.1 
50 M SIRT5 
with 5 mM 
half-suramin 
1.09 ± 0.10 (5.6 ± 0.3)  103 4.8 3.8 ± 0.5 2.7 
 
5.4.2.6. ITC profiles for the binding of suramin to SIRT5 mutants 
The crystal structure of SIRT5-suramin complex demonstrates that Y102 and R105 
coordinate with the negatively charged sulfonyl moieties of suramin. To determine the direct 
binding affinities of suramin to Y102A and R105I mutant SIRT5, the isothermal titration 
microcalorimetric (ITC) studies for the binding of suramin to SIRT5 mutants were performed as 
described above as well as in section §4.5.2. Figure 5.56 shows the raw calorimetric data and the 
ITC-derived binding isotherms for the interaction of suramin to R105I mutant SIRT5 under the 
experimental condition used for the binding of suramin to wild-type SIRT5 (see Figure 5.53). 
Note that unlike the two-phase binding of suramin to wild-type SIRT5, the data of Figure 5.56 
clearly shows that suramin binds to R105I mutant only in one phase with binding stoichiometry 
(n) of 0.91 ± 0.01. Evidently, the binding of suramin to R105I mutant enzyme does not trigger 
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the dimerization of the protein.  The magnitudes of Ka and ∆H° values derived from the data of 
Figure 5.56 were found to be (9.1 ± 0.3) × 104 M-1 and 11.3 ± 0.1 kcal/mol, respectively. 
Clearly, the binding of suramin to R105I mutant enzyme is impaired both enthalpically as well as 
from the free energy point of view vis a vis the binding of suramin to the wild-type SIRT5 (see 
Table 5.11).  Hence, R105 residue is not only responsible for the enhanced binding of suramin to 
the enzyme but it also induces the dimeric state of the enzyme when [SIRT5] > [suramin].  
Moreover, only 10% of R105I mutant enzyme was inhibited by 250 µM suramin, suggesting that 
the above inhibitory feature is further impaired by the presence of NAD+, utilized during the 
steady-state kinetic studies but not during the direct binding studies.  
The ITC experiment of suramin toY102A was performed by titrating 12 µM Y102A with 
45 aliquots of 300 µM suramin in the same buffer at 25 °C and the result is shown in Figure 5.57. 
The thermodynamic parameters n, ΔHº and Ka were determined to be as 0.8 ± 0.1, (6.7 ± 0.8) 
kcal/mol and (2.5 ± 0.5) × 105 M-1, respectively. A comparative account of the ITC data suggests 
that although the binding of suramin to Y102A mutant SIRT5 (vis a vis the wild-type enzyme) is 
minimally affected from the free energy point of view, it is significantly impaired from the 
enthalpic point of view. Hence, there is a marked enthalpy-entropy compensation in binding of 
suramin to Y102A mutant enzyme as compared to the wild type enzyme. Also, it is noteworthy 
that the binding affinity of suramin to Y102A mutant enzyme derived from the above ITC data 
(Kd = 4.03 M) is comparable to the inhibition constants (Ki) determined for the inhibition of 
suramin on both the deacetylase and desuccinylase activities of Y102A (6.8 ± 1.7 µM for the 
deacetylase activity and 3.7 ± 1.4 µM for the desuccinylase activity; see Table 5.8 in section 
§5.3.3). 
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The ITC binding studies of suramin to Y102A/R105I double mutant of SIRT5 were 
performed by titrating 20 µM enzyme with 45 aliquots of 500 µM suramin in the above buffer at 
25 °C (Figure 5.56). The solid lines represent the best fit of the experimental data for the one site 
binding model, yielding the thermodynamic parameters n, Ka and ΔHº as being equal to 0.71 ± 
0.05, (10.7 ± 0.8) kcal/mol and (1.4 ± 0.1) × 105 M-1, respectively. The binding affinity derived 
from the Ka is 7.3 M, which is about 3 fold lower than the inhibition constant determined by 
steady-state kinetic studies (25.7 ± 3.0 µM; see Table 5.8 in section §5.3.3) 
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Figure 5.56. ITC profile of SIRT5 R105I titrated with suramin in 50 mM HEPES, pH 7.5 
containing 100 mM NaCl, 10 % glycerol and 1 mM TCEP at 25 0C. The top panels show the raw 
data generated by titration of 12 µM SIRT5 R105I by 45 injections (5 µl each) of 400 µM 
suramin. The area under each peak was integrated and plotted against the molar ratio of suramin 
to SIRT5 R105I. The solid lines represent the best fit of the experimental data for the one 
binding site model, yielding the thermodynmaic parameters of n, ΔHº and Ka as 0.91 ± 0.01, 
(11.3 ± 0.80) kcal/mol and (9.1 ± 0.4) × 104 M-1, respectively. 
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Figure 5.57. ITC profile of SIRT5 Y102A titrated with suramin in 50 mM HEPES, pH 7.5 
containing 100 mM NaCl, 10 % glycerol and 1 mM TCEP at 25 0C. The top panels show the raw 
data generated by titration of 12 µM SIRT5 Y102A by 45 injections (5 µl each) of 400 µM 
suramin. The area under each peak was integrated and plotted against the molar ratio of suramin 
to SIRT5 Y102A. The solid lines represent the best fit of the experimental data for the one 
binding site model, yielding the thermodynmaic parameters of n, ΔHº and Ka as 0.8 ± 0.1, (6.7 
± 0.8) kcal/mol and (2.5 ± 0.5) × 105 M-1, respectively. 
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Figure 5.58. ITC profile of SIRT5 Y102A/R105I titrated with suramin in 25 mM HEPES, pH 7.5 
containing 100 mM NaCl, 10 % glycerol and 1 mM TCEP at 25 0C. The top panels show the raw 
data generated by titration of 20 µM SIRT5 Y102A/R105I by 45 injections (5 µl each) of 500 
µM suramin. The area under each peak was integrated and plotted against the molar ratio of 
suramin to SIRT5 Y102A/R105I. The solid lines represent the best fit of the experimental data 
for the one binding site model, yielding the thermodynmaic parameters of n, ΔHº and Ka as 0.7 ± 
0.1, (10.7 ± 0.8) kcal/mol and (1.4 ± 0.1) × 105 M-1, respectively. 
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5.4.2.7. Binding and inhibition studies of half suramin to SIRT5 
The symmetrical “bis” form of suramin has been known to undergo hydrolytic cleavage 
to generate nearly two identical fragments of the naphthylsulfonate derivatives (Figure 5.42), 
referred herein as  “half suramin” , which was generated by hydrolysis of suramin following the 
procedures described by Kettenes-van den Bosch et al (271).  Briefly, native suramin was 
dissolved in deionized water and heated in a water bath at 80 °C. The heated solution was 
removed from the water bath after six hours followed by cooling in an ice bath.  The above 
treated produced half-suramin, which was further purified via a C18 HPLC column. Although 
the “half-suramin” was unlikely to bridge between the two SIRT5 molecules (Figure 5.59), its 
binding thermodynamic profile was conceived to shed light on the mechanistic feature of SIRT5-
suramin interaction. The ITC studies for the binding of half-suramin to SIRT5 were performed as 
described above as well as in section §4.5.2. Figure 5.61 shows a representative ITC profile for 
the titration of SIRT5 (60 µM) by 45 aliquots (5 µL each) of 5 mM half-suramin in the standard 
buffer. The experimental data conformed to the single-site binding model with stoichiometry (n), 
enthalpy change (∆H°) and the equilibrium association constant (Ka) as being equal to 0.83 ± 
0.10, 3.82 ± 0.45 kcal/mol and (5.6 ± 0.3)  103 M-1, respectively. Note that as compared to the 
binding of full suramin to SIRT5 (Table 5.11), the ∆H° and Ka values for the binding of half 
suramin to SIRT5 are about 4 and 30 fold less favorable, respectively. The ITC derived 
thermodynamic parameters for the binding of half suramin to SIRT5 are summarized in Table 
5.10. To ascertain whether the binding isotherm for the SIRT5-suramin complex invariably 
conformed to the one site binding model (Figure 5.53), the above ITC studies were also 
performed at different concentration of suramin.  Under no condition did the  second binding site 
emerge in ITC titration profiles involving different concentrations of SIRT5. In addition, the 
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stoichiometry of SIRT5-half-suramin complex is invariably close to unity, suggesting that half-
suramin does not bridge between two SIRT5 molecules.  
To compare the inhibition effect of half-suramin on SIRT1 and SIRT5, the steady-state 
kinetic rates of SIRT1 catalyzed deacetylation reaction and SIRT5 catalyzed desuccinylation 
reaction were measured as a function of increasing concentration of half suramin. The Ki 
determined by fitting the data in Figure 5.62 using the competitive equation (Eq.4.5 in 
section§4.3.4) are 13.1 ± 0.7 µM and 1.3 ± 0.2 mM, respectively, indicating that the inhibitory 
potencies of half suramin for both SIRT1 and SIRT5 are significantly lower than that those 
observed with full suramin molecule. 
 
Figure 5.59. Structure of half-suramin  
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Figure 5.60. Binding isotherm for the interaction of half-suramin with SIRT5. Binding affinity of 
the SIRT5-suramin complex. The decrease in fluorescence intensity of 1 µM SIRT5 (ex = 280 
nm) at 334 nm upon titration of suratmin is plotted as a function of suramin concentration. The 
smooth line is the best fit of the data for the Kd value of the SIRT5-suramin complex being equal 
to 9.4  ± 0.8 µM. 
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Figure 5.61. ITC profile of SIRT5 titrated with half-suramin. 25 mM HEPES, pH 7.5 containing 
100 mM NaCl, 10 % glycerol and 1 mM TCEP at 25 0C. The top panels show the raw data 
generated by titration of 80 µM SIRT5 by 45 injections (5 µl each) of 1 mM half-suramin. The 
area under each peak was integrated and plotted against the molar ratio of half-suramin to 
SIRT5. The thermodynamic parameters determined from the fitting are listed in Table 5.10. 
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Figure 5.62. Effects of half-suramin on SIRT1 and SIRT5 catalyzed reactions. (A) Activity of 
SIRT1 in the presence of 150 µM Fluor-de-lys® substrate, 500 µM NAD+, and increasing 
concentration of half-suramin. The solid smooth lines represent the best fit of the data for the Ki 
value as 13.1 ± 0.7 µM (B) Activity of SIRT5 in the presence of 150 µM Ac-SucLys-AMC 
substrate, 50 µM NAD+, and increasing concentration of half-suramin. The solid smooth lines 
represent the best fit of the data for the Ki value as 1.3 ± 0.2 mM. 
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5.4.2.8. Oligomeric States of SIRT5 in the presence of suramin 
To ascertain whether or not the crystallographically derived dimeric state of SIRT5 in the 
presence of suramin really exists  in the aqueous solution (or the above feature emerged merely 
due to an artifact of  the crystallization condition (238)), size exclusion chromatographic studies 
were performed (via a Superdex 200 column) in the presence of varying concentrations of 
suramin. Such studies were intended to decipher the relationship between the alternative modes 
of binding of suramin to SIRT5, discerned from the ITC titration profiles (Figures 5.53 and 5.54).  
To perform size exclusion chromatographic studies, a superdex 200 column was 
assembled  using a packing reservoir (XK16/70 column) on the AKTA design pump P-901 as 
described in the Methods section §4.5.3. The total volume of the resin (Vt) after packing 
calculated based on the height of the resin was approximately 124.055. To determine the the void 
volume (Vo) of the column, 2 mL of  2 mg/ml blue dextran was loaded and eluted from the 
column pre-equilibrated with 25 mM HEPES, pH 7.5, containing 100 mM NaCl as described in 
the Methods section. The Vo determined based on the elution volume of blue dextran was 45.372. 
The calibration curve for the column was generated with five molecular weight standards, 
namely cytochrome C (12.4 kDa), carbonic anhydrase (29 kDa), BSA (66 kDa), yeast ADH (150 
kDa) and -amylase (200 kDa) (Sigma-Aldrich). Figure 5.63 shows the Kav of the five protein 
standards plotted as a function of the corresponding log molecular weight. The solid smooth line 
represents the linear fitting of the data, yielding the slope and intercept to be 0.3686 ± 0.0178 
and 1.0829 ± 0.0325, respectively.  
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Figure 5.63. Calibration curve for the column superdex 200 using five known proteins as 
standards. The Kav of 5 known protein standards (cytochrome C, carbonic anhydrase, BSA, 
Yeast ADH and -amylase) is plotted as a function of the corresponding log molecular weight. 
The solid smooth line represents the linear fitting of the data, yielding the slope and intercept to 
be 0.3686 ± 0.0178 and 1.0829 ± 0.0325, respectively. 
 
After the calibration of the column, the experiments were performed by loading SIRT5 
with different concentrations of suramin and recording the elution profile by monitoring the 
absorption of the effluents at 280 nm (see Methods section §4.5.3). Figure 5.64 shows the elution 
profiles of SIRT5 in the presence of increasing concentrations of suramin in 25 mM HEPES, pH 
7.5, containing 100 mM NaCl, and 1 mM TCEP. To ensure that the suramin concentration 
remains unchanged while the enzyme migrates through the column, enzyme was mixed with 
appropriate concentration of suramin prior to loading the column, and the column was 
equilibrated with the same concentration of suramin. First, a control experiment was performed 
in the absence of suramin. Figure 5.64A shows the elution profile (A280 vs. elution volume) of 
30 µM SIRT5 alone (without suramin) from the above column. Note that although most of 
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SIRT5 elutes as a major symmetrical peak at 91 mL, there is a small (albeit discernible) shoulder 
band around 86 mL. To deconvolute the individual peaks of Figure 5.64A, we fitted the elution 
profile was fitted by Eq. 4.13 using the peak analysis module of Origin 8.5, and extracted the 
peak elution volumes of the minor and major peaks as being equal to 86 ml and 91 ml 
respectively.  From the standard plot derived from the elution profiles of known molecular 
weight protein standards under an identical experimental condition (Figure 5.63), the above peak 
elution volumes of SIRT5 could be translated to 33 kDa and 24 kDa molecular weights, 
respectively. Of these values, 24 kDa molecular weight of SIRT5 (eluting as a major peak) is 
somewhat smaller than the predicted molecular weight of monomeric SIRT5 (31 kDa). The 
origin of the above discrepancy presumably lies in the shape of SIRT5 eluting from the column. 
However, it was somewhat surprising to observe that the 33 kDa molecular weight peak of 
SIRT5 eluted as a shoulder band.  The latter peak was unlikely to be due to the contamination of 
other protein in our SIRT5 preparation since it was absent in the presence of 1, 5 and 10 µM 
suramin, This coupled with the fact that the above peak re-emerged when the eluants of the 
major peak were re-chromatographed on the same column, led to the suggestion that the shoulder 
peak was indeed the dimeric form of SIRT5 but it was eluting at a much lower molecular weight 
(33 kDa) fraction (data not shown) presumably due to a dynamic equilibrium between the 
monomeric and dimeric forms of SIRT5. The above size exclusion chromatographic studies of 
SIRT5 were then performed in the presence of increasing concentrations of suramin. Figure 
5.64B, 5.64C, 5.64D, and 5.64E show the elution profiles of 30 µM SIRT5 in the presence of 1, 
5, 10, and 20 µM concentrations of suramin, respectively. Note that in the presence of 1 µM 
suramin (Figure 5.64B), SIRT5 elutes as two equally predominant peaks corresponding to the 
molecular weights of 24 kDa (monomer) and 49 kDa (dimer), respectively. When the 
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concentration of suramin was increased to 5 µM (Figure 5.64C), the dimeric peak (49 kDa) of 
SIRT5 became the most pronounced, while the monomeric peak (24 kDa) significantly 
decreased in magnitude. Surprisingly, upon further increase in suramin concentration to 10 µM 
(Figure 5.64D), both monomeric and dimeric peaks of SIRT5 became nearly equally pronounced, 
similar to the situation observed in case of 1 µM suramin (Figure 5.64B).  Upon further increase 
in suramin concentration to 20 µM (Figure 5.64E), the monomeric peak of SIRT5 became most 
pronounced while the dimeric peak decreased in magnitude.  A cumulative account of these data 
lead to the suggestion that at lower concentration of suramin (Figure 5.64B and 5.64C), SIRT5 
exists as a dimer presumably due to bridging of two monomeric units of SIRT5 by suramin, On 
the other hand, in the absence of suramin (Figure 5.64A) as well as in the presence of high 
concentration suramin (Figure 5.64E) SIRT5 predominantly exists in the monomeric form.  To 
quantitate the distribution between the monomeric and dimeric forms of SIRT5 as a function of 
suramin, the areas of the resolved peaks were determined using the Guassian Function (Eq.4.13). 
Based on the determined areas, the molar ratios of the dimers versus monomers of SIRT5 were 
calculated and plotted against the corresponding concentrations of suramin (Figure 5.65).  The 
latter plot clearly shows that the percent of SIRT5 dimer increase from 6% to 77% with suramin 
concentration varying from 0 to 10 µM, and decrease back to 5% when suramin concentration 
further increases to 20 µM.  
 
 220 
 
 
 
Figure 5.64. Size exclusion chromatography profile and multiple peeks analysis for 26 µM 
SIRT5 the absence and presence of suramin. Size exclusion chromatography profile and multiple 
peeks analysis for 26 µM SIRT5 in the, in the absence (A), presence of 1 µM (B), 5 µM (C), 10 
M (D) and 20 µM (E) suramin. 
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Figure 5.65. Molar ratios of monomer/total and dimer/total are plotted against different 
concentrations of suramin from size exclusion chromatography profiles. 
 
5.4.2.9. AFM images of SIRT5 as a function of suramin concentration 
To determine the size distribution as well as topology of SIRT5 as a function of suramin 
concentration, atomic force microscopic (AFM) studies were performed on a mica surface in 
collaboration with Dr. Yongki Choi from Department of Physics at North Dakota State 
University. The samples were prepared by premixing 10 µM SIRT5 with suramin at the 
following four conditions: SIRT5 in the absence of suramin, and SIRT5 and suramin at the molar 
ratios of 1:1, 4:1, and 1:10, respectively. The above mixtures were dropped on top of a freshly 
cleaved mica surface and incubated them for 10 minutes at the room temperature. The mica 
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surface was rinsed and dried prior to subjecting the samples to AFM assisted height 
measurement. The AFM measurements were carried out in a non-contact mode at a scanning rate 
of 1.3 Hz and the resonance frequency of 145 kHz (see Methods section §4.6). The AFM images 
of SIRT5-suramin complexes are shown in Figure 5.66 (panels A-D).  Note the prevalence of 
both dim (representing the monomeric form of SIRT5) and bright (representing the dimeric form 
of SIRT5) in different panels of Figure 5.66. In the absence of suramin (Figure 5.66A), the dim 
spots are most predominant, suggesting that in the absence of suramin, a major fraction of SIRT5 
exists in the monomeric form. This is further evident by zooming and measuring the heights of 
two neighboring dim spots of Figure 5.64A as shown in Figure 5.66 panel E, The graphic 
analysis of the zoomed images reveal their heights being equal to 2.3 nm, corresponding to the 
crystallographically determined width of SIRT5. As the concentration of suramin increased 
(Figure 5.66, panels B and C), whereas the number of dimmer spots decreased, the number of 
brighter spots increased, suggesting an increase in the number of SIRT5 dimers upon increase in 
suramin concentration. Figure 5.66F shows the height measurements of zoomed brighter spots 
from the AFM image of panel C, yielding the height of SIRT5 molecules being equal to 4.3 nm, 
representing the dimeric form of SIRT5. When the suramin concentration was further increased 
(molar ratio of SIRT5 to suramin being equal to 1:10 (Figure 5.66, panel D), the dim spots 
became more predominant as compared to the bright spots, suggesting that at the above molar 
ratio of SIRT5 to suramin, the enzyme reverts back to the monomeric form as noted with size 
exclusion chromatographic analysis of SIRT5 in the presence of increasing concentrations of 
suramin (section §5.4.2.8). To determine the size distribution of all SIRT5  molecules (in the 
presence of varying concentrations of suramin), the number of SIRT5 molecules in the presence 
of varying concentrations of suramin were plotted as a function of their heights as shown in the 
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corresponding panels of Figure 5.66. The solid smooth lines of Figure 5.67 are the best fit of the 
data for the log normal distribution function of the protein molecules and their heights using eq. 
4.17 as described in the Methods section (§4.6). Although the peak heights of different panels 
were found to range between 2.2 and 2.4 nm, the arithmetic average of the plots of A, B, C, and 
D were found to be 2.9, 4.9, 3.6, and 3.3 nm, respectively. Clearly, the dimeric form of SIRT5 
becomes more abundant at lower molar ratios of SIRT5 to suramin, but as the above ratio 
increases, the dimeric SIRT5 reverts back to the monomeric form. These data are consistent with 
size exclusion chromatographic analysis of SIRT5 in the presence of increasing concentrations of 
suramin.  
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Figure 5.66. AFM images of SIRT5 on a mica surface at various concentrations of Sumarin. (A) 
SIRT5 in the absence of suramin, (B) SIRT5 and sumarin at the molar ratio of 1:1, (C) SIRT5 
and sumarin at the molar ratio of 4:1, and (D) SIRT5 and sumarin at the molar ratio of 1:10; (E) 
two monomeric SIRT5 circled in (A) are zoomed in and their height profile is shown as below. 
The heights are about 2.3nm; (F) two multimeric SIRT5 circled in (C) are zoomed in and their 
height profile is shown as below. The heights are about 4.3 nm. The scale bars are 1 µm for (A)-
(D) and 50 µm for (E) and (F). 
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Figure 5.67. Size distributions of SIRT5 at various concentrations of sumarin. (A) SIRT5 in the 
absence of suramin, (B) SIRT5 and sumarin at the ratio of 1:1, (C) SIRT5 and sumarin at the 
ratio of 4:1, (D) SIRT5 and sumarin at 1:10. The solid lines represent the fit of log-normal 
distribution function.  The peak heights are 2.2, 2.3, 2.4, and 2.2 nm for (A), (B), (C), and (D), 
respectively. The average height is about 2.3 nm. 
 
5.4.2.10. Molecular modeling 
To gain insight into the structural basis of alternative modes of binding of suramin to 
SIRT5, we performed the molecular modeling studies were performed by collaborating with Dr. 
Farukh Jabeen from Center for Computationally Assisted Science and Technology at North 
Dakota State University using the Molecular Operating Environment (MOE)) software. The 
crystal structure of SIRT5-suramin complex was retrieved from protein data bank (PDB code: 
2NYR), and following separation of the ligand (suramin) from the protein structure, they were 
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individually subjected to the energy minimizations via the structure preparation module of MOE. 
The optimized structure of suramin was docked to the energy minimized SIRT5 (dimeric form) 
via the MOE-Dock program. As shown in Figure 5.68A, the best docked structure (revealed by 
the score function) showed a similar binding mode of suramin as observed in the crystal structure 
of SIRT5-suramin complex. On the other hand, when suramin was docked to the monomeric 
form of SIRT5, it was observed that while half of the suramin molecule bound at the active site 
pocket of SIRT5 had similar orientation as observed crystallographically, the remaining half of 
the suramin structure protruded away from the protein mass (Figure 5.68B). The above modeling 
conclusions are similar to those obtained by Trapp et al. However, to probe whether or not the 
protruded structure of suramin had the potential to bend and interact on the surface of 
monomeric SIRT5, the structure of suramin was drawn in a cyclic form and subjected it to 
energy minimization (Figure 5.69A). When we the optimized suramin structure was docked to 
SIRT5, it exhibited an entirely different binding mode both within the active site pocket of the 
enzyme as well as of outside.  As shown in Figure 5.69B and C, half of the suramin molecule, 
protruding from the enzyme’s active pocket, formed hydrogen bonds with bonding with Gln83 
and Gly224 (2.44 Aº) present on the surface of the protein. The latter binding mode justifies our 
experimental data that when [suramin] >> [SIRT5], only the monomeric form of the enzyme-
ligand complex becomes predominant. The binding of half suramin structure on the surface of 
the SIRT5 monomer supports our experimental data that both binding affinity and inhibitory 
potency of full suramin is higher than that of the half suramin.  
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Figure 5.68. Molecular modeling of SIRT5 with suramin. (A) Docking of suramin to dimeric 
form of SIRT5. (B) Docking of suramin to monomeric form of SIRT5. The crystal structure of 
SIRT5-suramin complex used for the docking was retrieved from protein data bank (PDB code: 
2NYR). 
A
B
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Figure 5.69. Molecular modeling of SIRT5 with energy minimized suramin. (A) Strucgure of 
energy minimized suramin. (B) Docking pose of surmine in 3D space (ligand is shown in stick 
mode in cyan color, heavy atoms are shown in elemental color, and receptor is shown in solid 
surface mode) (C) Hydrogen bond of sulfonate groups of suramin with Gln224, and Gln83 
(shown in solid green line marked with distances). 
 
5.4.3. Binding of nicotinamide to SIRT5  
Steady-state kinetic studies for the inhibition of nicotinamide on SIRT1 and SRIT5 
variants (section §5.3.5) show that the descuccinylation reaction (catalyzed by wild-type SIRT5 
and its SIRT5 Y102A mutant) unequivocally exhibits the competitive inhibition of nicotinamide 
against NAD+, suggesting that the “base-exchange” mechanism is either nonexistent or 
negligible in the latter cases. An alternative explanation for the inhibition mechanism could be 
that nicotinamide competitively displaces NAD+ from the enzyme-substrate-NAD+ complex. In 
order to investigate the binding of nicotinamide to SIRT5, isothermal titration calorimetric (ITC) 
A
B
C
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studies were performed to determine the thermodynamic parameters for the binding of 
nicotinamide to SIRT5 and SIRT5-substrate complex in 50 mM HEPES buffer, pH 7.5, 
containing 100 mM NaCl, 10 % glycerol and 1 mM TCEP at 25 °C. Figure 5.68 shows the ITC 
profile of nicotinamide to SIRT5 (Figure 5.68A)  and HEPES buffer (Figure 5.68B), suggesting 
that only miniscule heat signals were generated as a result of heat dilution for the titration of 
nicotinamide to SIRT5 in the absence of Ac-Suclys-AMC substrate. On the other hand, in the 
presence of 10 mM NAD+ (Figure 5.69), nicotinamide produces higher magnitude of the heat 
signal, suggesting tighter binding affinity of the inhibitor to the enzyme. The data of Figure 5.69 
was analyzed by using the single site binding model, yielding the magnitudes of n, ∆H° and Ka 
as being equal to 2.1 ± 0.1, (1.3 ± 0.1) kcal/mol and (2.7 ± 0.2) × 104 M-1, respectively. The 
latter value translates to the ∆G° of binding as being equal to  4.2 ± 0.1 kcal/mol. Given the ∆H° 
and ∆G° values, the T∆S° was calculated to be 2.9 kcal/mol. Note that ITC data shows that the 
Kd value (41 M) for the binding of nicotinamide to the enzyme-substrate complex is 
comparable to the Km value of NAD
+ (69 M) during the wild-type SIRT5 catalyzed 
descuccinylation reaction. Thus, the possibility of nicotinamide competitively displacing NAD+ 
from the enzyme-substrate-NAD+ complex is further supported. 
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Figure 5.70. ITC profile for the binding of nicotinamide to SIRT5. (A) The top panels show the 
raw data generated by titration of 30 µM SIRT5 by 45 injections (5 µl each) of 10 mM 
nicotinamide. (B) The top panels show the raw data generated by titration of HEPES buffer by 
45 injections (5 µl each) of 2 mM. The area under each peak was integrated and plotted against 
the molar ratio of nicotinamide to SIRT5.  
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Figure 5.71. ITC profile for the binding of nicotinamide to SIRT5-substrate complex. The top 
panels show the raw data generated by titration of 40 µM SIRT5 by 45 injections (5 µl each) of 2 
mM nicotinamide in the presence of 1 mM Ac-Suclys-AMC substrate. The area under each peak 
was integrated and plotted against the molar ratio of nicotinamide to SIRT5. The solid lines 
represent the best fit of the experimental data for the one binding site model, yielding the 
thermodynmaic parameters of n, Ka and ΔHº as 2.1 ± 0.1, (1.3 ± 0.1) kcal/mol and (2.7 ± 0.2) × 
104 M-1, respectively. 
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5.4.4. Binding of EX527 to SIRT5 variants 
As described in section 5.3.7, the IC50 value of EX527 against the deacetylase activity of 
SIRT5 Y102A/R105I double mutant is much lower than SIRT5 wild type and its single mutants 
Y102A and R105I. Thus, it is reasonable to surmise that the enhanced inhibition potency is due 
to a tighter binding affinity of EX527 to SIRT5 Y102A/R105I double mutant. In order to probe 
the above hypothesis, isothermal titration calorimetry (ITC) studies were performed to determine 
the thermodynamic parameters for the binding of EX527 to SIRT5. Since previous studies 
suggest that the binding of EX527 is enhanced in the presence of NAD+ (45), the experiment was 
performed both in the absence and presence of NAD+. Figure 5.70 shows the ITC profile for the 
titration of SIRT5 Y102A/R105I double mutant by increasing 45 aliquots of 1 mM EX527 in the 
absence and presence of 10 mM NAD+ in 50 mM HEPES buffer, pH 7.5, containing 100 mM 
NaCl, 10 % glycerol and 1 mM TCEP at 25 °C. The raw calorimetric data for the interaction of 
EX527 to SIRT5 Y102A/R105I double mutant and their binding isotherms are shown in the top 
and the bottom panels of the figures, respectively. Figure 5.70A shows that EX527 only binds 
weakly to SIRT5 Y102A/R105I mutant in the absence of NAD+. However, in the presence of 10 
mM NAD+ (Figure 5.70B), EX527 produces higher magnitude of the heat signal, suggesting 
tighter binding affinity of the inhibitor to the double mutant enzyme. The data of Figure 5.70B 
was analyzed for the single site binding model, yielding the magnitudes of n, ∆H° and Ka as 
being equal to 1.2 ± 0.0, 5.3 ± 0.1 kcal/mol and (2.5 ± 0.2) × 105 M-1, respectively. The latter 
value translates to the ∆G° of binding as being equal to  7.3 ± 0.1 kcal/mol. Given the ∆H° and 
∆G° values, the T∆S° was calculated to be 2.03 kcal/mol. In view of these thermodynamic 
parameters, it is evident that the binding of EX527 to Y102A/R105 double mutant of SIRT5 is 
dominated by the enthalpic contribution to the overall binding free energy. When the same set of 
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experiments was performed for the binding of EX527 to the wild type SIRT5 under the identical 
condition, only miniscule heat signals were generated either in the absence or the presence of 
NAD+ (Figure 5.71). Hence, Y102 and R105 preclude the binding of EX527 to wild-type SIRT5. 
 
Figure 5.72. ITC profile for the binding of EX527 to SIRT5 Y102A/R105I in the absence (A) 
and presence (B) of 10 mM NAD+. The top panels show the raw data generated by titration of 20 
µM SIRT5 Y102A/R105I by 45 injections (5 µl each) of 500 µM EX527. The area under each 
peak was integrated and plotted against the molar ratio of EX527 to SIRT5 Y102A/R105I. The 
solid lines (right panel) represent the best fit of the experimental data for the one binding site 
model, yielding the magnitudes of n, Ka and ΔHº as being equal to 1.2 ± 0.0,  5.3 ± 0.1 kcal/mol 
and (2.5 ± 0.2) × 105 M-1, respectively. 
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Figure 5.73. ITC profile for the binding of EX527 to SIRT5 in the absence (A) and presence (B) 
of 10 mM NAD+. The top panels show the raw data generated by titration of 20 µM SIRT5 by 45 
injections (5 µl each) of 500 µM EX527. The area under each peak was integrated and plotted 
against the molar ratio of EX527 to SIRT5 Y102A/R105I. 
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5.5. Thermal Stabilities of SIRT1 and SIRT5 Variants 
5.5.1. Thermal unfolding of SIRT1 and SIRT5 variants 
The influence of three mutations of SIRT5, namely Y102A, R105I, and Y102A/R105I,  
on thermal stability of the enzyme  was probed by performing comparative  thermal unfolding 
studies. The latter were performed by measuring the loss in the secondary structural feature of 
the protein by CD spectroscopy. The latter approach was employed to monitor the ellipticity of 
the enzymes at 208 nm as a function of temperature. As shown in Figures 5.72 to 5.76., the 
increase in temperature increases the ellipticities of the enzymes at 208 nm in a sigmoidal 
manner, resulting in the attainment of plateau at high temperatures. A casual perusal of the data 
of Figures 5.72 to 5.75 reveal that while wild-type SIRT5 and Y102A  mutant enzyme exhibit a 
single stage melting transition (Figure 5.72 and 5.73),  R105I and Y102A/R105I mutant enzymes 
exhibit the two stage melting transitions (Figure 5.74 and 5.75). When the above experiment was 
performed with wild-type SIRT1 (Figure 5.76), the overall profile exhibited a single stage 
melting transition, similar to that observed with the wild-type SIRT5 (Figure 5.72) and its 
Y102A mutant variant (Figure 5.73). Depending on the nature of melting transition profiles of 
the enzymes, attempts were made to analyze the data of Figures 5.72 to 5.76 either by single (Eq. 
4.15) or double (Eq. 4.16) transition Boltzmann equations as described in the Methods section 
(section §4.5.4). Since the analyses of the data of Figures 5.74 and 5.75 by two independent 
phases Boltzmann equation (Eq. 4.16) did not produce reliable results, recourse was made to 
analyze the individual melting transitions by the single phase Boltzmann equation (Eq 4.15). The 
derived Tm values (the temperature at which half of the proteins lost the secondary structural 
features) from the best fit of the data are summarized in Table 5.12. The data of Table 5.12 
clearly shows that both wild-type SIRT1 and SIRT5 exhibit the single phase denaturation profile, 
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but the Tm value of SIRT1 (62.7 ± 0.4 °C) is about 10 degree higher than that of wild-type SIRT5 
(52.9 ± 0.04 °C). On the other hand, the Tm value of the wild-type SIRT5 is about 11 degree 
higher than that of the Y102A mutant (41.8 ± 0.03°C), suggesting that Y102A mutation 
destabilizes the enzyme structure. It is important to emphasize that of two Tm values of  R105I 
mutant of SIRT5, while the Tm value of the first transition phase (58.1 ± 1.0 °C) resembles that of  
the  wild-type SIRT5 (52.9 ± 0.04 °C), the Tm value of the second transition phase (72 ± 0.1 °C) 
is about 20 degree  higher. On the other hand, while the Tm value of the first transition phase of 
Y102A/R105I double mutant (42.9 ± 0.1 °C) resembles that of Y102A mutant enzyme (41.8 ± 
0.03 °C), the Tm value of the second transition phase (79.0 ± 0.1 °C) is about 5 degree higher 
than that of the second phase of R105I mutant (72.0 ± 0.1 °C). Clearly, Y102 and R105 residues 
exhibit differential effects on thermal stability of the enzyme.  
To further investigate whether the fully denatured enzymes acquired the secondary 
structural features upon cooling to the room temperature (25 °C), the individual enzyme samples 
were heated to their final melting temperatures, cooled them to room temperature (25 °C), and 
recorded their CD spectra (Figure 5.77).  Surprisingly, while the above treatment of wild-type 
SIRT5 resulted in nearly complete loss of the secondary structural feature that of the R105I 
mutant showed modest secondary structure. On the other hand, the Y102A/R105I mutant 
enzyme showed the secondary structural feature similar to that of the wild-type enzyme. 
However, none of the heat treated (and subsequently cooled) samples showed any enzyme 
activity.  
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Figure 5.74. Thermal denaturation SIRT5. The ellipticity change of SIRT1 was monitored at 208 
nm as a function of increasing temperatures. The scan was performed at a heating rate of 1 ºC 
min-1 in 5 mM Tris-HCl buffer, pH 7.5 using a quartz cuvette of 1 mm path length. 
 
 
 
Figure 5.75. Thermal denaturation of SIRT5 Y102A. The ellipticity change of SIRT5 Y102A 
was monitored at 208 nm as a function of increasing temperatures. The scan was performed at a 
heating rate of 1 ºC min-1 in 5 mM Tris-HCl buffer, pH 7.5 using a quartz cuvette of 1 mm path 
length. 
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Figure 5.76. Thermal denaturation of SIRT5 R105I. The ellipticity change of SIRT5 R105I was 
monitored at 208 nm as a function of increasing temperatures. The scan was performed at a 
heating rate of 1 ºC min-1 in 5 mM Tris-HCl buffer, pH 7.5 using a quartz cuvette of 1 mm path 
length. 
 
 
Figure 5.77. Thermal denaturation of SIRT5 Y102A/R105I. The ellipticity change of SIRT5 
Y102A/R105I was monitored at 208 nm as a function of increasing temperatures. The scan was 
performed at a heating rate of 1 ºC min-1 in 5 mM Tris-HCl buffer, pH 7.5 using a quartz cuvette 
of 1 mm path length. 
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Figure 5.78. Thermal denaturation of SIRT1. The ellipticity change of SIRT1 was monitored at 
208 nm as a function of increasing temperatures. The scan was performed at a heating rate of 1 
ºC min-1 in 5 mM Tris-HCl buffer, pH 7.5 using a quartz cuvette of 1 mm path length. 
 
Table 5.12. Melting temperatures of SIRT1 and SIRT5 variants 
 Tm (°C) 
SIRT5 wild type 52.9 ± 0.04 
SIRT5 Y102A 41.8 ± 0.03 
SIRT5 R105I 
58.1 ± 1.0 
72.0 ± 0.1 
SIRT5 Y102A/R105I 
42.9 ± 0.1 
79.0 ± 0.1 
SIRT1 62.7 ± 0.4 
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Figure 5.79. CD spectra of wild-type (black) and R105I (red) and Y102A (blue) mutants of 
SIRT5 after completion of the melting phases. 
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5.5.2. Thermal stability of SIRT5 in the presence of suramin 
Binding of a ligand to protein is often associated with modulation in secondary structure 
of the protein. In order to investigate the change of the above feature for the binding of suramin 
to SIRT5, the CD spectra of SIRT5 in the absence and presence of suramin were recorded under 
the same experimental condition as described in the Method section. Figure 5.78 shows CD 
spectra of SIRT5 upon the binding of suramin (blue dashed line). The overall spectrum is 
comparable with the apo-SIRT5 except for a slight change between 210-220 nm, which is 
presumably due to the structural changes within the flexible loop connecting the Rossmann fold 
domain and the zinc binding domain (see Discussion section)(34).   
In order to compare the thermal stability of SIRT5 when bound with suramin, the thermal 
stability of the suramin-bound form of SIRT5 was investigated by measuring the loss of the 
secondary structure (monitored by the ellipticity at 208 nm) as a function of temperature. as 
described in the Methods section (§4.3.4). Figure 5.79 shows the thermal unfolding curve of 10 
M SIRT5 in the presence of 10 M suramin. The red smooth line represents the best fit of the 
data by the single phase Boltzmann equation (Eq 4.15), yielding the Tm value to be (62.7 ± 
0.4 °C). Note that the above value is about 10 degree higher the the Tm value of SIRT5 in the 
absence of suramin. The increased Tm suggests that the secondary structure of SIRT5 is 
stabilized upon the binding of suramin. 
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Figure 5.80. CD Spectra of SIRT5 in the absence and presence of suramin.  The mean residue 
ellipticities of 10 µM SIRT5 in the absence (black solid line) and presence (blue dashed line) of 
5µM suramin as a function of wavelength are shown. The experiments were performed in 5 mM 
Tris-HCl buffer, pH 7.5 using a quartz cuvette of 1 mm path length. 
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Figure 5.81. Thermal denaturation of SIRT5 in the presence of suramin. The ellipticity change of 
10 µM SIRT5 in the presence of 10 M suramin was monitored at 208 nm as a function of 
increasing temperatures. The scan was performed at a heating rate of 1 ºC min-1 in 5 mM Tris-
HCl buffer, pH 7.5 using a quartz cuvette of 1 mm path length. 
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6. DISCUSSION 
6.1. Contribution of Y102 and R105 Residues of SIRT5 in Catalysis  
Previous studies have shown  that human SIRT5 has considerably lower deacetylase 
activity as compared to that of  human SIRT1, SIRT2 and SIRT3 (272). While SIRT1 primarily 
catalyzes the deacetylation reaction (of acetylated lysine residues) in selected proteins, SIRT5 
preferentially cleaves the negatively charged acyl moieties (viz., succinyl-, malonyl-, glutaryl-) 
from their lysine conjugates in enzymes and proteins (11, 257, 273). The above unique feature of 
SIRT5 appears to be encoded in the active site residues, Y102 and R105, of the enzyme, and 
these residues are substituted by  A313 and I316 of SIRT1, respectively (Figure 5.5 of section 
§5.1.2). Whether the difference in the above residues between SIRT1 and SIRT5 served as the 
sole determinant of the substrate selectivity was probed by replacing Y102 and R105 residues of 
SIRT5 by corresponding Ala and Ile residues in SIRT1, respectively, via site directed 
mutagenesis. A detailed account of the kinetic data of wild-type SIRT1 and SIRT5 and Y102A, 
R105l, and Y102A/R105I mutants of the latter enzyme unraveled the fact that aside from the 
specific amino acid residues within the active site pockets, the overall structural features of the 
enzyme dictate the substrate specificity as well as the catalytic efficiencies of the enzymes. It has 
been widely accepted that sirtuin catalyzed reactions follow a sequential mechanism in which the 
acetylated peptide binds first followed by the binding of NAD+ to generate the enzyme-substrate-
NAD+  ternary complex, which undergoes the chemical transformation reaction to produce the 
reaction products (274). Since all sirtuins share a highly conserved catalytic core, it is not 
surprising that they utilize similar bi-substrate ternary complex mechanism. Although attempt 
was not made to differentiate among alternative bi-substrate reaction mechanisms with wild-type 
SIRT1 and SIRT5 and its mutants, the kinetic data (collected in a matrix format with varying 
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concentrations of the substrate(s) and NAD+) were analyzed by the sequential mechanism to 
derive the “true” (instead of “apparent”) kinetic parameters of the enzymes. The data of Table 
5.1 clearly reveals that for structurally similar fluorogenic substrates, the specificity constant 
(kcat/Km) for the SIRT5 catalyzed desuccinylation reaction is about one order of magnitude 
higher than that for the SIRT1 catalyzed deacetylation reaction, and none of the SIRT5 mutants 
(either catalyzing the descuccinylation or deacetylation reaction) yield the specificity constants 
similar to or higher than that of the wild-type enzyme. 
Although the Km,sub for the double mutant (SIRT5: Y102A/R105I) is comparable to that 
obtained for  SIRT1, the  kcat value of the former enzyme was about 25 fold lower than that of  
the latter enzyme. Hence, although Y102A and/or R105I mutations in SIRT5 promote the 
deacetylase activity, the catalytic machinery of the mutant enzymes is not as efficient as that of 
SIRT1. Clearly, the substrate specificity of SIRT1 and SIRT5 is not manifested exclusively by 
the (above noted) “two” residues. Previous studies have shown that the conserved catalytic core 
of SIRT1 has very low catalytic activity toward several known protein substrates. The N- and C-
terminal regions of SIRT1 increased the catalytic efficiency of SIRT1 by between 12- and 45-
fold (56). Unlike SIRT1, SIRT5 does not possess the above two regions that potentiate the 
enzyme catalytic efficiency, which is at least the partial reason for explaining the different Kcat 
values between the double mutant SIRT5 (which mimics SIRT1 catalytic core) and SIRT1. 
In the presence of high concentrations of NAD+ (found under certain physiological 
conditions), the latter interacts with non-mammalian sirtuins such as Sir2Af1 and Sir2Af2 in a 
nonproductive manner (29, 275). The binding affinities for NAD+ for SIRT1 and SIRT3 under in 
vitro condition have been found to be  in the millimolar range (228). Of  seven human sirtuins, 
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only SIRT6 has been shown to bind NAD+ tightly (Kd = 27 µM) in the absence of  acylated 
substrates (35). 
However, it is becoming increasingly clear that the binding affinity of NAD+ in different 
sirtuins is modulated by the nature of the acylated substrates (15). Such difference in the 
substrate dependent changes in the binding affinity of NAD+ is evident from our kinetic data.  As 
noted in the previous chapter, the Km for NAD
+ during the desuccinylation reaction (given by the 
wild-type SIRT5 and Y102A mutant) is lower than that for the deacetylation (given by SIRT1 
and Y102A and Y102A/R105I mutants of SIRT5) reaction. Particularly in case of Y102A 
enzyme, which catalyzes both deacetylation and desuccinylation reactions, the Km for NAD
+ for 
the desuccinylation reaction is about 10 fold lower than that for the deacetylation reaction. This 
difference is presumably due to the electrostatic interaction between R105 and the phosphate 
moieties of NAD+ during the descuccinylation reaction.  
6.2. Inhibition of Desuccinylase Activity of SIRT5 
Although several sirtuin inhibitors inhibit both deacetylase and desuccinylase reactions, 
their modes of action and mechanistic details have been found to be different for the above 
reactions as elaborated with respect to the following inhibitors.  
6.2.1. Inhibition of nicotinamide 
In cases where the mode of nicotinamide inhibition could be reliably determined, only the 
deacetylation reaction (catalyzed by SIRT1 and SIRT5 Y102A/R015I mutant) showed the mixed 
inhibition of nicotinamide against NAD+; the descuccinylation reaction (catalyzed by wild-type 
SIRT5 and its SIRT5 Y102A mutant) unequivocally showed the competitive inhibition against 
NAD+. Such inhibitory feature suggested that the “base-exchange” mechanism was either 
nonexistent or negligible during the desuccinylation reaction.   
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The model discrimination analysis for the wild-type SIRT5 and its Y012A mutant 
catalyzed reactions (section §5.3.5) unambiguously demonstrate that the nicotinamide inhibition 
(against NAD+) is purely “competitive” in nature, and the enzyme is nearly 100% inhibited in the 
presence of saturating concentration of the inhibitor. Based on the kinetic and modeling grounds, 
Guan et al. argued that “apparent competitive” inhibition of nicotinamide (against NAD+) in 
human SIRT3 catalyzed reaction may also involve the contribution of the base-exchange 
mechanism (267). However, it is non-intuitive as to how a “purely” competitive inhibitor, which 
inhibits the enzyme activity by nearly 100%, would reverse the deacylation step by exclusively 
interacting with the enzyme-acylimidate complex but not with the enzyme-substrate complex; 
the latter scenario could easily give rise to the pure competitive inhibition profile. The possibility 
of nicotinamide competitively displacing NAD+ from the enzyme-substrate-NAD+ complex is 
further supported by the isothermal titration calorimetric data (Figure 5.69) for the binding of 
nicotinamide to SIRT5-substrate complex. The ITC data shows that that only miniscule heat 
signals were generated as a result of heat dilution for the titration of nicotinamide to SIRT5 in 
the absence of Ac-Suclys-AMC substrate, while higher magnitude of the heat signal was 
generated in the presence of succinylated substrate. The Kd value (41 M) for the binding of 
nicotinamide to the enzyme-substrate complex is comparable to the Km value of NAD
+ (69 M) 
during the wild-type SIRT5 catalyzed descuccinylation reaction. Unlike the descuccinylation 
reaction, the nicotinamide inhibition data for the deacetylation reaction shows the mixed non-
competitive type of inhibition as observed with Sir2 enzymes in which the base-exchange 
mechanism has been unambiguously demonstrated (227).  
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6.2.2. Inhibition of EX527 
The fact that SIRT1 selective inhibitor, EX527, also inhibits the SIRT3 catalyzed reaction 
with reduced potency, but neither binds to wild-type SIRT5 nor inhibits its catalysis (45) is 
consistent with our finding that Y102 and R105 are responsible for precluding its avidity to the 
latter enzyme site. Since the magnitude of inhibition of SIRT5 R05I mutant by EX527 is higher 
than that determined with SIRT5 Y102A mutant (Figure 5.43), it appears logical to conclude that 
R105 in SIRT5 is a major contributor of resisting the inhibition. But this simplistic justification 
falls short in explaining a marked increase in the inhibitory potency of EX527 for Y012A/R105I 
double mutant enzyme. Evidently, Y102 and R105 coordinate with each other in controlling the 
accessibility (consequently inhibition) of the inhibitor to the enzyme. Interestingly, the inhibition 
constant of EX527 for Y102A/R105I mutant enzyme (21.7 ± 1.0 M) is comparable to that 
obtained with the wild-type SIRT3, albeit it is still considerably higher than that obtained with 
SIRT1.  
Previous studies have demonstrated that the binding affinities of EX527 to SIRT1 and 
SIRT3 are significantly higher in the presence of NAD+, and the protein structure is more 
thermodynamically stable only in the presence of NAD+ (45, 268). Zhao et al. crystallized SIRT1 
in complex with NAD+ and an EX527 analogue (Figure 6.1), providing insight into the 
mechanism for the binding and inhibition of EX527 to sirtuins (elaborated in section §1.7.2.2). 
Consistently, the isothermal titration calorimetric studies in section §5.4.4 suggest that the 
binding of EX527 to Y102A/R105I produced significantly higher heat signal in the presence of 
NAD+, suggesting tighter binding affinity of the inhibitor to the double mutant enzyme in the 
presence of NAD+. Furthermore, our ITC data for the binding of EX527 to Y102A/R105I double 
mutant enzyme reveals that the overall binding free energy is dominated by enthalpic rather than 
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entropic contribution. We conjecture that the lack of inhibition of wild-type SIRT5 by EX527 is 
contributed both by the steric hindrance (imposed by Y102 and R105 residues; see Figure 6.2) as 
well as by relatively higher level of solvation of the enzyme’s active site pocket which is not 
conducive for binding of the predominantly hydrophobic molecules like EX527.   
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Figure 6.1. Structure of EX527, the analogue, and the catalytic domain of SIRT1 bound with 
EX527 analog and NAD+. (A) Schematic representation of EX527 to the left and the analogue to 
the right. (B) The crystal structure of SIRT1 bound to NAD+ and the EX527 analogue. EX527 
analogue and NAD+ are presented in purple and yellow, respectively. 
 
 
A
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Figure 6.2. Superimposition of SIRT1 and SIRT5 showing the binding site of EX527. The 
crystal structure of SIRT1-EX527 analog complex was superimposed on the structure of SIRT5. 
SIRT1, SIRT5 and EX527 analog are shown in grey, pink, and cyan, respectively. Y102 and 
R105 in SIRT5 are labeled in orange, whereas A313 and I316 are labeled in yellow. 
 
6.2.3. Inhibition of suramin 
In view of the structural data that suramin occupies both the peptide and NAD+ binding 
sites in SIRT5, the suramin was expected to competitively inhibit the enzyme against both 
substrates. However, the kinetic analyses revealed that although the mode of inhibition of SIRT5 
by suramin with respect to the succinylated substrate was competitive in nature, such inhibition 
with respect to NAD+ was unambiguously mixed type. The latter inhibitory mode led to the 
suggestion that suramin could, at the best, partially (but not fully) compete against the binding of 
NAD+.  
R105 (SIRT5)
EX527 analog
Y102 (SIRT5)
I316 (SIRT1)
A313 (SIRT1)
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Further inhibition studies of suramin on single and double mutants (Y102A, R105I, and 
Y102A/R105I) of SIRT5 questioned the reliability of the structural data in predicting the mode 
of inhibition of suramin in SIRT5 catalysis. For example, although Y102 formed hydrogen bond 
with the sulfonate moiety of suramin in the crystal structure of SIRT5-suramin complex, Y102A 
mutation did not show any significant change in the inhibitory potency of suramin. The Ki values 
of suramin with respect to deacetylase and desuccinylase reactions of Y102A mutant enzyme 
being 3.7 ± 1.4 µM and 6.8 ± 1.7 µM, respectively, were found to be comparable to its Kd value 
(4.0 µM). Clearly, the presence of enzyme substrates did not alter the intrinsic binding affinity of 
suramin to the active site pocket of the mutant enzyme. The kinetic and thermodynamic data for 
the binding of suramin to wild-type mutant SIRT5 further attests to the cooperative versus 
antagonistic roles of Y102 and R105 residues in binding of the inhibitor and its inhibitory 
potency. While Y102 and R105 residues mutually cooperate with each other in accommodating 
suramin (in the absence of substrates) within the active site pocket of SIRT5, the above residues 
play opposite roles during suramin mediated inhibition of the enzyme.  While Y102 suppresses 
the inhibition of the enzyme by suramin, R105 promotes the inhibition.   
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Figure 6.3. Coordination of Y102 and R105 with the sulfonate group of suramin. Hydrogen 
bonds are shown as dashed orange lines. 
 
6.3. Mutation Induced Changes in the Secondary Structural Features of SIRT1 and SIRT5 
and Its Mutant Variants  
In view of the above discussion, it may imply that the differential substrate specificity as 
well as the inhibitory features of SIRT1 and SIRT5 are primarily modulated by the two specific 
amino acid residues within the active site pockets of the above enzymes. Whether such amino 
acid residues just alter the microenvironments of the enzyme’s active site pockets or they 
modulate the global conformational states of the enzymes becomes evident by examining the 
secondary structural features of the wild-type SIRT1 and SIRT5 and its mutants. Although the 
Y102 (SIRT5)
R105 (SIRT5)
2.8 Å
2.7 Å
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difference in the CD spectra between the wild-type SIRT1 and SIRT5 can be ascribed to the 
prevalence of the higher degree of random coil structure (due to extended N and C terminal 
residues) in case of the former enzyme, the difference in the CD spectral features among SIRT5 
mutant enzymes clearly indicate to the subtle, albeit discernible, difference in the protein 
structures. The latter feature becomes more pronounced upon examining the temperature 
dependent changes in the secondary structures of the wild-type and mutant enzymes. It is 
explicitly evident that while wild-type SIRT1 and SIRT5 as well as Y102A mutant show the 
single step transition profile during the temperature dependent changes in the secondary 
structures of the protein, both Arg mutants (viz., R105I and Y102A/R015I) conform to the 
double step transitions with significantly different Tm values. It is noteworthy that Y102A 
mutation decreases the Tm value of the wild-type SIRT5 by about 11 degree, suggesting that the 
above mutation has destabilizing effect on the protein structure. While the Tm of the first phases 
of R105I and Y102A/R105I is similar to the Tm values of wild type and Y102A mutant enzymes, 
respectively, the Tm value of the second phases of the Arg mutants are both above 70 °C. 
The question arises why R105 mutations in SIRT5 cause two sequential thermal 
transitions. Its origin may lie in two plausible scenarios: (1) the R105 mutation results in the 
reorganization of the protein domains such that they undergo independent thermal 
unfolding/transitions at two temperatures, (2) the R105 mutation creates two slowly 
interconvertible protein conformations which unfold differently. However, none of the above 
scenarios is consistent with the CD spectral data of the unfolded enzymes. The CD spectral data 
of wild-type SIRT5 as well as Y102A mutant enzymes show higher contribution of the random 
coil structure. But this is not the case with the R105I mutant enzyme. The CD spectra after 
heating of  R105I and Y102A/R105I mutant enzymes show dominant α helical and β sheet 
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structures, but rarely any contribution of the random coil structure (as observed with the heated 
samples of wild-type SIRT5 and its Y102 mutant; Figure 5.76). Hence, it is tempting to speculate 
that R105 mutant enzyme (cooperatively) acquires a more stable protein conformation (which 
melts at a much higher temperature) while undergoing unfolding of the native conformational 
state of the enzyme. This is presumably the reason why melting transition profile of the double 
mutant enzyme is not reliably fitted by the (independent) two-step Boltzmann equation (Eq. 
4.16). Irrespectively, the denaturation does not preserve the active site pocket of the double 
mutant enzyme to facilitate catalysis.      
In summary, the detailed comparative studies between SIRT1 and SIRT5 sheds light on 
the selectivity of the enzymes for different substrates and their distinct modes of inhibition by 
nicotinamide and EX527 inhibitors. The experimental data clearly suggest a marked 
cooperation/coordination between the Y102 and R105 residues in modulating the above features, 
and the latter appears to be facilitated by changes in the protein structure. Whether or not such 
structural differences are discernible via X-ray crystallographic analysis must await further 
studies.  
6.4. Barbiturate Derivative as Sirtuin Inhibitors 
Two barbiturate derivatives (MDS3-16 and MH5-75) were found to selectively inhibit 
SIRT5 with micromolar potency from the screening. MDS-3-16 did not show any inhibition 
against SIRT1, while 10 M concentration of MH5-75 exhibited only 20% inhibition against 
SRIT1.  
The steady-state kinetic data revealed that MH5-75 served as the mixed inhibitor against 
succinylated substrate and the  non-competitive inhibition against NAD+ during SIRT5 catalyzed 
reaction. The mixed inhibition of MH-5-75 against the Ac-Suclys-AMC may indicate that the 
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ligand partially occupies the active site where the succinylated substrate binds. Of the two 
inhibition constants derived from the mixed inhibition model, Ki’ value was twofold higher than 
that of the Ki value, suggesting the binding of the inhibitor is weakened upon binding of the 
succinylated substrate, which is presumably due to the conformational change induced by 
enzyme-substrate interaction. The noncompetitive inhibition of MH5-75 with respect to NAD+ 
suggests that the conformational change upon the formation of the ternary complex does not 
further affect the binding of the inhibitor. Note that the three Ki values determined from the 
analysis are not significantly different, suggesting that the binding of MH5-75 is not apparently 
affected by the binding of the succinylated substrate and NAD+. As mentioned in the 
Introduction section (§1.7.2.3), several thiobarbiturates have been identified as potent sirtuin 
inhibitors(245). The docking of the thiobarbiturates with SIRT5 by Maurer et al. shows that the 
thiobarbiturate ring mimicks the succinyl group of the substrate, forming hydrogen bonds with 
Tyr 102, Arg105 and Gln 140 (Figure 6.2). The interaction is stabilized by strong electrostatic 
interactions between acidic thiobarbiturate and basic guanidinium group of Arg105. This 
inhibition mode is supposed to generate competitive inhibition for the thiobarbiturate to SIRT5. 
However, such expected competitive feature is not observed in the inhibition of SIRT5 by MH5-
75, which is a barbiturate derivative. The mixed inhibition model for the inhibition of SIRT5 
desuccinylation reaction by MH5-75 with respect to the succinylated substrate suggests that the 
inhibitor at most partially occupied the active site pocket of the enzyme.  
Combining the above analysis, the inhibition mechanism is depicted in Figure 6.4. The 
inhibitor binds to the enzyme both in the absence and presence of the succinylated substrate 
(presented as A) and NAD+ (presented as B), forming unproductive complexes SIRT5-MH5-75 
(EI), SIRT5-MH5-75-substrate (EAI) and SIRT5-MH5-75-substrate-NAD+ (EABI). 
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Figure 6.4. Binding and Inhibition mechanism of MH5-75 against SIRT5. A and B represent the 
succinylated substrate and NAD+. P1, P2, P3 represent the three products from SIRT5 catalyzed 
desuccinylation reaction. Ki and Ki’ determined by steady-state kinetic experiment are 20 and 40 
M, respectively. 
 
 
Figure 6.5. Sirtuin inhibitors with a barbiturate or thiobarbiturate scaffold. 
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A unique feature of MH5-75 is that the structure contains a coumarin group, which 
exhibits electronic spectroscopic properties. The absorption spectrum of MH5-75 is 
characterized by two peaks at 264 and 410 nm, respectively (section §5.4.1).  Of these two peaks, 
the 410 nm peak is slowly red shifts to 445 nm upon binding of MH5-75 to the enzyme, 
suggesting that the enzyme induces an extended conjugation in the coumarin structure within the 
active site pocket of SIRT5. Based on the above results the binding mode of MH5-75 to SIRT5 is 
modified in Figure 6.5. However, due to the extremely poor solubility of the compound (0.56 g 
L-1 in DMSO, and much lower in aqueous media), it could not be used for further experiments 
such as transient kinetic or isothermal titration calorimetric studies to further analyze the 
underlying mechanism for the enzyme-inhibitor interaction. Alternative approaches, such as 
prepare the inhibitor in complex with some solubilizing agent, need to be considered to solve this 
problem. By collaborating with Dr. Mallik, our lab used to develop two-pronged inhibitors with 
both improved solubility and selectivity (276-278), and similar approach could be utilized to 
develop more potent inhibitors for sirtuins.  
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Figure 6.6. Docking result for one representative thiobarbiturate at SIRT5 active site pocket. 
Hydrogen bonds are shown as dashed orange lines. 
 
6.5. Suramin-mediated Changes in the Structural Features of SIRT5 
6.5.1. Suramin-mediated changes in the conformational states of SIRT5 
The structure of apo-SIRT5 is not available, making it impossible to directly evaluate the 
structural changes of SIRT5 induced by the binding of suramin by crystallographic studies. 
Hence, the direct binding studies of SIRT5 with suramin using spectroscopic approaches in the 
previous chapter provide valuable information for the conformational changes of the enzyme 
induced by the binding of suramin. First, comparison between the CD spectra of apo-SIRT5 and 
SIRT5- suramin complex (Figure 5.78) shows the overall spectrum is comparable with the apo-
SIRT5 except for a slight change between 210-220 nm, suggesting that the overall secondary 
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structure of SIRT5 remains unchanged upon binding of suramin. Second, the Tm for the thermal 
denaturation of SIRT5 bound to suramin is about 10 degree higher (Tm = 62.7 ± 0.4 °C) than that 
of the apo enzyme (Tm = 52.9 ± 0.04 °C).  
To explain the spectral change between 210-220 nm, three available crystal structures of 
SIRT5 (is compared with SIRT5-suramin complex (Figure 6.8): the structure of SIRT5 in 
complex with ADP-ribose (Figure 6.8B), the structure of SIRT5 in complex with H3K9(suc) 
peptide (Figure 6.8C) (279), and the ternary complex of SIRT5-H3K9(suc)-NAD+ (Figure 
6.68D). The spectral change between 210-220 nm as well as the increased thermal stability of the 
enzyme-ligand complex is presumably attributed by the structural change in the loop region 
connecting the Rossmann fold and the zinc-binding domain. Two significant structural changes 
could be observed. First, the flexible loop connecting the Rossmann fold and the zinc-binding 
domain (Val67-Tyr76) is partially disordered in the SIRT5-ADP ribose complex, but becomes 
ordered in the structure of SIRT5 bound to suramin (Figures 6.8A and B). Interestingly, this loop 
is disordered in the structure of SIRT5-H3K9(suc) peptide, but is ordered in the structure of 
SIRT5 bound with both H3K9(suc) peptide substrate and and NAD+ (Figures 6.8C and D). The 
above observations suggest that the binding of suramin partially mimic the ternary complex of 
SIRT5-H3K9(suc) peptide-NAD+. Second, a C-terminal region (Glu277-Arg286) near the site A 
of the NAD+ binding pocket is ordered in the SIRT-ADP ribose structure, but is disordered in the 
structure of SIRT5 bound to suramin. This region is ordered in both the SIRT5-H3K9(suc) 
peptide and SIRT5-H3K9(suc) peptide-NAD+ complexes. Based on the above discussions, 
spectral change between 210-220 nm as well as the increased thermal stability of the enzyme-
ligand complex is possibly attributed by the structural change in the loop region connecting the 
Rossmann fold and the zinc-binding domain. 
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Figure 6.7. Crystal structures of SIRT5 in complex with suramin or substrates. (A) The structure 
of SIRT5 in complex with suramin. (B) The structure of SIRT5 in complex with ADP-ribose. (C) 
The structure of SIRT5 in complex with H3K9 peptide. (D) Ternary complex of SIRT5-H3K9-
NAD+. Two regions, Val67-Tyr76 and Glu277-Arg286, are marked in red and purple, 
respectively. 
 
The conformational modulation in the protein structure of SIRT5 induced by the binding 
of suramin is also reflected in the fluorescence spectroscopic studies in section §5.4.2.1. Upon 
the binding of suramin, the intrinsic protein fluorescence of SIRT5 was quenched without any 
shift in the fluorescence emission peak, and both the short and long lifetimes of SIRT5 were 
A
C D
B
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reduced upon the binding of suramin. However, the precise deduction of the microenvironment of 
individual tryptophan moieties in SIRT5 could not be achieved due to the inherent complexity of 
the fluorescence decay curves. 
Transient kinetic studies for the binding of suramin to SIRT5 using the signal from the 
fluorescence quenching of the intrinsic protein fluorescence suggest that the binding event 
conforms to the two-step binding model (Figure 6.9). While the fast phase was attributed to the 
initial binding/encounter of the inhibitor to the active site of the enzyme, the slow phase was due 
to the isomerization of the initial encounter complex. Due to technical difficulties in performing 
the transient kinetic experiments at lower concentrations of suramin while maintaining the 
pseudo-first condition, the individual microscopic rate constants for SIRT5-sruamin interactions 
could not be reliably determined. Nevertheless, since both of the two observed rate constants on 
suramin concentrations were almost constant (Figure 5.51), most likely the lowest concentration 
of suramin used in the experiment (4 M) has almost been saturated for the binding of suramin 
to SIRT5. Hence, the estimated Kd based on this observation is in the nanomolar range (less than 
10% of suramin concentrations). It is highly possible that the binding event studied by transient 
kinetics of the fluorescence change for the binding of suramin to SIRT5 represent the tighter 
binding site (0.1 M determined from the fluorescence quenching and isothermal titration 
calorimetric studies).  
 
Figure 6.8. Two-step binding mechanism for the binding of suramin to SIRT5. The binding of 
the first step reaches rapid equilibration for association/dissociation of suramin to SIRT5, 
forming a transient intermediate which undergoes a slow isomerization/relaxation to produce the 
final ligand-protein complex 
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6.5.2. Suramin-mediated changes in the oligomeric states of SIRT5 
The experimental data presented in section 5 provide, for the first time, a detailed account 
of suramin mediated changes in the oligomerization state of SIRT5, and such changes are 
encoded in the molar ratios of SIRT5 to suramin. SIRT5 exists both at monomeric and dimeric 
states at low and high molar ratios of SIRT5 to suramin, respectively, and the prevalence of such 
oligomeric states is demonstrable by isothermal titration calorimetric, size exclusion 
chromatographic, AFM imaging, and molecular modeling studies.  
The experimental data presented herein does not support the crystallographically derived 
notion that SIRT5 exclusively exists in the dimeric state in the presence of suramin.  Since the 
structural data are devoid of strong bonding interactions between two SIRT5 molecules (in the 
presence of suramin), and that the dimeric state appears to be induced by suramin, it is unlikely 
that the dimeric form of SIRT5 would be only thermodynamically stable in the presence of 
different concentrations of SIRT5. Our modeling data as well as those of Trapp et al clearly 
demonstrate that suramin can form both 1:1 and 1:2 complex with SIRT5 (as evident 
experimental), and thus it appears likely that only one of such complexes (i.e., 1:2 complex) 
predominates in the crystalline state for which the crystal structure was solved. This is one of the 
limitations of the crystallographic structure based predictions of molecular/mechanistic features 
in the aqueous solution.  
The SEC data clearly demonstrates that even in the absence of suramin, SIRT5 exists in a 
dynamic equilibrium between the monomeric and dimeric forms albeit the monomeric form 
represent the most predominant enzyme species. Since the initial increase in suramin 
concentration predominates the dimeric over monomeric form of SIRT5, which reverts back to 
the monomeric vs. dimeric forms at further increase in suramin concentration, leads to the 
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suggestion that the oligomeric states of SIRT5 is dictated by the relative abundance of the 
enzyme and suramin in conjunction with their thermodynamic parameters. The ITC data clearly 
demonstrates that in titration of high concentration of SIRT5 by suramin (Figure 5.53; section 
§5.4.2.4), the first phase (ascribed to be due to the formation of the dimeric form of the enzyme) 
has considerably lower stoichiometry but much higher free energy than that observed with the 
second phase. On the other hand, the enthalpic contribution of the first phase is much lower than 
that of the second phase. Hence, it is not surprising that the first phase remains elusive when the 
ITC titration is performed at lower concentrations of the enzyme (Figure 5.54B; section §5.4.2.4). 
Consistently, the suramin induced formation of SIRT5 dimer (during the first phase) is an 
entropically driven process. We believe this is a result of desolvation of the surface of the 
monomeric SIRT5 involved in the formation of the dimeric form of the enzyme in the presence 
of suramin. This hypothesis is corroborated by the fact that there are no strong binding 
interactions between the SIRT5 surfaces involved in the dimer formation.  
The demonstration that when the molar ratios of suramin to SIRT5 are high, the enzyme 
exists in the monomeric form, implying that half of the suramin molecule protrudes away from 
the enzyme’s active site pocket as evident from the molecular modeling data of Trapp et al. as 
well as those presented in sections §5.4.2.4 to §5.4.2.8 (238). However, such model fails to 
explain as to why the binding affinity (Kd) as well as the inhibition constant of half-suramin for 
SIRT5 is at least 2 orders of magnitude lower than that of full suramin. Evidently, it is unlikely 
that half of the suramin molecule (in full suramin structure), protruding away from the active site 
pocket of SIRT5, would be dangling in the solvent media.  Hence, the only reasonable 
explanation of the marked difference in the binding affinity of full vs. half suramin for SIRT5 is 
that the protruded/dangling region of full suramin interacts on the surface of the enzyme.  This 
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model is akin to the binding of the “two-prong” inhibitors to carbonic anhydrases and matrix 
metalloproteinases developed in our lab (276, 278).  Both biophysical and crystallographic data 
unequivocally demonstrated that while one end of our two prong inhibitors interact at the active 
site pocket of carbonic anhydrase isozymes, the other end interacts on the enzymes’ surface. In 
fact, the two-prong binding mode suramin to SIRT5 is evident when the energy minimized 
structure of suramin molecule is docked to the monomeric form of SIRT5 by collaborating with 
Dr. Farukh Jabeen from Center for Computationally Assisted Science and Technology at 
University of North Dakota. As illustrated in Figure 5.69 (section §5.4.2.10), half of the suramin 
molecule, protruding from the enzyme’s active pocket, formed hydrogen bonds with bonding 
with Gln83 and Gly224 present on the surface of the protein. The latter binding mode justifies 
the experimental data that when [suramin] >> [SIRT5], only the monomeric form of the enzyme-
ligand complex becomes predominant. The binding of half suramin structure on the surface of 
the SIRT5 monomer supports the experimental data that both binding affinity and inhibitory 
potency of full suramin is higher than that of the half suramin. This alternative mode of binding 
of suramin to SIRT5 leading to the formation of dimeric versus monomeric form of the enzyme 
is depicted as the cartoon of Figure 6.11. 
 
 
 
.  
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Figure 6.10. Proposed SIRT5-suramin binding mechanism. 
 
The question arises whether the dimeric form of SIRT5 is “pre-existent” or it is 
exclusively “induced” by suramin in the aqueous solution.  The fact that a small, albeit 
discernible, dimeric peak of SIRT5 is evident in our size exclusion chromatographic studies even 
in the absence of suramin suggests that a small fraction of the enzyme can pre-exist as dimer.  In 
our attempt to probe whether the SIRT5 dimer (in the absence of suramin) exists in a dynamic 
equilibrium with the predominant monomeric form of SIRT5, we collected the monomeric peak 
fractions of SIRT5, concentrated them via amicon-concentrator, and re-chromatographed on the 
original size exclusion column. Interestingly, we noted the re-emergence of the dimeric peak of 
SIRT5 (data not shown), suggesting that there is a pre-existing equilibrium between the 
monomeric and dimeric forms of SIRT5, and such equilibrium is shifted to the dimeric form of 
the enzyme in the presence of suramin, particularly under the condition of lower molar ratios of 
suramin to SIRT5. The suramin induced increase in the dimeric form of SIRT5 appears to be 
thermodynamically favored as the carbonyl oxygen of urea (of full suramin) forms a hydrogen 
bond with interfacial Y255 (2.6 Aº) in the dimer. It should be mentioned that suramin induced 
dimerization is not unique for SIRT5. The above feature has aslo been observed with other 
Suramin Suramin
SIRT5 Dimer Monomer
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suramin binding proteins such as aFGF and TNFα (280, 281). In case of aFGF, it has been noted 
that suramin induced the microaggregation of the protein (under physiological condition) 
prevents its aggregation to the cell surface receptors. However, at higher molecular ratios of 
suramin to aFGF, the latter reverts back to the monomeric form (similar to that observed with 
SIRT5) precluding its interaction with the cell surface receptors.  
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